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ABSTRACT 
Synthesis and Characterization of Novel Platinum(II) and Platinum(IV) Complexes 
Containing 4,4′-Disubstituted-2,2′-bipyridine Ligands for the Treatment of Cancer 
By 
Van Vo 
Dr. Pradip K. Bhowmik, Examination Committee Co-Chair 
Dr. Bryan L. Spangelo, Examination Committee Co-Chair 
Department of Chemistry 
University of Nevada, Las Vegas 
 
 Three series of platinum(II) and platinum(IV) complexes containing 4,4′-
disubstituted-2,2′-bipyridine ligands have been synthesized and characterized by 1H 
NMR, 
13
C NMR spectroscopy, elemental analysis, mass spectroscopy, and differential 
scanning calorimetry measurements. The MTS cell proliferation assay was used to 
examine the in vitro anti-proliferative activities of these complexes in various human 
breast, lung, and prostate cancer cells. The cell’s response to the complexes varies 
between different cell lines; however, the low EC50 values determined from the MTS data 
indicate that several of the complexes are much more potent than cisplatin. 
 Flow cytometric analysis of selected compounds revealed induction of apoptosis 
and some necrosis.  One of the complexes, Pt(II)-4C, was further studied by examining 
its interaction with DNA and its effect on mitogen-activated protein kinase (MAPK) 
signaling.  Data from UV-Vis analysis with calf thymus DNA, gel electrophoresis with 
plasmid pBR322 DNA, and inductively coupled plasma-atomic emission spectrometry 
(ICP-AES) indicate that Pt(II)-4C is able to bind to DNA, cause unwinding of the 
circular plasmid DNA, as well as covalently modify cellular DNA. Results from western 
iv 
 
blotting, flow cytometric immunofluorescence, and immunofluorescence microscopy 
indicate activation of JNK, ERK, and p38.  Cells treated with Pt(II)-4C in the presence 
of JNK and p38 inhibitors had increased cell viability compared to cells treated with 
Pt(II)-4C alone indicating that JNK and p38 are involved in Pt(II)-4C induced cell 
death. 
 These results demonstrate the potential utilization of these novel complexes for 
the treatment of cancer.  
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CHAPTER 1 
  
INTRODUCTION 
 
1.1 General statement 
This dissertation has been organized as manuscripts (Chapters 2–5). Chapter 2 
corresponds to the contents of a published paper
1
 with the format modified to fit the 
formatting requirements. Chapters 3–5 are manuscripts in preparation. 
1.2 Background and Significance 
1.2.1 Cancer and current treatment options 
Currently, about 25% of the deaths in the United States are due to cancer, making 
it the second leading cause of death. In 2014, an estimated 1.7 million new cancer cases 
(855,000 males and 810,000 females) and 586,000 cancer deaths (310,000 males and 
276,000 females) are projected to occur.
2
 Prostate and lung cancers are the top two 
leading cancer types in males; whereas, breast and lung cancers are the top two leading 
cancers in females. 
Not only is cancer a leading cause of death in the U.S., but it is also a leading 
cause of death worldwide. In 2012, there were an estimated 14.1 million new cases of 
cancer and 8.2 million cancer-related deaths worldwide.
3
 With an estimated 1.7 million 
new cancer cases diagnosed in 2012 (25% of all cancers), breast cancer is the most 
frequent cancer among women and is the second most common cancer in the world. 
Overall, with 522,000 deaths, breast cancer ranks as the fifth cause of death from cancer.  
Lung cancer remains as the most commonly diagnosed and cause of cancer-related death 
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in the world with an estimated 1.8 million new cases and 1.6 million deaths in 2012. In 
2012, there were an estimated 1.1 million new cases of prostate cancer worldwide, 
making it the second most common cancer in men and the fourth common cancer overall.  
Additionally, it is the fifth leading cause of cancer-related death (307,000 deaths) in 
men.
3 
If the trends for the global cancer rates remain the same, it is projected that the 
number of new cases of cancer will increase to 22.2 million and the number of cancer-
related deaths will increase to 13.2 million by the year 2030.
4
 These are an increase of 
about 60% compared to the estimates from 2012, which is a cause for concern. 
 Cancer treatment varies depending on the type of cancer and its stage.  The three 
classical approaches to cancer treatment are surgery, radiotherapy, and chemotherapy.  If 
the cancer is localized, surgery is usually the first approach; however, if surgery cannot 
be performed or does not successfully remove all of the diseased cells, then radiotherapy, 
chemotherapy, or a combination of the three is used. For certain breast and prostate 
cancers, hormonal therapy is an alternative treatment option.  Additionally, with the 
recent technological advances and a better understanding of cancer cell biology, more 
selective treatment options such as targeted therapy and immunotherapy are now 
available.
5,6
  
1.2.2 Platinum (Pt)-based chemotherapy 
1.2.2.1 Cisplatin and related compounds 
Many new innovative methods of cancer treatment are continuously being 
introduced; however, chemotherapy remains a standard treatment option. A 
chemotherapeutic drug that is commonly prescribed for the treatment of many cancers is 
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cisplatin (CDDP), a square-planar Pt(II) compound coordinated to two ammonia and two 
chloride ligands in cis configuration (Figure 1-1). Cisplatin was first synthesized by 
Peyrone in 1844 and Rosenberg accidentally discovered its antitumoral property in 1965, 
which sparked an interest in the development of platinum complexes as chemotherapeutic 
drugs in the 1960s.
7–11
 Cisplatin gained approval for clinical treatment by the U.S. Food 
and Drug Administration (FDA) in the late 1970s and is now widely used in the treatment 
of many malignancies, including glioblastoma multiforme, cancers of the bladder, lung,  
 
Figure 1 – 1. Structures of cisplatin and platinum(II) complexes in clinical use. 
 
breast, uterus and cervix, and testicular cancer.
11,12
 Research on platinum drugs has 
resulted in the synthesis of thousands of platinum complexes; however, only a few have 
been approved for clinical use. Along with cisplatin, two other Pt(II) complexes, 
carboplatin and oxaliplatin, are approved for use worldwide (Figure 1-1). Additionally, 
five other Pt(II) complexes are used in selected countries; lobaplatin and dicycloplatin in 
China, nedaplatin and miriplatin in Japan, and heptaplatin in Korea.
9–11,13–16
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Figure 1 – 2. General structure of Pt(II) and Pt(IV) complexes. 
 
As many researchers remain focused on improving Pt(II) complexes, some are 
expanding into the development of Pt(IV) complexes. Unlike Pt(II) complexes which 
have four coordinating ligands attached to the Pt center (giving it a +2 oxidation state), 
Pt(IV) complexes have six coordinating ligands (giving it a +4 oxidation state) (Figure 1-
2). These complexes are generally prepared by oxidation of Pt(II) compounds with Cl2 or 
H2O2 and further modified by reactions with various reagents to produce the desired axial 
ligands.
13,17,18
 They are described as prodrugs because these compounds require 
activation through intracellular enzymatic reduction to Pt(II). The use of Pt(IV) 
complexes as prodrugs is of interest due to advantages of the Pt(IV) structure over Pt(II). 
They have a low-spin d
6
 octahedral geometry, which make these compounds more inert 
to substitution reactions than its Pt(II) counterparts. The decreased reactivity leads to a 
reduction in side effects and the potential for oral administration. The added coordination 
of the axial ligands of Pt(IV) complexes allow for greater flexibility in strategies that 
improve solubility and target selectivity.
13,19
 Along with cisplatin, several Pt(IV) 
complexes (cis-[Pt(NH3)2Cl4], trans-[Pt(NH3)2Cl4] and [Pt(en)Cl4]) were described by 
Rosenberg et al.; however, they were less effective than cisplatin.
20
 Since then, 
Iproplatin, tetraplatin, and satraplatin are several other Pt(IV) complexes which have 
entered clinical trials (Figure 1-3). Tetraplatin was abandoned in Phase I clinical trials 
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due to severe neurotoxicity. Iproplatin was abandoned because it was less effective than 
cisplatin and carboplatin. Satraplatin can be administered orally and is less toxic than 
cisplatin, but there is no improvement in overall survival benefit. It is still undergoing 
clinical trials in combination with other chemotherapeutic agents.
13,19–21
  
 
Figure 1 – 3. Structures of some platinum(IV) complexes that have entered clinical trials. 
 
Presently, about 50% of cancer chemotherapeutic regimens consist of platinum 
(Pt)-based drugs; however, treatment with platinum drugs is accompanied by severe side 
effects such as nephrotoxicity, neuropathy, ototoxicity, and myelosuppression. 
Additionally, other drawbacks such as intrinsic or acquired resistance and limited activity 
against some major types of cancer have impeded the clinical utility of these 
drugs.
9,10,13,20,21
 To circumvent these drawbacks, the quest for improved platinum drugs 
continues with the goal of discovering compounds with greater efficacy and reduced 
toxicity.  
1.2.2.2 Cellular response to platinum drugs 
 The cytotoxic effect of cisplatin is mainly due to the formation of DNA adducts 
even though only a small percentage (5–10%) of the intracellular cisplatin concentration 
is found in the nucleus.
22
 When administered into the body, cisplatin is kept inactivated 
by the high chloride ion concentration in the extracellular space.  Once inside the cell 
where the chloride ion concentration is low, cisplatin is activated by substitution of the 
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labile chloride ligands with water molecules and then undergoes nucleophilic attack of 
the N7 position of guanine (and adenine to a lesser extent) to form irreversible cisplatin-
DNA cross-links.
7,8,12,13,22
 Although the overall structure of the DNA double helix stays 
the same, the arrangement of several bases are disrupted because of unwinding and a high 
degree of bending toward the major groove.
13,23,24
  Cisplatin-induced DNA damage elicits 
various cellular responses such as cell cycle arrest, activation of repair mechanisms, 
stress response, and cell death pathways. The two pathways that are of interest for this 
dissertation are the p53 and the mitogen-activated protein kinases (MAPK). 
 The p53 protein is a tumor suppressor that is involved in many processes 
including activation of DNA repair, cell cycle arrest, and initiation of apoptosis.
25
 During 
normal cellular conditions, p53 has a short half-life and is kept at a low level by the 
Mdm2 ubiquitin ligase. However, the interaction of p53 with Mdm2 decreases when 
stimulated by stress signals, which allows for the accumulation and phosphorylation of 
p53.
25,26
 Activated p53 can then interact with other proteins such as p21 (cell cycle 
protein) or Bax (apoptotic protein).
26
 Current data from the literature indicate that the role 
of p53 in cisplatin treated cells varies depending on the cell line and duration of 
treatment. In some reports, cisplatin-induced apoptosis is described as requiring 
functional p53; however, the opposite is reported by some authors indicating that cells 
with wild-type p53 are resistant to cisplatin treatment and sensitivity is achieved by 
inhibition of its expression.
22,26
 
 The MAPKs are proteins that are activated by various stimuli to regulate cellular 
processes such as proliferation, differentiation, movement, survival, and programmed 
death.
22,26
 Three major MAPK members are extracellular signal-regulated kinases (ERK), 
7 
 
c-Jun N-terminal kinases (JNK), and p38 kinases. Generally, ERK has a role in cell 
proliferation and development; however, JNK and p38 have roles in apoptotic signaling, 
inflammatory responses, and protective responses.
22
 These proteins are activated through 
phosphorylation by upstream kinases and, in turn, phosphorylate downstream targets to 
activate them.  ERK, JNK, and p38 have all been demonstrated to be activated by 
cisplatin; however, similar to p53, their roles also vary between different cell lines and 
duration of treatment. In some studies, in accordance with their roles, ERK activation 
protects cells from apoptosis, whereas, activation of JNK and p38 leads to apoptotic cell 
death; on the other hand, some studies demonstrated the opposite.
22,26–28
 
1.3 Research objectives 
Described herein is a multidisciplinary dissertation project involving various 
fields of science including synthetic organic chemistry, inorganic chemistry, analytical 
chemistry, and cancer biochemistry, for the development of novel chemotherapeutic 
agents.   
The nitrogen containing 2,2′-bipyridine compounds are attractive ligands to use 
for the synthesis of platinum drugs because of their high redox stability and ease of 
functionalization.
29,30
 Various metal complexes containing 2,2′-bipyridine have been 
reported to have antitumor activity,
31–39
 but these compounds have drawbacks such as 
requiring special glassware or reaction conditions, and having lower activity than 
cisplatin. These drawbacks contributed to the motivation to develop platinum complexes 
containing the 2,2′-bipyridyl moiety with improved efficacy. 
The goals of this project are to synthesize and characterize novel Pt(II) and Pt(IV) 
cisplatin analogues containing 4,4′-disubstituted-2,2′-bipyridine, examine the cytotoxicity 
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of the synthesized compounds using a variety of human cancer cell lines, and characterize 
the mechanism of action of the novel platinum complexes on selected human cancer 
cells.  These goals are accomplished with the following aims: 
 Aim I: Synthesis and characterization of novel Pt(II) and Pt(IV) cisplatin 
analogues  
Rationale. Although platinum-based drugs are used in about 50% of cancer 
chemotherapeutic regimens,
 
drawbacks such as cellular resistance, toxic side 
effects, and the narrow spectrum of activity warrant the need for development of 
platinum drugs with superior characteristics. Additionally, the National Cancer 
Institute has reported a shortage of chemotherapeutic drugs for several years.  
Synthesis of new drugs will not only alleviate this shortage problem and 
circumvent the drawbacks of current platinum drugs, but also allow patients to 
have access to alternative treatment options.     
o Study 1: Synthesis of new platinum compounds containing 4,4′-disubstituted-
2,2′-bipyridine using various organic reactions and purification methods (i.e., 
recrystallization, extraction, and column chromatography). 
o Study 2: Characterize the chemical structures and confirm the purity of the 
compounds using elemental analysis, 
1
H and 
13
C NMR (nuclear magnetic 
resonance spectroscopy), and DSC (differential scanning calorimetry). 
 Aim II: Assessment of the cytotoxicity of the synthesized compounds in multiple 
human cancer cell lines and determination of the cell death pathway (apoptosis vs. 
necrosis) induced by the active platinum complexes.  
9 
 
Rationale. Often a chemotherapeutic drug such as cisplatin is effective for some 
type of cancers, but ineffective in others.  Thus, it is necessary to examine the 
cytotoxicity of the compounds in various cancer cells to determine the potency 
and potential application of these compounds. 
o Study 1: Determine the cytotoxicity profiles of the synthesized platinum 
compounds in various human cancer cell lines using the MTS colorimetric 
cell proliferation assay. 
o Study 2: Detect changes in the cell cycle and cell death pathways (apoptosis 
or necrosis) activated by the platinum complexes using DNA laddering assay, 
flow cytometry, and fluorescence microscopy.  
 Aim III: Characterization of the mechanism of action of the novel cisplatin 
analogues on selected human cancer cells 
Rationale.  Understanding the cellular effect of a drug is important when 
developing treatment strategies and predicting possible side effects. There is still 
much to be explored about the biological effects of cisplatin; however, it is known 
that cisplatin binds to DNA and forms adducts that damage the DNA and 
activates the apoptotic pathway.  The synthesized platinum(II) complexes have a 
platinum center that is similar to cisplatin [Pt(IV) complexes are expected to be 
intracellularly reduced to Pt(II)] and may bind to DNA to cause damage in a 
mechanism analogous to cisplatin. 
o Study 1: Analyze the interaction of the novel platinum complexes with DNA 
using UV-Vis spectroscopy with calf thymus DNA and gel electrophoresis 
with plasmid pBR322 DNA. 
10 
 
o Study 2: Determine the uptake of the novel platinum compounds and the level 
of DNA binding in select human cancer cell lines using inductively coupled 
plasma-atomic emission spectrometry (ICP-AES) 
o Study 3: Identify the proteins mediating cell death responses activated by the 
novel platinum compounds in select human cancer cell lines using western 
blotting analysis, flow cytometry, and immunofluorescence microscopy. 
 
Chapters 2–5 describe the synthesis of three novel Pt(II) and Pt(IV) complexes 
and the structural characterization of these complexes by 
1
H NMR, 
13
C NMR 
spectroscopy, elemental analysis, mass spectroscopy, and differential scanning calori-
metry (DSC) measurements. The anti-proliferative activities of these compounds against 
a panel of human cancer cell lines are also described and compared to that of cisplatin 
and carboplatin. Additionally, the structure-activity relationship is explored to provide a 
rational basis for the discovery of novel platinum compounds with increased 
effectiveness and low toxic side effects. Furthermore, data from various experimental 
techniques (UV-Vis spectroscopy and gel electrophoresis to study interactions with 
DNA; ICP-AES for the detection of platinum uptake by cells and binding to DNA; 
western blotting, immunofluorescence, and flow cytometry for analysis of changes in 
protein expression) are presented to describe the interactions of these complexes with 
biological molecules and gain insight into the mechanism of action, which will further aid 
in the development of promising chemotherapeutic agents.   
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CHAPTER 2  
SYNTHESIS OF [PTCL2(4,4′-DIALKOXY-2,2′-BIPYRIDINE)] 
COMPLEXES AND THEIR IN VITRO ANTICANCER PROPERTIES
*
  
2.1 Abstract 
A series of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes of the general 
formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6, 
8) were synthesized and characterized using 
1
H NMR, 
13
C NMR spectroscopy, elemental 
analysis, mass spectroscopy, and differential scanning calorimetry measurements. The in 
vitro anti-proliferative activities of these compounds were evaluated against human 
cancer cell lines A549 (lung adenocarcinoma), DU145 (prostate carcinoma), MCF-7 
(breast adenocarcinoma), and MDA-MB-435 (melanoma) using the MTS cell 
proliferation assay. Several Pt(II) coordination compounds were found to have greatly 
enhanced activity compared to cisplatin after a one hour treatment in all cell lines tested. 
A structure-activity relationship was observed, that is, the activity increases as the carbon 
chain length of the alkyl group increases. The activity was maximum when the carbon 
chain length reached four or five carbons and decreased with the longer carbon chain 
length.  Fluorescence microscopy and flow cytometry data indicate that the main mode of 
cell death is through apoptosis with some necrotic responses. 
 
                                                 
*
 This chapter corresponds to the content of the published paper: 
Vo V, Tanthmanatham O, Han H, Bhowmik
 
PK, Spangelo BL. Synthesis of [PtCl2(4,4′-
dialkoxy-2,2′-bipyridine)] complexes and their in vitro anticancer properties. 
Metallomics, 2013, 5, 973-987. 
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2.2 Introduction 
Cisplatin (CDDP) is a relatively small coordination compound of platinum (Pt) 
that was approved by the US FDA in 1978 for the clinical treatment of various cancers.
1–3
 
Thirty-five years since its FDA approval cisplatin has remained one of the most 
commonly prescribed chemotherapeutic drugs.  However, the clinical application of 
cisplatin is limited due to toxic side effects, such as kidney damage and cellular 
resistance (either intrinsic or acquired).
3–7
 Due to these issues, numerous cisplatin 
analogues have been synthesized and investigated with varying anti-neoplastic activity. 
Currently, only two cisplatin analogues have been approved by the US FDA. The first 
was carboplatin, which was approved in 1989, for the treatment of lung and ovarian 
cancer. The second was oxaliplatin, approved in 2002, for the treatment of colorectal 
cancer.
1,6
 Although these drugs have less toxic side effects than cisplatin, they are only as 
effective or in some cases less effective than cisplatin. Additionally, side effects such as 
myelosuppression have limited their usefulness.
1,8 
The first report for the synthesis of 2,2′-bipyridine dates back to 1888 by Fritz 
Blau
9
 and then by Newkome et al.
10
 and it is now one of the most extensively studied 
chelating agents. The 2,2′-bipyridine compounds are commonly used as bidentate 
transition metal ligands because various functional groups can easily be attached and they 
have high redox stability.
11,12
 These compounds are used in electron-transfer processes, 
luminescent devices, and nanomaterials. Additionally, they have applications in areas 
such as photonics and electrochemistry.
10,11
 Various metal complexes containing 2,2′-
bipyridine have been reported to have antitumor activity,
13–21
 some of the representative 
Pt-complexes (1–10) are depicted in Fig. 2-1. 
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Figure 2 – 1. Some representative chemical structures of known [Pt(II)Cl2(4,4′-
disubstituted-2,2′-bipyridine)] complexes. 
 
Complex 1 was reported to have some activity against NCI-H460 lung cancer 
cells, but was less active than cisplatin (determined by MTT assay with a 48 h 
treatment).
22
 Complexes 2 and 3 were reported to be at least 100 times more lethal than 
cisplatin as determined in clonogenic survival assays of MDA-MB-231 human breast 
cancer cells and its two engineered derivatives treated for 1 h with the complexes. It was 
also demonstrated that 3 was more lethal than cisplatin in human prostate (DU145) and 
lung (A549) cancer cells.
17
 Complexes 4 and 5 were shown to be more lethal than 
cisplatin in A549, DU145, and MDA-MB-435 (now classified as a melanoma cell line) 
when tested using a clonogenic survival assay with a 1 h treatment duration.
19
 The 
activity of complexes 6-10 has been tested in MCF-7 (breast cancer), MDA-MB-231, and 
A549 cells.
20 
 Complexes 6-8 exhibited anti-proliferative activity against MDA-MB-231, 
but no significant activity against MCF-7 and A549 cells. Complexes 9 and 10 did not 
have significant activity against any of the cell lines tested.  
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Although complexes 2-5 were demonstrated to be effective, the synthesis of the 
ligands for the more active complexes (3 and 5) involved the use of the strong base 
lithium diisopropylamide (LDA) to deprotonate the starting 4,4′-dimethyl-2,2′-bipyridine 
compound.
19,23
 This strong base is inconvenient to use, since it reacts violently with 
water; thus, the reaction must be performed in a specialized glassware under argon or 
nitrogen. Additionally, other properties (e.g., corrosivity and pyrophoricity) make this 
base quite difficult to use.
24
 Synthesis of the ligands for complexes 6-10 require 
fluorinated alcohols that are quite expensive. Additionally, the synthetic reaction has a 
step that produces moisture-sensitive alkoxide as an intermediate.
20,25
 Working with the 
moisture-sensitive compounds requires the additional step of drying all glassware and 
reagents before use. 
In an effort to find a more suitable replacement for current anticancer Pt 
compounds, an improved method for a two-step synthesis of a series of [Pt(II)Cl2(4,4′-
dialkoxy-2,2′-bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-
2,2′-bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6, 8) was developed. This method does 
not require the use of strong bases and gives high yields, resulting in cost-effective 
preparation of prospective antitumor drugs. Platinum complexes of these novel chemical 
structures have not, to our knowledge, been previously reported. Herein, we describe 
their synthesis and characterization by 
1
H NMR, 
13
C NMR spectroscopy, elemental 
analysis, mass spectroscopy, and differential scanning calorimetry (DSC) measurements. 
The anti-proliferative activities of these compounds against a panel of human cancer cell 
lines are described and compared to that of cisplatin—a gold standard for cancer therapy. 
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2.3 Experimental 
2.3.1 General 
All starting materials including 4,4′-dimethoxy-2,2′-bipyridine and reagents for 
the synthetic procedures were purchased from the commercial vendors (Sigma-Aldrich, 
TCI, Alfa-Aesar, or Acros) unless otherwise noted. They were of high purity and were 
used without further purification unless noted in the procedure. Minimum essential 
medium (MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsin-
EDTA, and penicillin-streptomycin were purchased from Life Technologies (Carlsbad, 
CA). The RPMI 1640 medium was purchased from ATCC (Manassas, VA) and HEPES, 
crystal violet, CDDP and dimethyl sulfoxide (DMSO) were purchased from Sigma-
Aldrich. All reagents and enzymes used for flow cytometry were of analytical grade 
qualities and were purchased from Sigma-Aldrich, unless otherwise noted. 
2.3.2 Chemical characterization instrumentation 
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or 
the indicated temperature using deuterated dimethyl sulfoxide (DMSO-d6) or chloroform 
(CDCl3) as the solvents: 
1
H NMR, 400 MHz; and 
13
C NMR, 100 MHz. Either residual 
solvent or tetramethylsilane (TMS) were used as the internal chemical shift reference. 
Thermal transitions were determined by using a TA Instruments DSC 2010 differential 
scanning calorimeter in nitrogen at heating and cooling rates of 10 °C min
-1
. The 
temperature axis of the DSC thermogram was calibrated with reference standards of high 
purity indium and tin before use. An amount of 2–3 mg of compound was used in this 
measurement. The Tonset and Tmax temperatures of a melting endotherm of a compound 
were recorded from the DSC thermogram as Mp (Tonset–Tmax). Elemental analysis was 
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determined by NuMega Resonance Labs Inc. (San Diego, CA) by using a Perkin Elmer 
PE2400-Series II with a CHNS/O analyzer. Mass analysis was also determined by 
NuMega Resonance Labs Inc. by using a Perkin Elmer PE-SCIEX API-150. 
2.3.3 Preparation of 2,2′-bipyridine-4,4′-diol 
The 2,2′-bipyridine-4,4′-diol was synthesized according to a previously published 
procedure with a slight modification of the reaction condition.
26
 Briefly, 48 wt% HBr in 
H2O (15.5 equiv.) was slowly added to a solution of 4,4′-dimethoxy-2,2′-bipyridine (1.0 
equiv.) in glacial acetic acid and the resulting mixture was heated to reflux for a period of 
72 h. The solvents were removed under vacuum resulting in the product residue that was 
dissolved in H2O. Insoluble material was removed by filtration and the pH of the filtrate 
was adjusted to neutral using NH4OH. The colourless solid product precipitated out and 
was collected by vacuum filtration. It was then washed with plenty of H2O and dried at 
80 °C in vacuo. The compound was then used without further purification in the next 
step. 
2.3.4 Preparation of 4,4′-dialkoxy-2,2′-bipyridine 
The appropriate alkyl halide (2.2 equiv.) was slowly added to a mixture of 2,2′-
bipyridine-4,4′-diol (1 equiv.) and Cs2CO3 or K2CO3 (2.2 equiv.) in DMF at ca. 60 °C. 
The suspension was heated to reflux for 48 h then allowed to cool to room temperature. 
The salt was removed by vacuum filtration and washed with DMF. Rotary evaporator 
was used to remove the solvent from the solution resulting in the solid residue that was 
washed with water and collected by vacuum filtration. Recrystallization from acetone-
H2O afforded the pure product as shiny, colourless crystals. 
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4,4′-Diethoxy-2,2′-bipyridine (L-2C). Yield: 86%, white crystals. Mp 122–124 
°C.
27’28 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 8.46 (d, 1H, J = 5.7 Hz), 7.90 
(d, 1H, J = 2.5 Hz), 6.99 (dd, 1H, J = 5.7, 2.6 Hz), 4.20 (q, 2H, J = 7.0 Hz), 1.37 (t, 3H, J 
= 7.0 Hz). 
13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 165.9, 157.3, 150.9, 111.5, 
106.8, 64.0, 14.8. ESI-MS: m/z 245.40 [M + H]
+
. 
4,4′-Dipropoxy-2,2′-bipyridine (L-3C). Yield: 93%, white crystals. Mp 97–99 
°C. 
1
H NMR (342 K, 400 MHz, DMSO-d6): δ (ppm) = 8.45 (d, 1H, J = 5.6 Hz), 7.90 (d, 
1H, J = 2.5 Hz), 6.97 (dd, 1H, J = 5.6, 2.6 Hz), 4.11 (t, 2H, J = 6.5 Hz), 1.83–1.74 (m, 
2H), 1.01 (t, 3H, J = 7.4 Hz). 
13
C NMR (302 K, 100 MHz, DMSO-d6): δ (ppm) = 165.5, 
156.8, 150.4, 110.9, 106.3, 69.1, 21.7, 10.2. Anal. Calcd for C16H20N2O2 (272.34 g mol
-
1
): C, 70.56; H, 7.40; N, 10.29%; found: C, 70.70; H, 7.80; N, 10.56%; ESI-MS: m/z 
273.30 [M + H]
+
. 
4,4′-Dibutoxy-2,2′-bipyridine (L-4C). Yield: 86%, white crystals. Mp 99–101 
°C.
29 1
H NMR (332 K, 400 MHz, DMSO-d6): δ (ppm) = 8.46 (d, 1H, J = 5.6 Hz), 7.90 (d, 
1H, J = 2.5 Hz), 6.98 (dd, 1H, J = 5.6, 2.6 Hz), 4.15 (t, 2H, J = 6.5 Hz), 1.78–1.71 (m, 
2H), 1.51–1.42 (m, 2H), 0.95 (t, 3H, J = 7.4 Hz). 13C NMR (332 K, 100 MHz, DMSO-
d6): δ (ppm) = 166.1, 157.5, 150.9, 111.4, 107.1, 68.0, 30.9, 19.0, 14.0. Anal. Calcd for 
C18H24N2O2 (300.40 g mol
-1
): C, 71.97; H, 8.05; N, 9.33%; found: C, 72.56; H, 7.81; N, 
9.45%; ESI-MS: m/z 301.30 [M + H]
+
. 
4,4′-Dipentyloxy-2,2′-bipyridine (L-5C). Yield: 78%, white crystals. Mp 85–86 
°C. 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.6 Hz), 7.95 (d, 1H, 
J = 2.5 Hz), 6.82 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.86–1.79 (m, 2H), 
1.50–1.35 (m, 4H), 0.94 (t, 3H, J = 7.1 Hz). 13C NMR (298 K, 100 MHz, CDCl3): δ 
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(ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.1, 28.6, 28.1, 22.4, 14.0. Anal. Calcd for 
C20H28N2O2 (328.45 g mol
-1
): C, 73.14; H, 8.59; N, 8.53%; found: C, 72.89; H, 8.90; N, 
8.61%; ESI-MS: m/z 329.60 [M + H]
+
. 
4,4′-Dihexyloxy-2,2′-bipyridine (L-6C). Yield: 65%, white crystals. Mp 95–96 
°C. 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.7 Hz), 7.95 (d, 1H, 
J = 2.5 Hz), 6.82 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.85–1.77 (m, 2H), 
1.51–1.44 (m, 2H), 1.39–1.30 (m, 4H), 0.91 (t, 3H, J = 7.0 Hz). 13C NMR (298 K, 100 
MHz, CDCl3): δ (ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.1, 31.5, 28.9, 25.6, 22.6, 
14.0. Anal. Calcd for C22H32N2O2 (356.50 g mol
-1
): C, 74.12; H, 9.05; N, 8.98%; found: 
C, 74.71; H, 8.83; N, 7.80%; ESI-MS: m/z 357.70 [M + H]
+
. 
4,4′-Dioctyloxy-2,2′-bipyridine (L-8C). Yield: 79%, white crystals. Mp 91–93 
°C. 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.45 (d, 1H, J = 5.7 Hz), 7.95 (d, 1H, 
J = 2.6 Hz), 6.81 (dd, 1H, J = 5.7, 2.6 Hz), 4.12 (t, 2H, J = 6.5 Hz), 1.85–1.78 (m, 2H), 
1.50–1.43 (m, 2H), 1.38–1.26 (m, 8H), 0.89 (t, 3H, J = 7.0 Hz). 13C NMR (298 K, 100 
MHz, CDCl3): δ (ppm) = 166.2, 157.9, 150.1, 111.3, 106.7, 68.0, 31.8, 29.3, 29.2, 29.0, 
26.0, 22.7, 14.1. Anal. Calcd for C26H40N2O2 (412.61 g mol
-1
): C, 75.68; H, 9.77; N, 
6.79%; found: C, 75.63; H, 10.12; N, 6.90%; ESI-MS: m/z 413.9 [M + H]
+
. 
2.3.5 Preparation of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes 
The salt K2[PtCl4] (1.2 equiv.) was dissolved in 1–2 mL of H2O and then added to 
a solution of 4,4′-dialkoxy-2,2′-bipyridine (1.0 equiv.) in acetone. The mixture was 
heated to reflux for 24 h. The product (yellow solid) precipitated out either in hot 
condition or upon cooling. Water was added to ensure the complete precipitation of the 
product. The crude product was separated by vacuum filtration. The pure product was 
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obtained by first washing with cold water and then hot hexane, unless otherwise noted. 
[PtCl2(4,4′-dimethoxy-2,2′-bipyridine)] (Pt-1C). Yield: 92%, bright yellow 
powder (by washing with hot methanol). Mp 311–316 °C. 1H NMR (298 K, 400 MHz, 
DMSO-d6): δ (ppm) = 9.13 (d, 1H, J =6.8 Hz), 8.19 (d, 1H, J =2.8 Hz), 7.40 (dd, 1H, J = 
6.9, 2.8 Hz), 4.05 (s, 3H). 
13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 168.2, 
158.4, 149.5, 113.2, 111.1, 57.6. Anal. Calcd for C12H12Cl2N2O2Pt (482.23 g mol
-1
): C, 
29.89; H, 2.51; N, 5.81%; found: C, 30.04; H, 2.75; N, 5.77%. 
[PtCl2(4,4′-diethoxy-2,2′-bipyridine)] (Pt-2C). Yield: 97%, bright yellow 
powder (by washing with hot acetone). Mp 318–322 °C. 1H NMR (332 K, 400 MHz, 
DMSO-d6): δ (ppm) = 9.15 (d, 1H, J = 6.8 Hz), 8.14 (d, 1H, J = 2.8 Hz), 7.35 (dd, 1H, J 
= 6.8, 2.7 Hz), 4.36 (q, 2H, J = 7.0 Hz), 1.41 (t, 3H, J = 7.0 Hz). 
13
C NMR (332 K, 100 
MHz, DMSO-d6): δ (ppm) = 167.5, 158.6, 149.6, 113.4, 111.3, 66.1, 14.5. Anal. Calcd 
for C14H16Cl2N2O2Pt (510.28 g mol
-1
): C, 32.95; H, 3.16; N, 5.49%; found: C, 33.30; H, 
2.84; N, 5.80%; ESI-MS: m/z 548.80 [M + K]
+
. 
[PtCl2(4,4′-dipropoxy-2,2′-bipyridine)] (Pt-3C). Yield: 95%, bright yellow 
powder. Mp 269–272 °C. 1H NMR (342 K, 400 MHz, DMSO-d6): δ (ppm) = 9.15 (d, 1H, 
J = 6.8 Hz), 8.13 (d, 1H, J = 2.8 Hz), 7.34 (dd, 1H, J = 6.8, 2.8 Hz), 4.27 (t, 2H, J = 6.5 
Hz), 1.87–1.78 (m, 2H), 1.03 (t, 3H, J = 7.4 Hz). 13C NMR (302 K, 100 MHz, DMSO-
d6): δ (ppm) = 167.7, 158.5, 149.6, 113.4, 111.3, 71.6, 22.0, 10.5. Anal. Calcd for 
C16H20Cl2N2O2Pt (538.33 g mol
-1
): C, 35.70; H, 3.74; N, 5.20%; found: C, 35.41; H, 
3.89; N, 5.27%; ESI-MS: m/z 560.20 [M + Na]
+
. 
[PtCl2(4,4′-dibutoxy-2,2′-bipyridine)] (Pt-4C). Yield: 93%, bright yellow 
powder. Mp 229–230 °C. 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.13 (d, 1H, 
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J = 6.9 Hz), 8.20 (d, 1H, J = 2.8 Hz), 7.40 (dd, 1H, J = 6.9, 2.8 Hz), 4.30 (t, 2H, J = 6.5 
Hz), 1.83–1.76 (m, 2H), 1.53–1.44 (m, 2H), 0.97 (t, 3H, J = 7.3 Hz). 13C NMR (298 K, 
100 MHz, DMSO-d6): δ (ppm) = 167.6, 158.5, 149.5, 113.4, 111.3, 69.9, 30.6, 19.0, 14.0. 
Anal. Calcd for C18H24Cl2N2O2Pt (566.39 g mol
-1
): C, 38.17; H, 4.27; N, 4.95%; found: 
C, 38.18; H, 4.61; N, 4.99%; ESI-MS: m/z 588.40 [M + Na]
+
. 
[PtCl2(4,4′-dipentoxy-2,2′-bipyridine)] (Pt-5C). Yield: 92%, bright yellow 
powder. Mp 173–175 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.81 (d, 1H, J = 
6.8 Hz), 7.47 (d, 1H, J = 2.7 Hz), 6.73 (dd, 1H, J = 6.8, 2.7 Hz), 4.29 (t, 2H, J = 6.4 Hz), 
1.92–1.85 (m, 2H), 1.54–1.38 (m, 4H), 0.97 (t, 3H, J = 7.2 Hz). 13C NMR (298 K, 100 
MHz, CDCl3): δ (ppm) = 167.0, 158.0, 148.9, 112.7, 110.2, 70.1, 28.4, 27.9, 22.4, 14.0. 
Anal. Calcd for C20H28Cl2N2O2Pt (594.44 g mol
-1
): C, 40.41; H, 4.75; N, 4.71%; found: 
C, 40.46; H, 5.00; N, 4.58%; ESI-MS: m/z 616.80 [M + Na]+. 
[PtCl2(4,4′-dihexyloxy-2,2′-bipyridine)] (Pt-6C). Yield: 61%, bright yellow 
powder. Mp 176–179 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.78 (d, 1H, J = 
6.8 Hz), 7.47 (d, 1H, J = 2.7 Hz), 6.71 (dd, 1H, J = 6.8, 2.7 Hz), 4.29 (t, 2H, J = 6.4 Hz), 
1.91–1.84 (m, 2H), 1.56–1.48 (m, 2H), 1.41–1.33 (m, 4H), 0.93 (t, 3H, J = 7.0 Hz). 13C 
NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 167.0, 158.0, 148.8, 112.7, 110.2, 70.2, 31.5, 
28.7, 25.5, 22.6, 14.1. Anal. Calcd for C22H32Cl2N2O2Pt (622.49 g mol
-1
): C, 42.45; H, 
5.18; N, 4.50%; found: C, 42.53; H, 5.40; N, 4.68%; ESI-MS: m/z 644.40 [M + Na]
+
. 
[PtCl2(4,4′-dioctyloxy-2,2′-bipyridine)] (Pt-8C). Yield: 61%, bright yellow 
powder (recrystallized from CHCl3-CH3OH). Mp 169–172 °C. 
1
H NMR (298 K, 400 
MHz, CDCl3): δ (ppm) = 8.83 (d, 1H, J = 6.8 Hz), 7.47 (d, 1H, J = 2.8 Hz), 6.74 (dd, 1H, 
J = 6.8, 2.7 Hz), 4.30 (t, 2H, J = 6.4 Hz), 1.92–1.85 (m, 2H), 1.56–1.48 (m, 2H), 1.41–
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1.28 (m, 8H), 0.91 (t, 3H, J = 7.0 Hz). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 
167.1, 158.0, 148.9, 112.7, 110.2, 70.2, 31.8, 29.3, 29.2, 28.8, 25.9, 22.7, 14.1. Anal. 
Calcd for C26H40Cl2N2O2Pt (678.60 g mol
-1
): C, 46.02; H, 5.94; N, 4.13%; found: C, 
46.26; H, 6.04; N, 4.29%; ESI-MS: m/z 701.20 [M + Na]
+
. 
2.3.6 Cell culture 
Human cancer cell lines A549 (lung adenocarcinoma), DU145 (prostate 
carcinoma), MCF-7 (breast adenocarcinoma), and MDA-MB-435 (melanoma) were 
obtained from American Culture Type Collection (ATCC). The A549, MCF-7, and 
MDA-MB-435 cells were grown in MEM supplemented with 10% FBS, 25 mM HEPES 
buffer (pH 7.4), penicillin (100 U mL
-1
) and streptomycin (100 µg mL
-1
). The DU145 cell 
line was grown in RPMI 1640 supplemented with 10% FBS, 25 mM HEPES buffer (pH 
7.4), penicillin (100 U mL
-1
) and streptomycin (100 µg mL
-1
). All cell lines were 
maintained at 37 °C in a humidified, 5% CO2 atmosphere. 
2.3.7 Preparation of stock solutions 
CDDP stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 
5% glucose, ligands and synthesized Pt-complexes were dissolved in DMSO. 
2.3.8 Cell viability assay 
Cells were cultured at a density of 2 x 10
3
 cells per well in flat bottomed 96-well 
plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50% 
confluence. The cells were then treated with solvent or the appropriate drugs for 1 h, 
washed thrice with 100 µL PBS, and incubated in 100 µL of fresh medium.  After 2 d, 
the medium was replaced with 120 µL of medium containing CellTiter 96® Aqueous One 
Solution Reagent (MTS reagent) (Promega, Madison, WI). After 4 h in culture the cell 
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viability was determined by measuring the absorbance at 490 nm using a Tecan Infinite 
M1000 microplate reader. The 48 h treatment was done in a similar method, except the 
cells were not washed after treatment and the MTS reagent was immediately added. 
Viability of treated groups was calculated as a percent of control and graphed with 
GraphPad Prism. 
2.3.9 Flow cytometry 
2.3.9.1 Propidium iodide (PI) staining 
 Cells (~50% confluent) were incubated at 37 °C in a humidified, 5% CO2 
atmosphere for 1 h with the indicated concentration of Pt-4C. After 1 h, cells were 
washed with 5 mL PBS and fresh medium added. Cells were incubated at 37 °C in a 
humidified, 5% CO2 atmosphere for 12, 24, and 48 h, at which point cells were harvested, 
counted and centrifuged at 500 x g for 5 min. Cells were then washed two times with 5 
mL PBS, fixed by resuspending in 0.1 mL PBS and 1 mL of cold 95% ethanol with 
gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis, fixed cells 
were washed once with 1-2 mL PBS and centrifuged at 500 × g for 5 minutes. Cells were 
resuspended in 100 µL of 1.0% Triton X-100 buffer solution. The RNAse solution (100 
µL of a 1.0 mg mL
-1
) was added and allowed to stand at room temperature for 10-15 min. 
While in the dark, 200 µL of a 100 µg mL
-1
 PI stain was added to make a final 
concentration of 50 µg mL
-1
 and gently vortexed. Cell mixture was incubated at room 
temperature for 30 min. Cytometry acquisition was done on Becton Dickinson FACS 
Calibur with the argon laser set at 488 nm on the linear Flow Channel 2 (FL-2) with 
Doublet Discriminatory Module (DDM) and threshold set on FL-2. 
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2.3.9.2 Annexin V-FITC/PI staining 
  Cells (40-50% confluent) were incubated at 37 °C in a humidified, 5% CO2 
atmosphere for 1 h with the indicated concentration of Pt-4C. After 1 h, cells were 
washed with 5 mL PBS and fresh medium was added. Cells were incubated at 37 °C in a 
humidified, 5% CO2 atmosphere for 12, 24, and 48 h, at which point cells were harvested 
and counted. Next, the cells were centrifuged at 500 × g for 5 min and washed once with 
5 mL Ca
2+
 and Mg
2+
 free PBS. Pellets were then washed in 2.0 mL 1X Annexin-V 
Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g for 5 min. The 
pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San Jose, CA) and 
incubated in the dark for 15 min. Just before acquisition, the volume of cells-conjugate 
mixture was adjusted by addition of 1X Annexin-V binding buffer.  Acquisition to 
discriminate between apoptotic and necrotic cells was done by staining the cell-conjugate 
mixture with 10 µL of PI (50 µg mL
-1
) solution (BD Bioscience, San Jose, CA). 
Acquisitions were done on FACS Calibur Cytometer on the FL1 (Annexin) and FL3 (PI) 
channels with threshold and Duplet Discriminating Module (DDM) set at FL1. The level 
of shift in events distribution in the Annexin-V only and Annexin-V-PI populations in 
comparison to control is indicative of degree of effectiveness of the treatment agents. A 
quantitative measure of these event shifts was accomplished by gating. 
2.3.10 Fluorescence microscopy 
A number of 5000 or 10 000 cells per well were seeded in a 4 well chamber slide 
with a final volume of 0.5 mL. Cells were incubated at 37 °C for ~72 h and then treated 
with EC50 concentration of Pt-4C for 1 h at 37 °C. Cells were washed twice with 0.5 mL 
PBS and fresh medium (0.5 mL) was added. Cells were incubated at 37 °C for 2 h. While 
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in the dark, medium was removed, cells were washed with 0.5 mL PBS, and then 0.5 mL 
of 2 µg mL
-1
 Hoechst 33342 and 10 µg mL
-1
 PI stain (in PBS) was added for a final 
concentration of 1 µg mL
-1 
Hoechst 33342 and 5 µg mL
-1
 PI. Cells were incubated for 15 
min at room temperature. Images were acquired within 5 min with a Nikon Eclipse 
microscope, model TE2000-U. Three random areas on each slide were imaged for bright 
field, cells stained with Hoechst, and cells stained with PI (9 images were obtained for 
each slide: 3 for bright field, 3 for Hoechst staining, and 3 for PI staining). 
2.3.11 DNA laddering 
Cells (~50% confluent) were treated with 10-35 µM Pt-4C for 1 h. 24 h post 
treatment, cells were collected, washed with PBS, and the pellet resuspended in 500 µL 
of lysis buffer (100 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 0.5% Triton X-100, 
200 mM NaCl, 100 µg mL
-1
 proteinase K). After 2 h of incubation at 56 °C, 500 µL of 2-
propanol was added, mixed by inversion, and DNA was precipitated overnight at -20 °C. 
The DNA was pelleted by centrifugation at 16 000 × g for 15 min at 4 °C. The pellet was 
washed once with 70% ethanol and air dried by inverting the tube on a tissue for 10 min. 
The DNA was dissolved in 20 µL of TE Buffer (10 mM Tris, 1 mM EDTA) containing 
0.2 mg mL
-1
 RNAse A and incubated at 37 °C for 1 h. The DNA concentration was 
determined with the NanoDrop ND-1000 Spectrophotometer and 2 µg of DNA was 
analyzed on a 2% agarose gel in TBE buffer (2 mM EDTA, pH 8.0; 89 mM Tris; 89 mM 
boric acid). The gel was stained with 1 µg mL
-1 
ethidium bromide for 30 min, rinsed with 
water, and exposed to UV light. 
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2.3.12 Statistical analysis 
GraphPad Prism 4 was used to graph viability curves. ModFit version 3.0 was 
used for the flow cytometry analysis. Microsoft Office Excel was used to run Student’s t-
test; values with p < 0.05 were considered significant. Student’s t-tests were used to 
verify significant differences among the EC50 values. 
2.4 Results and discussion 
2.4.1 Synthesis and characterization 
Except for 4,4′-dimethoxy-2,2′-bipyridine (henceforth referred to as L-1C), which 
was purchased from a commercial vendor, all ligands were synthesized by reacting a 
respective primary alkyl halide with a mixture of 2,2′-bipyridine-4,4′-diol and Cs2CO3 or 
K2CO3 in DMF on heating to reflux for 48 h. For the synthesis of L-2C—L-4C with high 
yields, Cs2CO3 was used instead of the usual K2CO3 because the latter base gave 
relatively low yields. However, the synthesis of L-5C, L-6C and L-8C with K2CO3 gave 
respectable yields. The platinum complexes were formed by adding an aqueous solution 
of K2[PtCl4] to a solution of the ligand in acetone and on heating to reflux for 24 h 
(Scheme 2-1). All ligands are white and produce a colourless solution when dissolved in  
 
Scheme 2 – 1. Scheme for the synthesis of Pt(II)-complexes (Pt-2C—Pt-6C, Pt-8C). 
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Figure 2 – 2. Chemical structures of CDDP and the synthesized [Pt(II)Cl2(4,4′-dialkoxy-
2,2′-bipyridine)] complexes. 
 
organic solvents; however, all the platinum complexes are yellow solids and generate a 
yellow solution when dissolved in organic solvents. Thus, the progress of the reaction 
was monitored visually by the appearance of a yellow solution or precipitate. The 
chemical structures of cisplatin and the synthesized platinum complexes are shown in 
Fig. 2-2.  L-2C
27,28 
and L-4C
29
 were previously synthesized using an alternative method 
with longer synthetic steps and produces a dinitro intermediate that is potentially 
explosive. The synthesis and the in vitro cytotoxicity of the platinum complex Pt-1C 
have been reported previously.
19
 The synthesis of Pt-2C has also been previously 
reported for its electrochemical and electronic properties;
30
 however, no literature on 
activity against cancer cells is available to date. The Pt-complexes, Pt-3C—Pt-6C and 
Pt-8C, have not been reported in the literature.  
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Figure 2 – 3. The aromatic region of ligands and platinum(II)-complexes from 1H NMR 
spectra. Spectra were recorded in DMSO-d6 and CDCl3 at the temperatures indicated in 
the Experimental section (* solvent peak). 
All of the compounds were characterized by 
1
H and 
13
C NMR spectroscopy, 
elemental analysis, mass spectrometry, and DSC measurements. Elemental and mass 
spectrometry analyses of the complexes were in excellent agreement (within 0.5% for 
elemental analyses and 5 ppm for mass spectrometry) with the expected values; thus, 
validating the molecular formulae of these compounds. The 
1
H and 
13
C NMR spectra of 
the compounds L-2C—L-4C, and Pt-2C—Pt-4C were recorded in DMSO-d6, whereas 
L-2C
Pt-2C
Pt-3C
L-3C
L-4C
9.5 9.0 8.5 8.0 7.5 7.0 6.5
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those of the compounds L-5C—L-8C, and Pt-5C—Pt-8C were recorded in CDCl3. The 
spectra of all of the compounds displayed the expected proton and carbon resonances. 
The 
1
H NMR chemical shifts of the aromatic region of the ligands and platinum 
complexes are depicted in Fig. 2-3 and summarized in Table 2-1. The chemical shifts of 
the protons at the 6,6′ positions are the most downfield, protons at the 5,5′ positions are 
the most upfield and protons at the 3,3′ positions are in between. When 4,4′-dialkoxy-
2,2′-bipyridine was coordinated to platinum(II), all aromatic proton peaks of the 
complexes in DMSO-d6 are shifted downfield compared to the ligand while only the peak 
corresponding to the protons at the 6,6′ positions of complexes recorded in CDCl3 are 
shifted downfield, and peaks corresponding to the 5,5′ and 3,3′ positions are shifted 
upfield. Similarly, the carbon signals at the 5,5′ positions, those of 3,3′ position and 
methylene carbon signal next to the oxygen in both the deuterated solvents were shifted 
downfield to varying degrees, but the carbon signals at 6,6′ positions in these solvents 
were slightly shifted to upfield (Fig. 2S-1, Appendix 1). The difference in the direction of 
the chemical shifts is due to differences in the interaction of the compounds with the 
organic solvents of varying polarity used (Table 2-1). 
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Table 2 – 1. Chemical shifts (ppm) in the aromatic region of ligands and platinum(II)Cl2 
complexes from 
1
H NMR spectra recorded in DMSO-d6 and CDCl3 at the temperatures 
indicated in the Experimental section 
Compound Solvent H-6,6′ (ppm) H-5,5′ (ppm) H-3,3′ (ppm) 
L-2C (Pt-2C) DMSO-d6 8.46 (9.15) 6.99 (7.35) 7.90 (8.14) 
L-3C (Pt-3C) DMSO-d6 8.45 (9.15) 6.97 (7.34) 7.90 (8.13) 
L-4C (Pt-4C) DMSO-d6 8.46 (9.13) 6.98 (7.40) 7.90 (8.20) 
L-5C (Pt-5C) CDCl3 8.45 (8.81) 6.82 (6.73) 7.95 (7.47) 
L-6C (Pt-6C) CDCl3 8.45 (8.78) 6.82 (6.71) 7.95 (7.47) 
L-8C (Pt-8C) CDCl3 8.45 (8.83) 6.81 (6.74) 7.95 (7.47) 
 
Thermal transitions of the synthesized compounds were determined by DSC 
measurements. Each of the DSC thermograms for ligands L-2C—L-8C displayed a 
single endotherm in the first heating cycle and a single exotherm in the first cooling cycle 
corresponding to its melting and crystallization transitions, respectively. 
Correspondingly, there were a melting endotherm in the second heating cycle and a 
crystallization exotherm in the second cooling cycle. L-2C had the highest melting at 124 
°C and L-5C had the lowest at 86 °C. L-3C, L-4C, L-6C, and L-8C had melting points 
ranging between 93-100 °C with no apparent trends. Platinum complexes had varying 
DSC thermograms. The DSC thermograms of Pt(II) complexes produced rather complex 
thermal properties. For example, Pt-2C and Pt-3C showed a single endotherm in the first 
heating cycle (Fig. 2S-2, Appendix 1), but no exotherm in the first cooling cycle. 
Correspondingly, there was no melting endotherm in the second heating cycle and no 
exotherm in the second cooling cycle. These complexes once melted could not crystallize 
and, therefore, formed amorphous phases. Pt-4C showed a sharp single endotherm 
(melting) in the first heating cycle, but showed a broad, exotherm in the first cooling 
cycle. Correspondingly, it showed a slightly broad endotherm at a lower temperature 
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when compared with that in the first heating cycle, but showed a broad exotherm in the 
second cooling cycle (not shown). Pt-5C showed two sharp endotherms in the first 
heating cycle and two broad exotherms in the first cooling cycle. Correspondingly, it 
showed two endotherms in the second heating cycle and two broad exotherms in the 
second cooling cycle. The first low- temperature endotherm was related to the crystal-to-
crystal transition and the high-temperature one was related to its melting transition (Fig. 
2S-2, Appendix 1). Pt-6C showed three endotherms in the first heating cycle, but no 
exotherms in the first cooling cycle. During the second heating cycle, once it traversed 
through the glass transition temperature, it showed a cold crystallization exotherm and 
three endotherms. Again, there were no exotherms in the second cooling cycle. The two 
low-temperature endotherms were related to the crystal-to-crystal transitions and the 
highest-temperature endotherm was related to its melting transition. The observed 
crystal-crystal transitions of these two Pt(II)-complexes are in excellent agreement with 
those of other Pt(II)-complexes.
31
 Pt-8C showed a sharp melting endotherm in the first 
heating cycle and a sharp exotherm in the first cooling cycle. Correspondingly, it showed 
a sharp melting transition in the second heating cycle and a sharp crystallization 
exotherm in the second cooling cycle (Fig. 2S-2, Appendix 1). It was found that the 
melting transitions of the Pt(II)-complexes were much higher than those of the ligands 
and decrease as the carbon number of the alkoxy group increases in the series examined. 
2.4.2 Biological properties 
2.4.2.1 In vitro cytotoxic activity 
Lung cancer is one of the leading causes of cancer death not only in the U.S., but 
also worldwide; thus, the activity of the ligands and Pt compounds were first tested in the  
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Figure 2 – 4. Cytotoxic activity of the synthesized ligands and Pt(II)Cl2 complexes vs. 
CDDP and carboplatin against A549 human lung cancer cells.  Cells were treated with 
the ligands, CDDP, or the platinum analogs at various concentrations for (A, B) 1 h or (C, 
D) 48 h and the viability was determined using the MTS assay. Data points represent 
mean ± SD of at least three independent experiments done in quadruplicates. 
 
 
human lung cancer cell line A549 and compared to cisplatin and carboplatin using an 
MTS colorimetric assay to determine cell viability. For a 1 h treatment, L-1C—L-5C had 
little to no effect on A549 cell viability (Fig. 2-4 A). Carboplatin also did not have any 
effect on the cells when treated for 1 h (Fig. 2-4 B). Cisplatin caused a concentration-
dependent decreased in A549 cell viability with a reduction of about 50% at 1000 µM. 
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Similar to carboplatin, the analogues containing 1 (Pt-1C) or 2 (Pt-2C) carbon chain 
length had no effect on the cells. When the carbon chain length was increased to three 
(Pt-3C), the cell viability decreased with increasing concentrations. The analogues 
containing four (Pt-4C) and five (Pt-5C) carbon chain lengths had similar activities and 
caused further decrease in cell viability compared to the Pt-3C. When the chain length 
was increased to 6 carbons (Pt-6C), the activity was reversed compared to Pt-4C and Pt-
5C and was similar to Pt-3C (Fig. 2-4 B). A549 cells remained unaffected by L-1C, L-
2C, and L-4C when the treatment was extended to 48 h; however, L-3C and L-5C 
decreased cell viability by 40% and 60%, respectively, at 100 µM (Fig. 2-4 C). The Pt-
1C analogue was still without effect when treatment was extended to 48 h; however, Pt-
2C was very effective and caused almost complete reduction of cell viability at 100 µM 
(Fig. 2-4 D). The activities of Pt-4C and Pt-5C were comparable to the 1 h treatment. 
Interestingly, the activities of Pt-3C and Pt-6C were now increased to levels similar to 
Pt-4C and Pt-5C. The activities of CDDP and carboplatin were also increased in the 48 h 
treatment compared to the 1 h treatment; however, both drugs were still less effective 
than Pt-2C—Pt-6C. The effective concentrations that result in 50% cell viability (EC50) 
for the complexes are given in Table 2-2. As shown, the EC50 of CDDP and carboplatin 
are much higher than Pt-2C—Pt-6C. L-6C, L-8C, and Pt-8C were not tested due to poor 
solubility in common solvents used for in vitro testing. 
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Table 2 – 2 Effective concentrations that gives 50% cell death (EC50) determined from 
A549 MTS assay data of at least three independent experiments 
 Compound EC50 (µM) for 1 h  EC50 (µM) for 48 h 
 CDDP 1000 ± 0 500 ± 100 
  Carboplatin > 1000 300 ± 30
a
 
 Pt-1C >100 >100 
  Pt-2C >100 66 ± 7
 a
 
 Pt-3C 48 ± 3
 a
 17 ± 1
 a
 
  Pt-4C 17 ± 1
 a
 15.4 ± 0.5
 a
 
 Pt-5C 18 ± 1
 a
 16.5 ± 0.5
 a
 
 Pt-6C 66 ± 16
 a
 19.1 ± 0.8
 a
 
 Pt-8C ND ND 
Data represent mean ± SD from three independent experiments done in quadruplicates.      
a
 P<0.05 compared to CDDP. 
 
 
The MTS cell viability results demonstrated a concentration and time-dependent 
effect of complexes of CDDP, carboplatin, and Pt-2C—Pt-6C against human A549 lung 
cancer cells. It is apparent that most of these complexes have higher activity than 
cisplatin and carboplatin. The trend of the activity of the complexes at 1 h exposure in 
A549 cells is Pt-4C ≈ Pt-5C > Pt-3C ≈ Pt-6C > CDDP > Pt-2C ≈ carboplatin ≈ Pt-1C. 
The activity of the complexes increases as the carbon number on the alkoxy group 
increases, which peaked with the complexes having four (Pt-4C) and five carbon chains 
(Pt-5C) and then decreased with the complex having a six carbon chain (Pt-6C). It is 
interesting to note that a difference of one carbon number caused the activity to increase 
or decrease by 3 or 4 times. This may be attributed to changes in molecular weight and 
lipophilicity, which could affect cellular uptake of the compounds.
32,33 
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Figure 2 – 5. Cytotoxicity of various human cancer cells (A) DU145, (B) MCF-7, and 
(C) MDA-MB-435 treated for 1 h with CDDP (■) or Pt-4C (♦). Data points represent 
mean ± SD of at least two independent experiments done in quadruplicates. 
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Based on the results of A549 cells, one of the highly effective compounds, Pt-4C, 
was used for further testing. To determine if Pt-4C has a broad spectrum of activity 
against other types of oncogenic cells, the activity of this complex was tested against a 
prostate cancer cell line (DU145), a melanoma cell line (MDA-MB-435), and a breast 
cancer cell line (MCF-7). Similar to A549, Pt-4C also had a concentration-dependent 
effect against all cell lines tested in a 1 h treatment (Fig. 2-5). The EC50 varied slightly 
among the different cell lines (Table 2-3); the EC50 of Pt-4C was in the low micromolar 
range, whereas, the EC50 of cisplatin was 25–63 times higher depending on the cell line. 
The MDA-MB-435 cell line was the most sensitive to Pt-4C treatment, followed by 
DU145. The MCF-7 cell line had the highest EC50 and was the least sensitive to Pt-4C. 
These results indicate that this compound is much more potent compared to cisplatin and 
has a broad spectrum of activity. 
 
Table 2 – 3 EC50 (µM) values of Pt-4C determined from MTS assay data of at least two 
independent experiments done in quadruplicates 
 Cell line Cancer  type CDDP Pt-4C 
 A549 lung 1000 ± 0 17 ± 1
 a
 
 DU145 prostate 500 ± 200 8 ± 2
 a
 
 MCF-7 breast 910 ± 90 32 ± 5
 a
 
 MDA-MB-435 melanoma 110 ± 40 4 ± 1
 a
 
Data represent mean ± SD from three independent experiments done in quadruplicates.   
a
 P<0.05 
compared to CDDP. 
 
2.4.2.2 Evaluation of apoptosis 
2.4.2.2.1 Cell cycle analysis by flow cytometry.  
The MTS data indicate that these Pt-complexes induce cell death in various 
human cancer cells. There are two major forms of cell death: apoptosis and necrosis. 
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Apoptosis is a genetically-driven programmed cell death characterized by features such 
as cell shrinkage and chromatin condensation and fragmentation.
34
 Necrosis results from 
physical injuries and may result from exposure to chemotherapeutic drugs. Necrotic cells 
swell up and lyse, releasing cellular contents and cause inflammatory responses. 
Apoptosis is the main mode of cell death in cells treated with cisplatin (human ovarian 
cancer cell line A2780,
35
 human cervix carcinoma cell line HeLa,
36
 ovarian cancer cells 
OV2008
37
). We hypothesized that the Pt-4C complex would also induce apoptosis; thus, 
Pt-4C treated cells were analyzed by flow cytometry using propidium iodide (PI) and 
Annexin V/PI double staining to detect apoptotic features. 
The effect of Pt-4C on the cell cycle distribution of A549, DU145, and MCF-7 
cells was examined by flow cytometry with PI staining (Fig. 2- 6). Cells were treated for 
1 h with EC50 concentration of Pt-4C and harvested 24 and 48 h after treatment. The cells 
were fixed, stained with PI and analyzed with a flow cytometer which measures the PI 
fluorescence. In A549 (Fig. 2-6 A), Pt-4C treatment did not induce any cell cycle arrest. 
However, it caused a decrease in all stages of the cell cycle and an increase in the sub-G1 
population. The effects of Pt-4C on the cell cycle distribution of DU145 cells (Fig. 2-6 
B) and MCF-7 cells (Fig. 2-6 C) were similar to A549 cells. Both MCF-7 and DU145 had 
a higher percentage of cells in sub-G1 after 48 h compared to 24 h. 
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 Control Pt-4C 
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B 
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Figure 2 – 6. Flow cytometry with PI staining (A) A549, (B) DU145, and (C) MCF7.  
Cells were treated with EC50 Pt-4C for 1 h then harvested 24 and 48 h after treatment.  
Cells were fixed, stained with PI and analyzed with a flow cytometer.  Data are 
representative plots of three independent experiments. 
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2.4.2.2.2 Detection of membrane changes by flow cytometry 
Analysis of the PI staining of Pt-4C treated cells demonstrate that the EC50 
concentration of Pt-4C did not induce cell cycle arrest in A549, DU145, and MCF-7 
cells, but caused a time-dependent increase in the sub-G1 population. The PI fluorescence 
intensity is proportional to DNA content; the sub-G1 peak represents cells with less DNA 
content than the cells in the G1 phase and are usually described as apoptotic cells.
20
 
However, cells undergoing necrosis have membrane damage and DNA content can leak 
out causing them to have less DNA than cells in G1 phase. Thus, it is unclear if the sub-
G1 peak represents cells undergoing apoptosis or necrosis. Consequently, Annexin V/PI 
staining was used to determine apoptotic vs. necrotic cell death. 
An event that happens in early apoptosis is flipping of phosphatidylserine to the 
membrane surface which is recognized by Annexin V. The effect of Pt-4C in A549, 
DU145, and MCF-7 cells was analyzed by flow cytometry with Annexin V to detect 
early apoptosis and PI staining to detect late apoptosis or necrosis. Cells were treated 
with EC50 concentration of Pt-4C for 1 h then harvested 12, 24, and 48 h post treatment. 
Cells were stained with Annexin V and PI and analyzed with a flow cytometer. For all 
time points, A549 cells treated with Pt-4C were decreased in quadrant four (Q4) and 
increased in both quadrant two (Q2) and quadrant three (Q3) populations, indicating an 
increase in early apoptotic and late apoptotic/necrotic cells with a corresponding decrease 
in live cells (Fig. 2-7). The 24 h group had higher percentages of early apoptotic and late 
apoptotic/ necrotic cells (cells in Q2 and Q3) than the 12 h group; however, the 48 h 
group had lower percentages than 24 h. Similar to A549, DU145 cells treated with Pt-4C 
were also decreased in Q4 and increased in both Q2 and Q3 compared to control,  
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Figure 2 – 7. A549 Flow with Annexin V/PI staining. A549 cells were treated with EC50 
Pt-4C for 1 h then harvested 12, 24, and 48 h after treatment.  Cells were stained with 
Annexin V and PI and analyzed with a flow cytometer.  Q1 is PI positive representing 
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3 
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is 
Annexin V/PI negative representing live cells.  Data are representative of three 
independent experiments. 
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Figure 2 – 8. DU145 Flow with Annexin V/PI staining. Cells were treated with EC50 Pt-
4C for 1 h then harvested 12, 24, and 48 h after treatment.  Cells were stained with 
Annexin V and PI and analyzed with a flow cytometer.  Q1 is PI positive representing 
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3 
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is 
Annexin V/PI negative representing live cells.  Data are representative plots of three 
independent experiments. 
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Figure 2 – 9. MCF-7 Flow with Annexin V/PI staining. Cells were treated with EC50 Pt-
4C for 1 h then harvested 12, 24, and 48 h after treatment.  Cells were stained with 
Annexin V and PI and analyzed with a flow cytometer.  Q1 is PI positive representing 
necrotic cells, Q2 is Annexin V/PI positive representing late apoptotic/necrotic cells, Q3 
is Annexin V positive and PI negative representing early apoptotic cells, and Q4 is 
Annexin V/PI negative representing live cells.  Data are representative plots of three 
independent experiments. 
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indicating a decrease in live cells and an increased in early apoptotic and late 
apoptotic/necrotic cells (Fig. 2-8). The percentages of cells in Q2 and Q3 (early apoptotic 
and late apoptotic/necrotic cells) were higher in the 24 h group than the 12 h group and 
the 48 h group had values similar to the 24 h group. MCF-7 cells treated with Pt-4C had 
increased early apoptotic and late apoptotic/necrotic cells (Q2 and Q3) in the 12 and 24 h 
groups, but only increased early apoptotic (Q3) cells in the 48 h group (Fig. 2-9). The 
increase in early apoptotic and late apoptotic/necrotic cells (Q2 and Q3 populations) was 
accompanied by a corresponding decrease in live cells (the Q4 population). These results 
demonstrate that Pt-4C induces apoptosis in these cell lines and some necrotic responses 
were also observed. 
2.4.2.2.3 Analysis of morphological changes by fluorescence microscopy and DNA 
laddering 
 The effect of Pt-4C in A549 cells was examined further by DNA laddering and 
fluorescence microscopy. One of the features of apoptosis is cleavage of DNA into 
fragments with increments of 180–200 bp which can be detected as a DNA ladder when 
separated on an agarose gel. To observe this phenomenon, A549 cells were treated with 
10–35 µM Pt-4C for 1 h and the DNA was extracted 24 h post treatment. The DNA was 
separated on an agarose gel to detect a ladder pattern. The DNA of control cells did not 
have the typical ladder pattern of apoptotic cells, whereas, the DNA of cells treated with 
Pt-4C at concentrations ranging from 10–35 µM shows the laddering pattern (Fig. 2-10). 
For analysis of cells using fluorescence microscopy, the cells were treated with the EC50 
concentration of Pt-4C for 1 h and then stained with Hoechst (Ho) and PI. PI is  
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Figure 2 – 10. A549 apoptotic DNA laddering.  Cells were treated for 1 h with varying 
concentrations of Pt-4C and DNA was extracted 24 h post treatment. 
 
 
Figure 2 – 11.  A549 fluorescence microscopy. Cells were stained with Hoechst (Ho) and 
propidium iodide (PI) 2 h post treatment with EC50 concentration of the Pt-4C for 1 h. 
Bright fluorescence indicates positive staining. PI stains necrotic cells and Ho stains live 
and apoptotic cells, with intense bright fluorescence indicating apoptotic cells.  Images 
are representative of at least two independent experiments. 
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membrane impermeable and only stains cells with membrane damage. Ho is membrane 
permeable and can stain both live cells and cells undergoing apoptosis; cells with intense 
bright fluorescence indicate apoptotic cells. To determine the effect of Pt-4C in A549, 
the cells were treated with the EC50 concentration of Pt-4C for 1 h, and then 2 h post 
treatment the cells were stained with Ho and PI. Control cells show some positive Ho 
staining, but no positive staining (Fig. 2-11). Cells treated with Pt-4C had more Ho and 
PI positive staining than control; many Ho positive cells were also PI positive. 
Additionally, bright field (BF) images showed altered cell morphology (shrunken and 
rounding up) in Pt-4C treated cells compared to control. These results confirm that Pt-4C 
induces apoptosis in A549 cells and are consistent with the mode of cell death induced by 
other Pt(II) complexes reported in the literature.
17,19,20
 
2.4.2.3 In vivo toxicity 
Pt-4C was sent to Molecular Diagnostic Services Laboratory (San Diego, CA) for  
in vivo toxicity testing in C57BL/6 female mice. The animals were divided into three 
groups: group one had three animals and received one intraperitoneal (IP) injection of Pt-
4C at a dose of 12.5 mg kg
-1
 d
-1
; group two had three animals and received a dose of 12.5 
mg kg
-1
 d
-1
 for three days; group three had one animal and was the vehicle control. One 
animal from group two exhibited slight lethargy after the first injection, but quickly 
recovered 2 h after the injection. All animals survived during the study period of 7 d post 
injection and no abnormal observations were noted indicating that this compound is not 
toxic in an animal model. 
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2.5 Conclusions 
A series of platinum(II) complexes containing 2,2′-bipyridyl with alkoxy 
substituents of increasing carbon chain length at the 4,4′ positions were successfully 
synthesized. The direct two step procedure generally gave moderate to high yields and 
did not require expensive fluorinated reagents or the use of a potentially dangerous strong 
base. These complexes were demonstrated to have a concentration and time-dependent 
effect on various cancer cells. Furthermore, a structure-activity relationship was also 
observed. Various methods employed indicate that one of the complexes, Pt-4C, induced 
apoptosis in A549, DU145, and MCF-7 cells. It is likely that the other Pt-complexes 
synthesized also induce cell death through apoptosis due to their similar chemical 
structures. All of these exciting results demonstrate the potential utilization of our 
platinum complexes as chemotherapeutic drugs in the treatment of a broad range of 
cancers. However, further studies are needed to evaluate the prospective translation of 
these compounds into clinical use. 
Understanding the cellular effects of a drug is important when developing 
treatment strategies and predicting possible side effects. There is still much to be 
explored about the biological effects of cisplatin; however, it is known that cisplatin 
binds to DNA and forms adducts that damage the DNA and activates the apoptotic 
pathway.
1,2,38–40
 The newly synthesized Pt(II) complexes have a platinum center that is 
similar to cisplatin and may bind to DNA to cause damage in a mechanism analogous to 
cisplatin. Differences in cellular uptake and DNA binding may underlie the pronounced 
improvement of the Pt-4C cytotoxicity profile compared to cisplatin. 
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Determination of the mechanism of action requires an examination of the 
signaling events that occur. Since Pt-4C induces apoptosis in A549, DU145 and MCF-7 
cells, it is necessary to investigate the involvement of proteins in the apoptotic pathway. 
A protein that is of interest is p53, a tumor suppressor protein that is involved in many 
processes including activation of DNA repair, cell cycle arrest, and initiation of 
apoptosis.
41
 The role of p53 in CDDP treated cells varies depending on the cell line and 
duration of treatment.
42–45
 Thus, it is likely that p53 expression is affected by treatment 
with Pt-4C and the other Pt-complexes. Interestingly, we have found that Pt-4C caused a 
transient dose-dependent induction of p53 expression in A549 cells, which is currently 
under investigation in our laboratory. Additionally, mitogen-activated protein kinases 
(ERK, JNK, p38) are involved in signaling for cell survival and apoptosis.
42 
Generally, 
ERK has a role in cell proliferation and development, whereas JNK and p38 have roles in 
apoptotic signaling. These proteins have been associated with CDDP treatment; however, 
similar to p53, their roles also vary depending on the cell line and duration of 
treatment.
42,45–47
 Thus, it will be interesting to examine the roles of these proteins in 
response to treatment with Pt-4C. 
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CHAPTER 3 
CHARACTERIZATION OF THE DNA BINDING AND MAPK PROTEIN 
ACTIVATION ACTIVITIES OF PT(II) COMPLEXES CONTAINING 4,4′-
DIALKOXY-2,2′-BIPYRIDINE LIGANDS 
 
3.1 Abstract 
 The study of the anti-proliferative activities of our previously reported novel 
platinum(II) complexes containing 4,4′-dialkoxy-2,2′-bipyridine ligands were expanded 
to various lung, prostate, and breast cancer cell lines to examine differential responses to 
these potential cancer drugs. The EC50 values obtained from MTS assays demonstrate a 
generally improved cytotoxicity profile compared to cisplatin and carboplatin in all cell 
lines.  One of the complexes, Pt(II)-4C, was studied further for its ability to interact with 
DNA and activation of important cell signaling pathways such as p53 and mitogen-
activated protein kinase (MAPK) cascades. 
UV-Vis analysis with calf thymus and gel electrophoresis with plasmid pBR322 
DNA indicated that Pt(II)-4C can bind to DNA and cause unwinding of circular DNA. 
Moreover, results from inductively coupled plasma-atomic emission spectroscopy (ICP-
AES) suggested that Pt(II)-4C can be taken up by A549 lung cancer cells and bind to 
intracellular DNA. 
Measurement of protein expression by immunofluorescence microscopy, flow 
cytometric immunofluorescence, and western blotting show increased p53 expression in 
Pt(II)-4C treated A459 cells and co-treatment with the p53 inhibitor, PFTα, resulted in 
increased cell viability compared to Pt(II)-4C treatment alone.  MAPK (JNK, ERK, and 
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p38) activation was also observed in A549 and DU145 (human prostate cancer) cells 
treated with Pt(II)-4C.  Activation of MAPK was accompanied by phosphorylation of 
histone H2AX (γH2AX). Treatment of A549 and DU145 cells with Pt(II)-4C in the 
presence of MAPK inhibitors resulted in reduced levels of γH2AX.  Furthermore, 
treatment of these two cell lines with Pt(II)-4C in the presence of the JNK and p38 
inhibitors resulted in increased cell viability compared to Pt(II)-4C treatment alone.  
Treatment of A549 with Pt(II)-4C in the presence of the ERK inhibitor resulted in 
decreased cell viability compared to Pt(II)-4C treatment alone, but no effect was 
observed in DU145 cells. These results indicate that JNK and p38 may be involved in cell 
death signaling in response to Pt(II)-4C treatment. 
3.2 Introduction 
 A chemotherapeutic drug that is commonly prescribed for the treatment of many 
cancers is cisplatin (CDDP), a square-planar Pt(II) compound.  Together with its two 
analogues, carboplatin and oxaliplatin, platinum drugs constitute about 50% of all cancer 
chemotherapeutic regimens.  However, treatment with these platinum drugs is 
accompanied by severe side effects such as nephrotoxicity, neuropathy, ototoxicity, and 
myelosuppression. Additionally, other drawbacks such as intrinsic or acquired resistance 
and limited activity against some major types of cancer have impeded the clinical utility 
of these drugs.
1–5
 Motivated to overcome these drawbacks, we have previously reported 
on the synthesis of a series of platinum(II) [Pt(II)] complexes containing 4,4′-dialkoxy-
2,2′-bipyridine ligands (with the dialkoxy having one to six carbons) and their anti-
proliferative activity against the A549 lung cancer cell line (Chapter 2).
6
 The improved 
anti-proliferative activity of these complexes compared to cisplatin warrant further 
59 
 
investigation of these compounds. Since only one of the complexes was tested in other 
cancer cells, it is necessary to expand the study of all the complexes in various cancer cell 
types to have a better indication of their effectiveness in different types of cancers. 
Furthermore, an understanding of the signaling pathways activated by these platinum 
complexes will provide the foundation necessary for developing strategies to utilize these 
compounds for the treatment of cancer.  Thus, we seek to determine the signaling 
pathways activated within cancer cells in response to treatment by these novel platinum 
complexes.   
The cytotoxic effect of cisplatin is mainly due to the formation of DNA adducts 
even though only a small percentage (5–10%) of the intracellular cisplatin concentration 
is found in the nucleus.
7
 Cisplatin-induced DNA damage elicits various cellular responses 
such as cell cycle arrest, activation of repair mechanisms, stress responses, and cell death 
pathways. The two pathways that are of interest are the p53 and the mitogen-activated 
protein kinase (MAPK) cascades. 
 The p53 protein is a tumor suppressor that is involved in many processes 
including activation of DNA repair, cell cycle arrest, and initiation of apoptosis.
8
 During 
normal cellular conditions, p53 has a short half-life and is kept at a low level by the 
Mdm2 ubiquitin ligase. However, the interaction of p53 with Mdm2 decreases when 
stimulated by stress signals, which allows for the accumulation and phosphorylation of 
p53.
8,9
 Activated p53 can then interact with other proteins such as p21 (cell cycle protein) 
or Bax (apoptotic protein)
9
 to culminate in various cellular outcomes such as cell survival 
and death.  
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Loss of p53 function can occur due to mutations in about 50% of all cancers.
10
 
The drug resistance of many cancers has been attributed to having mutant p53 and the 
differential p53 status has been taken advantage of for the development of treatment 
methods that are more specific by targeting p53.
11
 Current data from the literature 
indicate that the role of p53 in cisplatin treated cells varies depending on the cell line and 
duration of treatment. In some reports, cisplatin-induced apoptosis is described as 
requiring functional p53; however, the opposite is reported by some authors indicating 
that cells with wild-type p53 are resistant to cisplatin treatment and sensitivity is achieved 
by inhibition of its expression.
7,9
 
 The MAPKs are proteins that are activated by various stimuli to regulate cellular 
processes such as proliferation, differentiation, movement, survival, and programmed cell 
death.
7,9
 Three major MAPK members are extracellular signal-regulated kinases (ERK), 
c-Jun N-terminal kinases (JNK), and p38 kinases. Generally, ERK has a role in cell 
proliferation and development; however, JNK and p38 have roles in apoptotic signaling, 
inflammatory responses, and protective responses.
7
 These proteins are activated through 
phosphorylation by upstream kinases and, in turn, phosphorylate downstream targets to 
activate them.  ERK, JNK, and p38 have all been demonstrated to be activated by 
cisplatin; however, similar to p53, their roles also vary between different cell lines and 
duration of treatment. In some studies, in accordance with their roles, ERK activation 
protects cells from apoptosis, whereas, activation of JNK and p38 leads to apoptotic cell 
death; on the other hand, some studies demonstrated the reverse.
7,9,12,13
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Herein, the anti-proliferative activity of these complexes in various lung, prostate, 
and breast cancer cell lines are described.  Additionally, Pt(II)-4C interaction with DNA 
and its effect on p53 and MAPK signaling are investigated. 
3.3 Experimental 
3.3.1 General 
All general chemicals and reagents were purchased from common commercial 
vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless otherwise noted. Pt(II) 
complexes were synthesized as described in Chapter 2. Minimum essential medium 
(MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsin-EDTA, and 
penicillin-streptomycin were purchased from Life Technologies (Carlsbad, CA). The 
RPMI 1640 medium was purchased from ATCC (Manassas, VA). Cisplatin, carboplatin, 
HEPES, albumin from bovine serum (BSA), Tris-HCl, Trizma Base, and dimethyl 
sulfoxide (DMSO) were purchased from Sigma-Aldrich.  
3.3.2 Cell culture 
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1), 
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained 
from American Culture Type Collection (ATCC). The A549, HCC38, MCF-7, MDA-
MB-231, SK-BR-3, T-47D, and ZR-75-1 cells were grown in MEM supplemented with 
10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) and streptomycin 
(100 µg mL
-1
). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640 
supplemented with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) 
and streptomycin (100 µg mL
-1
). All cell lines were maintained at 37 °C in a humidified, 
5% CO2 atmosphere. 
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3.3.3 Cell viability assay 
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96-
well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50% 
confluence. The cells were then treated with solvent or the appropriate drugs (CDDP 
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose, 
synthesized Pt(II) complexes were dissolved in DMSO) for 1 h, washed three times with 
100 µL PBS, and incubated in 100 µL of fresh medium.  After 2 d, the medium was 
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent 
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and 
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan 
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method, 
except the cells were not washed after treatment and the MTS reagent was immediately 
added. Viability of treated groups was calculated as a percent of control and graphed with 
GraphPad Prism. 
The experiment was also done similarly for studies with p53 or MAPK inhibitors. 
The cells were pre-treated with pifithrin-α (PFTα) (Sigma-Aldrich #P4359) SB202190 
(p38 inhibitor, Sigma-Aldrich #S7067), PD-098,059 (ERK inhibitor, Sigma-Aldrich 
#P215), or SP600125 (JNK inhibitor, Sigma-Aldrich #S5567) for the indicated time, 
followed by co-treatment with the indicated concentrations of Pt(II)-4C, and post-
treatment with the inhibitors.  
3.3.4 UV-Vis spectroscopy 
The ability of Pt(II)-4C to bind DNA was determined analyzing its interaction 
with calf thymus DNA (CT-DNA) with UV-Vis spectroscopy.  CT-DNA was purchased 
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from Life Technologies (#15633-019, 10 mg/mL in Dnase, Rnase free water) and the 
DNA concentration per nucleotide was determined from the UV absorbance at 260 nm 
using the molar extinction coefficient ε260 = 6600 M
−1
cm
−1
.  CT-DNA (100 µM) was 
incubated with 0–140 µM of Pt(II)-4C (stock solution was dissolved in DMSO) in 10 
mM Tris-HCl (pH 7.2) containing 10% DMSO for 1 or 24 h at 37 °C and the absorbance 
was measured with the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific). Pt(II)-4C solutions of each concentration in the same buffer were used as 
blanks to eliminate the absorption of the Pt(II)-4C by itself. The study was also done by 
using a constant concentration of Pt(II)-4C (100 µM) and increasing the concentration of 
CT-DNA (0–100 µM).  The same buffer system was used and samples with only CT-
DNA at each concentration was used as blanks to eliminate the absorbance from the CT-
DNA. 
3.3.5 Agarose gel electrophoresis 
A solution of pBR322 plasmid DNA (0.125 µg) (Life Technologies #15367-014, 
supplied at 0.25 µg/µl in 10 mM Tris-HCl (pH 7.4), 5 mM NaCl, 0.1 mM EDTA) was 
mixed with increasing concentrations (0–100 µM) of Pt(II)-4C and brought to 25 µL 
with TE buffer (Tris-EDTA) containing 25% DMSO. Cisplatin was used as a control. 
The samples were incubated at 37 °C in the dark for 24 h. After incubation, 5 µL of 6X 
DNA loading buffer (0.25% bromophenol blue, 0.25% Orange G, 30% glycerol) was 
added to each sample and 25 µL was electrophoresed through a 1% agarose gel immersed 
in 1X TBE buffer (2 mM EDTA, pH 8.0; 89 mM Tris; 89 mM Boric Acid) for 50 min at 
100 V.  Finally, the gel was stained with ethidium bromide (EB) (1 µg mL
-1
) in the dark 
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for 30 min, followed by visualization on a Bio-Rad ChemiDoc XRS+ imaging system 
with a UV-Vis transilluminator.  
3.3.6 Cellular uptake and intracellular DNA binding of platinum 
Cells were seeded in 100 mm culture dishes and incubated at 37 °C until ~70-80% 
confluent.  The cells were treated with the indicated concentrations of Pt(II)-4C for 4 h 
and harvested by trypsinization.  The cells were washed twice with 10 mL of PBS, 
counted, and pelleted by centrifugation.  For the cellular uptake study, the cell pellet was 
stored at -20 °C until analysis.   
For intracellular DNA binding analysis, the cell pellet was resuspended in 500 µL 
of lysis buffer (100 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 0.5% Triton X-100, 
200 mM NaCl, 100 µg mL
-1
 proteinase K). After 2 h of incubation at 56 °C, 4 µL of a 0.2 
mg mL
-1
 RNAse A solution was added and the sample was incubated at room 
temperature for 15 min. The DNA was precipitated by addition of 2-propanol (500 µL), 
mixed by inversion, and stored overnight at -20 °C. The DNA was pelleted by 
centrifugation at 16 000 × g for 15 min at 4 °C. The pellet was washed with 70% ethanol 
and air dried by inverting the tube on a tissue for 10 min. The DNA was dissolved in 150 
µL of nuclease-free water and the DNA concentration was determined with the 
NanoDrop ND-1000 Spectrophotometer.  The samples were stored at -20 °C until 
analysis 
For platinum analysis, 200 µL of high purity concentrated HNO3 was added to the 
cell pellet and DNA samples, and the contents were transferred to borosilicate glass 
tubes.  After heating at 80 °C for 2 h to digest the samples, they were diluted with ultra-
pure water to a final concentration of 1% HNO3.  The samples were filtered with 0.45 µm 
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syringe filters and analyzed by inductively coupled plasma-atomic emission spectrometry 
(ICP-AES).  Platinum standards (0-50 µM) were used as an external calibration curve to 
calculate the amount of platinum in the samples.   
3.3.7 Western blot analysis 
Cells were seeded in 100 mm dishes and grown to subconfluence.  The cells were 
treated with increasing concentration of Pt(II)-4C for the indicated time, harvested, and 
collected.  The cells were lysed by vigorously vortexing in 300 µL M-PER lysis buffer 
(Thermo Scientific # 78503) containing 2X phosphatase inhibitor cocktail (Pierce 
#88667), 2X protease inhibitor cocktail (Thermo Scientific # 78410), 1X EDTA (Thermo 
Scientific # 78410).  The lysate was centrifuged at 14 000 × g for 15 min at 4 °C and 
supernatant was collected.  The protein concentration was determined using the 
bicinchoninic acid (BCA) protein assay (Pierce # PI-23235) by following the 
manufacturer’s instructions. The cell lysate was mixed with 1X LDS sample buffer (Life 
Technologies #B0007) and 1X DTT (Life Technologies #B0009), placed in boiling water 
for 5 min, and 30 µg of protein was separated on a Novex Bolt 4-12% Bis Tris Plus gel 
(Life Technologies # BG04125BOX) with Bolt MES SDS Running Buffer (Life 
Technologies # B0002).  The protein was transferred onto a nitrocellulose membrane 
(iBlot® Transfer Stack, Life Technologies # IB301001) using the iBlot® Gel Transfer 
Device. The membrane was treated with SuperSignal Western Blot Enhancer Antigen 
Pretreatment Solution (Thermo Scientific # 46640) for 10 min, washed according to the 
manufacture’s instruction, blocked with 5% bovine serum albumin (BSA) in 1X Tris-
buffered saline containing 0.05% Tween-20 (TBST) buffer for 1 h at room temperature. 
After rinsing with TBST, the membrane was incubated with the appropriate primary 
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antibody (dilution in SuperSignal Western Blot Enhancer Primary Antibody Diluent 
(Thermo Scientific # 46640)) at 4 °C overnight.  After washing with TBST, the 
membrane was incubated with the appropriate HRP-conjugated secondary antibody 
(diluted1:2000 in 5% BSA) for 1 h at room temperature.  Protein bands were detected 
with Clarity Western ECL Substrate (Bio-Rad # 170-5061) and imaged on the Bio-Rad 
ChemiDoc XRS+. 
SAPK/JNK Antibody (#9252), Phospho-SAPK/JNK (Thr183/Tyr185) 
Antibody (#9251), p38 MAPK Antibody (#9212), Phospho-p38 MAPK (Thr180/Tyr182) 
Antibody (#9211), p44/42 MAPK (Erk1/2) Antibody (#9102), Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) Antibody (#9101) were purchased from Cell Signaling 
Technologies.  Β-Actin Antibody (C4) (#sc-47778) and p53 Antibody (DO-1) (#sc-126) 
were purchased from Santa Cruz Biotechnology. 
3.3.8 Immunofluorescence microscopy 
Cells (125,000) were seeded into 35 mm dishes containing #1.5 glass coverslips 
and incubated for 48 h at 37 °C. The cells were treated with the indicated concentration 
of Pt(II)-4C (or co-treated with the MAPK inhibitors) for the indicated time at 37 °C, 
washed 2X with PBS, and fixed with 4% formaldehyde for 15 min at room temperature. 
The cells were washed 3X with PBS, permeabilized with 0.2% Triton X for 5 min at 
room temperature, washed 3X with PBS, and blocked with 5% BSA in PBS for 1 h at 37 
°C.  After blocking, the cells were washed 2X with PBS and incubated with mouse anti-
phospho-JNK (Santa Cruz Biotechnology #sc-6254), anti-phospho-ERK1/2 (Santa Cruz 
Biotechnology #sc-81492), anti-phospho-p38 (Santa Cruz Biotechnology #sc-7973), anti-
phospho-Histone H2A.X (Ser139) (EMD Millipore #05-636), p53 Antibody (DO-1) 
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(Santa Cruz Biotechnology #sc-126)  primary antibodies (1:50 dilution in 5% goat serum) 
at 4 °C overnight.  The cells were washed 4X for 5 min each on a rocker, followed by 
incubation with Alexa-Fluor 488 goat anti-mouse secondary antibody (Life Technologies 
#A11029) [1:400 dilution in 5% goat serum (Santa Cruz Biotechnology #sc-2043)] at 
room temperature 30 min.  The cells were washed 4X for 5 min each on a rocker, briefly 
rinsed with ultrapure H2O, and mounted on glass slides with Prolong Gold Antifade 
Reagent with DAPI (Life Technologies #P36935). Images were taken with the Nikon 
A1R confocal laser scanning microscopy system (CLSM) mounted on a Nikon Eclipse 
Ti.   
3.3.9 Flow cytometric immunofluorescence 
 Cells (100,000) were seeded in 60 mm dishes and grown for 3 d at 37 °C in a 
humidified, 5% CO2 atmosphere. The cells were treated with the indicated concentration 
of Pt(II)-4C for the indicated time and harvested. The cells were fixed by addition of 
16% formaldehyde to a final concentration of 4% and incubated at room temperature for 
10 min.  The cells were pelleted and the supernatant was discarded.  The cells were 
permeabilized by resuspension in 500 µL of ice-cold methanol and incubated at 4 °C for 
10 min.  The samples were stored at -20 °C until staining.  For staining, the cells were 
pelleted and washed 2X with 1% BSA in PBS.  The cells were pelleted, resuspended in 
BD Stain Buffer (BS Biosciences #554656) containing the appropriate conjugated 
primary antibody [p38 MAPK (pT180/pY182) Alexa 488 (BD Biosciences #612594), 
JNK (pT183/pY185) PE N9-66 (BD Biosciences #562480), ERK1/2 (pT202/pY204) 
PerCP-Cy5.5 20A (BD Biosciences # 560115), p53 (pS37) Alexa 647 J159-641.79  (BD 
Biosciences #560280), the γH2AX antibody was purchased as a part of a Cell 
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Proliferation kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After 
washing 2X with BD Stain Buffer, the cells were resuspended in PBS and analyzed on a 
Becton Dickinson FACS Calibur. 
3.3.10 Statistical analysis 
GraphPad Prism 5 was used to graph viability curves. ModFit version 3.0 was 
used for the flow cytometry analysis. Microsoft Office Excel was used to perform 
unpaired Student’s t-test; values with p < 0.05 were considered significant. Student’s t-
tests were used to verify significant differences among the EC50 values. 
3.4 Results and discussion 
3.4.1 Cytotoxicity of Pt(II) complexes  
 The cellular response to a particular drug can vary between different types of 
cancers.  In order to thoroughly examine the effectiveness of the dialkoxy-2,2′-bipyridyl 
Pt(II) complexes in different types of cancers, the anti-proliferative activities of all the 
complexes were determined in a lung (H520), two prostate (DU145 and PC-3), and six 
breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1) cancer cell 
lines. The cells were treated with increasing concentrations of the complexes for 1 or 48 h 
and the viability was measured using an MTS colorimetric cell proliferation assay. The 
effective concentrations which resulted in 50% cell viability (EC50) were obtained from 
the viability curves and tabulated in Tables 3-1–3-3. The novel Pt(II) complexes are 
generally more effective than cisplatin with EC50 values ranging from 1–80 µM, while 
the EC50 values of cisplatin are in the range of 20–900 µM. The EC50 values for the 1 h 
treatment with the two short chains complexes, Pt(II)-1C and Pt(II)-2C, were not 
obtainable in some cell lines (both complexes in H520 and MCF-7; Pt(II)-1C in PC-3 
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and MDA-MB-231 cells) with the highest concentration (100 µM) tested. Interestingly, 
the EC50 values tend to be higher in H520, MCF-7, and ZR-75-1, which all have wild 
type p53.
14,15
   
 Currently, cisplatin does not have a major role in the clinical treatment of breast 
cancers; however, some triple negative breast cancers (TNBC) are sensitive to platinum 
drugs.
16
 Comparison of the EC50 values for complexes Pt(II)-1C–Pt(II)-6C and cisplatin 
demonstrate that in most cases the new complexes are more effective than cisplatin in the 
breast cancer cell lines tested. Moreover, the response is similar between cell lines with 
differential hormone receptors expression (HCC38 and MDA-MB-231 are TNBC).
17 
 
Table 3 – 1. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in H520, 
DU145 and PC-3 post 1 or 48 h treatment   
 
Lung cancer Prostate cancer 
 
H520 DU145 PC-3 
Compound 1 h 48 h 1 h 48 h 1 h 48 h 
CDDP 200 ± 17 24 ± 2 400 ± 100 64 ± 8 200 ± 20 30 ± 1 
Carboplatin ND ND >1000 400 ± 100a ND ND 
Pt(II)-1C >100 30 ± 2 40 ± 10a 24 ± 2a,b >100 40 ± 7 
Pt(II)-2C >100 21 ± 1 20 ± 5a 11 ± 4a,b 22 ± 5a 21 ± 7 
Pt(II)-3C 40 ± 20 a 13 ± 5 a 6 ± 1a 4 ± 2a,b 5 ± 1a 5.1 ± 0.8a 
Pt(II)-4C 20  ± 1 a 14  ± 6 12  ± 8a 5  ± 2a,b 11  ± 2a 7.4  ± 0.5a 
Pt(II)-5C 23 ± 5 a 17 ± 3 8 ± 2a 6.0 ± 0.7a,b 7 ± 1a 7.3 ± 0.7a 
Pt(II)-6C >50 18 ± 1 2.1 ± 0.1a 1.9 ± 0.1a,b 2.24 ±0.03a 2.7 ± 0.1a 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
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Table 3 – 2. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in various 
human breast cancers post 1 h treatment  
Compound HCC38 MCF-7 
MDA-
MB-231 
SK-BR-3 T-47D ZR-75-1 
CDDP 300 ± 30 900 ± 60  50 ± 4 420 ± 80 900 ± 100 260 ± 10 
Carboplatin ND >1000 ND ND ND ND 
Pt(II)-1C 80 ± 20
a
 >100 >100 19 ± 5
a
 20 ± 1
a
 67 ± 27
a
 
Pt(II)-2C 18 ± 4
a
 >100 30 ± 20 2.2 ± 0.2
a
 5 ± 2
a
 58 ±  15
a
 
Pt(II)-3C 5 ± 2
a
 100  ± 0
a
 4 ± 2
a
 1.81 ± 0.03
a
 2.4 ± 0.1
a
 8.9 ± 0.4
a
 
Pt(II)-4C 12  ± 6
a
 22 ± 2
a
 4  ± 3
a
 5  ± 4
a
 12 ± 7
a
 21 ± 2
a
 
Pt(II)-5C 13 ± 5
a
 21 ± 5
a
 4 ± 2
a
 2.8 ± 0.8
a
 9 ± 3
a
 8 ± 3
a
 
Pt(II)-6C 16 ± 5
a
 80 ± 30
a
 6 ± 3
a
 1.84 ± 0.03
a
 3.2 ± 0.8
a
 7 ± 2
a
 
Values represent the mean ± SD of at least two independent experiments done in quadruplicates. 
ND = no data 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to carboplatin. 
 
 
Table 3 – 3. EC50 (µM) of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in various 
human breast cancers post 48 h treatment   
Compound HCC38 MCF-7 
MDA-
MB-231 
SK-BR-3 T-47D ZR-75-1 
CDDP 30 ± 8 35 ± 1 21 ± 3 23 ± 6 35 ± 6 30 ± 8 
Carboplatin ND 800 ± 100
a
 ND ND ND ND 
Pt(II)-1C 57 ± 2
a
 >100 >100 23 ± 2 21 ± 1
a
 26  ± 1 
Pt(II)-2C 20 ± 3 >100 20 ± 6 1.8 ± 0
a
 2.2 ± 0.4
a
 16.5  ± 0 
Pt(II)-3C 4.7 ± 0.5
a
 19  ± 4
a,b
 2.2 ± 0.1
a
 1.73 ± 0.01
a
 1.9 ± 0.1
a
 5  ± 1
a
 
Pt(II)-4C 7.3  ± 3 13 ± 1
a,b
 2.4  ± 0.6
a
 2.1  ± 0.2
a
 2.3 ± 0.4
a
 6.0  ± 0.9
a
 
Pt(II)-5C 10 ± 2 15 ± 7
 a,b
 4.1 ± 0.2
a
 2.4 ± 0.4
a
 3 ± 1
a
 6.6  ± 0.7
a
 
Pt(II)-6C 14 ± 4 12 ± 4
a,b
 4 ± 1
a
 1.8 ± 0
a
 2.1 ± 0.2
a
 6.4  ± 0.4
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to carboplatin. 
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3.4.2 UV-Vis analysis of DNA binding 
 Absorption spectroscopy is one of the methods commonly used to examine the 
characteristics of metal complex interaction with DNA. The interactions of metal 
complexes with DNA can cause changes in the absorption spectra such as an increase 
(hyperchromism) or decrease (hypochromism) in absorbance, or a redshift 
(bathochromism) or blueshift (hypsochromism) of the wavelength. Hypochromism and 
redshift are usually observed for an intercalative binding of the compound to DNA. 
Damage to the DNA double helical structure such as breakage is usually identified by a 
hyperchromic shift in the absorbance spectra.
18
 Various degrees of hyperchromic and 
hypochromic shifts have been described for different platinum complexes.
19–23
 The 
absorbance spectra for one of the platinum complexes reported with coordination to 2,2′-
bipyridine and substituted 1,10-phenanthroline ligands showed hypochromism.
22
  
Additionally, another complex similar to our compounds, but containing dicarboxylic 
acid substituents, also caused hypochromism in the absorbance spectra.
23
 Thus, it is 
hypothesized that the dialkoxy-2,2′-bipyridyl Pt(II) complexes will also cause similar 
effects.  
 Due to having consistently low EC50 values in all of the cell lines tested, Pt(II)-
4C was chosen for further studies.  The UV-Vis analysis of the interaction of Pt(II)-4C 
with CT-DNA was  first evaluated by incubation of the CT-DNA at a constant 
concentration (100 µM) with increasing concentrations of Pt(II)-4C for 1 or 24 h at 37 
°C.  Addition of Pt(II)-4C to CT-DNA for 1 h caused an increase in the DNA absorbance 
at 260 nm and, as illustrated in Figure 3-1 A, the increase in absorbance was 
concentration dependent.  Further incubation of the DNA with Pt(II)-4C for 24 h did not 
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caused any dramatic changes to the absorption spectra (Figure 3-1 B). The experiment 
was repeated by keeping the Pt(II)-4C concentration constant (100 µM) and varying the 
concentrations of CT-DNA. The spectra for the 1 h incubation show an absorbance 
maximum for Pt(II)-4C (in the absence of DNA) around 250 nm and a broad absorption 
around 300 nm (Figure 3-2 A).  Addition of 10 µM CT-DNA caused significant 
hyperchromism in the spectra and the Pt(II)-4C peak around 300 nm was shifted to 280 
nm (blueshift). Further addition of CT-DNA caused slight increases in the absorbance of 
Pt(II)-4C. Results obtained for the 24 h incubation was similar to the 1 h incubation, 
except the characteristic absorption peaks of Pt(II)-4C in the absence of DNA was not 
observed as for the 1 h treatment period (Figure 3-2 B). 
 The hyperchromism observed for Pt(II)-4C interaction with CT-DNA is 
indicative of electrostatic attractions that may have caused separation of the DNA 
structure.
24
  These results are in contrast to the hypochromism observed by Sun et al. for 
the structurally related Pt(II) complex containing dicarboxylic acid substituted 2,2′-
bipyridyl.
23 
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Figure 3 – 1. Absorption spectra of CT-DNA (100 µM) with increasing concentration of 
Pt(II)-4C. Samples were incubated at 37 °C for (A) 1 or (B) 48 h in 10 mM Tris-HCl 
(pH 7.2) containing 10% DMSO. Pt(II)-4C solutions of each concentration in the same 
buffer were used as blanks to eliminate the absorption of the Pt(II)-4C by itself. Spectra 
are representative of at least three independent experiments.  
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Figure 3 – 2. Absorption spectra of Pt(II)-4C (100 µM) with increasing concentration of 
CT-DNA. Samples were incubated at 37 °C for (A) 1 or (B) 48 h in 10 mM Tris-HCl (pH 
7.2) containing 10% DMSO. Samples with only CT-DNA in the same buffer at each 
concentration were used as blanks to eliminate the absorbance from the CT-DNA. 
Spectra are representative of at least three independent experiments. 
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3.4.3 Gel electrophoretic analysis of DNA cleavage 
 Cleavage of circular plasmid DNA is another method used to determine the 
effects of a compound on DNA. Plasmid DNA cleavage generates different forms of 
DNA that have varying migration rates in gel electrophoresis. To utilize this 
characteristic, the interaction of Pt(II)-4C was further studied by examining its 
interaction with plasmid pBR322 DNA. Plasmid pBR322 can have three forms; Form I is 
the intact supercoiled structure, Form II results when one of the DNA strands is cleaved 
forming an opened circular structure, and Form III is the linear structure generated when 
both DNA strands are cleaved.  Form I migrates the fastest in agarose gel electrophoresis, 
Form II migrates the slowest, and Form III migrates in between the two.
21–23
   
 The electrophoretic mobility shift of pBR322 incubated with increasing 
concentrations of Pt(II)-4C is shown in Figure 3-3.  After incubation for 24 h at 37 °C, 
Pt(II)-4C did not affect the mobility of Form I at concentrations of 5 and 15 µM.  At 25 
µM of Pt(II)-4C, a slight decrease in the mobility of Form I was observed and this 
pattern was more evident at 50 µM with a slight increase in intensity for the Form II 
band.  Treatment of pBR322 with 75 µM Pt(II)-4C resulted in three bands: a faint band 
in the  Form I region, an increased Form II band, and a smeared band in between.  This 
pattern is indicative of DNA cleavage by Pt(II)-4C. Cisplatin (100 µM) was used as a 
control. Cisplatin treatment resulted in two bands with decreased intensity and a different 
mobility pattern compared to DNA alone. Treatment with Pt(II)-4C resulted in different 
mobility patterns compared to cisplatin indicating that the interaction of Pt(II)-4C with 
DNA may be different than that of cisplatin. 
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Figure 3 – 3. Gel electrophoretic analysis of the Pt(II)-4C complex interaction with 
DNA. Plasmid pBR322 DNA (0.125 µg) was incubated for 24 h at 37 °C with increasing 
concentrations of Pt(II)-4C in TE buffer (Tris-EDTA) containing 25% DMSO, subjected 
to electrophoresis in a 1% agarose gel, stained with ethidium bromide, and visualized 
with a UV-Vis transilluminator. Gel images are representative of at least two independent 
experiments. 
 
3.4.4 Intracellular accumulation of Pt(II)-4C 
 Analysis of intracellular platinum concentrations were measured by ICP-AES to 
determine the extent of cellular uptake and DNA binding of Pt(II)-4C in A549 cells.  
A549 cells treated for 4 h with increasing concentrations of Pt(II)-4C had increasing 
accumulation of platinum in the cell (Figure 3-4 A), which was accompanied by a 
proportional increase in platinum bound to DNA (Figure 3-4 B).  These results correlate 
well with the concentration dependent anti-proliferative effect of Pt(II)-4C in A549 cells 
(Chapter 2).
6 
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Figure 3 – 4. Cellular uptake of Pt(II)-4C in A549 human lung cancer cells.  A549 cells 
were treated for 4 h with increasing concentrations of Pt(II)-4C and the amount of Pt (A) 
taken up by the cells or (B) bound to DNA was measured by ICP-AES. Values for the 
cell uptake are representative of two independent experiments and the values for Pt 
bound to DNA are from one trial. 
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3.4.5 Pt(II)-4C induced cell death in A549 cells is p53 dependent  
 The effects of Pt(II)-4C treatment on p53 signaling was examined in A549 cells 
to determine the role of p53 in Pt(II)-4C induced cell death. Immunofluorescence 
microscopy analysis of p53 expression in A549 cells treated with Pt(II)-4C showed 
increased p53 signal compared to control cells (Figure 3-5 A) with p53 localized in the 
nucleus.  This result was confirmed by western blotting, in which A549 cells treated with 
increasing concentrations of Pt(II)-4C had increasing p53 expression (Figure 3-5 B).  
Additionally, measurement of phosphorylated p53 (p-p53) levels in A549 cells treated 
with Pt(II)-4C by flow cytometry showed an increased shift in p53 signal compared to 
control (Figure 4-5 C).  The change of p-p53 expression calculated from the flow 
cytometry data indicated a 2–3 fold increase in activated p53 (Figure 4-5 D). 
 To determine the role of activated p53 in Pt(II)-4C induced cell death of A549 
cells, p53 was inhibited by the chemical inhibitor PFTα. As shown in Figure 3-6, 
treatment of A549 cells with Pt(II)-4C in the presence of PFTα resulted in increased cell 
viability compared to cells treated with Pt(II)-4C alone.  The partial reversal of Pt(II)-
4C induced cell death by inhibition of p53 suggests that p53 is involved in the cell death 
signaling response to Pt(II)-4C treatment in A549. This result is consistent with reports 
of the role of p53 in regulating apoptosis.
9,25 
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Figure 3 – 5. Expression of p53 in A549 cells. Expression of p53 was measured by (A) 
immunofluorescence microscopy of cells treated for 2 h with 100 uM of Pt(II)-4C 
(images are representative of two independent experiments done by taking images of at 
least three different fields) and (B) western blotting of cells treated for 3 h with 
increasing concentrations of Pt(II)-4C (representative of two independent experiments). 
(C) Flow cytometric analysis of phosphorylated p53 in cells treated for 6 h with 100 µM 
Pt(II)-4C (representative of three independent experiments). (D) Fold change (signal of 
treated cells/signal of control) in p-p53 fluorescence signal taken from the flow cytometry 
data.   
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Figure 3 – 6. Effect of p53 inhibition on Pt(II)-4C induced cell death in A549 cells. 
A549 cells were pre-treated with 50 µM PFTα (p53 inhibitor) for 1h, co-treated with 
PFTα and increasing concentrations of Pt(II)-4C for 1 h, and the cell viability was 
measured by the MTS assay after 48 h of incubation with PFTα.  
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3.4.6 Pt(II)-4C induces activation of MAPK 
 The involvement of MAPK members in response to Pt(II)-4C was determined in 
A549 and DU145 cells.  First, activation of JNK, p38, and ERK were analyzed using 
flow cytometry. The histogram of A549 and DU145 cells treated with 100 µM of Pt(II)-
4C showed a right shift of  phosphorylated p38 (Figure 3-7 A and E), JNK (Figure 3-7 B 
and F), and ERK (Figure 3-7 C and G) signals compared to control indicating activation 
of p38, JNK, and ERK.  The fold change calculated from the flow data indicate increases 
of 4–25 times compared to control (Figure 3-7 D and H) with p-ERK being the highest.  
Additionally, a concentration dependent increase in MAPK members was observed. 
 Western blotting analysis of proteins from A549 (Figure 3-8 A) and DU145 
(Figure 3-8 B) cells treated with increasing concentrations of Pt(II)-4C also showed a 
concentration dependent increase in p-JNK, p-p38, and p-ERK. The increase in 
phosphorylated proteins observed for A549 cells started at 25 µM, while this increase 
was observed at 5 µM in DU145 cells.  These results correspond to the MTS data 
showing a lower EC50 value for DU145 cells. 
 Activation of MAPK in A549 and DU145 cells treated with Pt(II)-4C was further 
analyzed with immunofluorescence microscopy.  Similar to the flow and western data, 
immunofluorescence images showed an increase in p-p38, p-JNK, and p-ERK signals in 
Pt(II)-4C treated A549 cells (Figure 3-9).  Moreover, activated JNK and ERK appeared 
to be localized to the nucleus, while activated p38 localization was cytoplasmic.  Similar 
results were obtained for DU145 cells (Figure 3-10). 
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Figure 3 – 7. Flow cytometric immunofluorescence analysis of MAPK activation in 
A549 and DU145 cells.  (A) p-p38, (B) p-JNK, and (C) p-ERK levels in A549 cells 
treated for 6 h with Pt(II)-4C. (E) p-p38, (F) p-JNK, and (G) p-ERK levels in DU145 
cells treated for 1 h with Pt(II)-4C. Fold change for (D) A549 and (H) DU145 cells 
calculated by taking the ratio of the fluorescence signals of treated cells to control. 
Histograms are representative of three independent experiments done in triplicate. 
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Figure 3 – 8. Western blot analysis of MAPK activation in A549 and DU145 cells. (A) 
A549 treated for 3 h with increasing concentrations of Pt(II)-4C. (B) DU145 treated for 
1 h with increasing concentrations of Pt(II)-4C. Images are representative of at least two 
independent experiments. 
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Figure 3 – 9. Immunofluorescence microscopy analysis of MAPK activation in A549 
cells treated for 2 h with 100 µM Pt(II)-4C. Images are representative of two 
experiments done by taking images of at least three different fields. 
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Figure 3 – 10. Immunofluorescence microscopy analysis of MAPK activation in DU145 
cells treated for 1 h with 30 µM Pt(II)-4C. Images are representative of two experiments 
done by taking images of at least three different fields. 
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3.4.7 Pt(II)-4C induced activation of H2AX is dependent on MAPK 
 DNA double-strand breaks (DSBs) cause the activation of histone H2AX through 
its phosphorylation at Ser-139.  Phosphorylated H2AX (γH2AX) is believed to play a 
role in DNA damage repair and regulation of apoptosis.
26
 MAPK members have been 
associated with phosphorylation of H2AX.
27,28
 Furthermore, phosphorylation of H2AX in 
cisplatin treated cells has been observed
29–32
 and its phosphorylation by MAPK in cells 
treated with oxaliplatin has also been reported.
33
  
 Since Pt(II)-4C causes DNA damage and activates MAPK, it is possible that 
γH2AX will also be induced.  As expected, immunofluorescence microscopy analysis 
showed an increased γH2AX fluorescence in A549 (Figure 3-10) and DU145 (Figure 3-
11) cells treated with Pt(II)-4C compared to control (also confirmed by flow cytometry, 
Figure 3S-1 shown in the appendix). Co-treatment of A549 and DU145 cells with Pt(II)-
4C and chemical inhibitors of p38 (SB202190), JNK (SP600125), and ERK (PD-
098,059) resulted in decreased γH2AX fluorescence compared to Pt(II)-4C treatment 
alone. In A549 cells, inhibition of p38 and JNK resulted in decreased γH2AX 
fluorescence comparable to the control; however, the decreased γH2AX fluorescence 
resulting from the inhibition of ERK was not as dramatic (Figure 3-11).  This was not 
observed for DU145 cells.  These results indicate that Pt(II)-4C causes DSB and induces 
phosphorylation of H2AX in a MAPK dependent manner. 
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Figure 3 – 11. Effect of MAPK inhibitors on Pt(II)-4C induced H2AX phosphorylation 
in A549 cells. Cells were pre-treated with 10 µM of MAPK inhibitors (PD: ERK 
inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 2 h, then co-treated with Pt(II)-4C 
(50 µM) for 2 h, and phosphorylated H2AX (γH2AX) was measured by 
immunofluorescence microscopy. Images are representative of two independent 
experiments. 
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Figure 3 – 12. Effect of MAPK inhibitors on Pt(II)-4C induced H2AX phosphorylation 
in DU145 cells. Cells were pre-treated with 10 µM of MAPK inhibitors (PD: ERK 
inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 24 h, then co-treated with Pt(II)-4C 
(30 µM) for 3 h, and phosphorylated H2AX (γH2AX) was measured by 
immunofluorescence microscopy. Images are from one experiment done by taking 
images of at least three different fields. 
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3.4.8 The effect on MAPK inhibitors on Pt(II)-4C induced cell death 
 To determine the role of MAPK in Pt(II)-4C induced cell death, the cell viability 
of A549 and DU145 cells treated with increasing concentrations of Pt(II)-4C in the 
absence or presence of the MAPK inhibitors was measured by the MTS assay. As shown 
in Figure 3-13 A, A549 cells treated with Pt(II)-4C in the presence of the ERK inhibitor 
had decreased cell viability compared to Pt(II)-4C treatment alone, while treatment in 
the presence of p38 and JNK inhibitors resulted in increased cell viability compared to 
Pt(II)-4C treatment alone. Similar results were observed for DU145 cells (Figure 3-13 
B), except inhibition of ERK had no effect on the Pt(II)-4C induced cell death 
(comparable results were obtained even when the concentration of the inhibitors was 
increased, Figure 3S-2 shown in the appendix) . These results indicate that Pt(II)-4C 
induced cell death is dependent on functional p38 and JNK in both A549 and DU145 
cells.  Additionally, functional ERK protects A549 cells from Pt(II)-4C induced cell 
death.  It is surprising that while Pt(II)-4C caused ERK activation in DU145 cells and its 
inhibition reduced the level of γH2AX formation, its inhibition did not affect Pt(II)-4C 
induced cell death.  Perhaps its activation is not sufficient enough to overcome the effects 
of Pt(II)-4C. 
 The results obtained are consistent with the reported roles of ERK in protection 
against apoptosis, and p38 and JNK as apoptosis inducers. 
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Figure 3 – 13. Effects of MAPK inhibitors on Pt(II)-4C induced cell death. (A) A549 
treated with increasing concentrations of Pt(II)-4C in the absence and presence of 40 µM 
of MAPK inhibitors (PD: ERK inhibitor, SB: p38 inhibitor, SP: JNK inhibitor) for 48 h 
and (B) DU145 treated with increasing concentrations of Pt(II)-4C in the absence and 
presence of 10 µM of MAPK inhibitors for 48 h.  Results are representative of at least 
three independent experiments done in quadruplicates. 
 
3.5 Conclusions 
The present work demonstrate that Pt(II) complexes containing 4,4′-dialkoxy-2,2′-
bipyridyl ligands are more potent than cisplatin in various human breast, prostate, and 
lung cancers.  One of the complexes, Pt(II)-4C, causes intracellular DNA strand breaks, 
activates p53 and MAPK signaling pathways, which may culminate in cell death.  In 
A549 cells, p53 and the MAPK members, p38 and JNK, are responsible for inducing cell 
death in response to Pt(II)-4C, while ERK protects A549 from cell death. In DU145 
cells, p38 and JNK are necessary for Pt(II)-4C induced cell death. 
MAPK and p53 are two of the many pathways activated by cisplatin treatment.  
They are involved in a complex network of signaling cascades that regulate cell survival 
and death.  For a more complete understanding of the effects of Pt(II)-4C, it would be 
91 
 
interesting to investigate the signaling of downstream target molecules of p53 and 
MAPKs such as proteins in the cell cycle, the repair pathway, and death pathways 
(apoptosis and autophagy) to determine the effects of Pt(II)-4C.   
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CHAPTER 4 
SYNTHESIS AND CHARACTERIZATION OF PT(II) COMPLEXES CONTAINING 
4,4′-DIOLIGOOXYETHYLENE-2,2′-BIPYRIDINE LIGANDS FOR CANCER 
TREATMENT 
 
4.1 Abstract 
 Five [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes were 
synthesized and their anti-proliferative activities were determined in a panel of human 
breast, lung, and prostate cancer cell lines. While in some cases, the synthesized platinum 
complexes were less active than cisplatin, they were generally more effective than 
carboplatin.  A549 and MCF-7 cells were the least sensitive to treatment, and the SK-BR-
3 and T-47D lines were most sensitive. 
 Two of the complexes, Pt(II)-4O,2C and Pt(II)-5O,1C, have some water 
solubility, but their activities were inferior to the non-water soluble compounds.  Pt(II)-
4O,2C was further studied in A549 and DU145 for analysis of cell death induction due to 
its activity and solubility.  A549 and DU145 cells treated with Pt(II)-4O,2C had an 
increase in phosphorylated H2AX, indicating that Pt(II)-4O,2C caused DNA damage. 
Furthermore, results from analysis of PI, Annexin V/PI, Hoechst/PI, and PARP cleavage 
indicated that Pt(II)-4O,2C induced apoptosis; however, some necrosis was also 
observed. 
4.2 Introduction 
 Since the discovery of its anti-tumoral property in the 1960s, cisplatin (a Pt(II) 
complex) has facilitated worldwide interest in utilizing metal compounds for clinical 
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applications.
1,2
 Currently, cisplatin and its two analogues (carboplatin and oxaliplatin) are 
approved worldwide for the treatment of various cancers. Additionally, five other Pt(II) 
complexes (lobaplatin, dicycloplatin, nedaplatin, miriplatin, and heptaplatin) are 
approved in selected countries.
2–8
 While platinum drugs are used in about 50% of all 
cancer chemotherapeutic regimens as single agents or in combination with other types of 
treatment, complications such as intrinsic or acquired resistance and severe side effects 
have restricted their usefulness.
2,4,8
 To minimize these inadequacies, many researchers are 
putting efforts toward the development of compounds with improved efficacies and lower 
toxic side effects. 
 Numerous metal compounds have now been developed as potential cancer drugs 
through methods such as replacing the platinum center with other metals (i.e. ruthenium, 
palladium, etc.), changing the leaving groups, altering the amine groups, oxidation of the 
platinum center, and incorporation into a delivery system.
1,7,9–11
 With an aspiration to 
develop alternative cancer drugs, we have previously reported on the synthesis and anti-
proliferative effects of some novel Pt(II) complexes in which the amine ligands are 
replaced with 4,4′-dialkoxy-2,2′-bipyryl ligands (Chapter 2).12  As have been 
demonstrated, these complexes are much more effective than cisplatin and carboplatin 
when evaluated in the A549 human lung cancer cell line.  Furthermore, one of the 
complexes, Pt(II)-4C, was also more effective than cisplatin in the DU145 prostate 
cancer line, the MCF-7 breast cancer line, and the MDA-MB-435 melanoma line. While 
the in vitro data gave promising results, our attempts to test the toxicity of Pt(II)-4C in 
mice revealed the challenges of solubilizing the compound.  Due to the hydrophobic 
nature of the compound, it had low solubility in some common organic solvents and 
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virtually none in water.  Thus, to improve these compounds, the dialkoxy substituents 
were modified to have increasing oxygen which will result in increasing hydrogen 
bonding and water solubility. 
 Herein, the synthesis of a series of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-
bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)] 
(where R = –(CH2CH2O)n(CH2)mCH3, n = 1–4, m = 0–3) is presented and their anti-
proliferative activities against a panel of human breast, lung, and prostate cancers in 
comparison to cisplatin are described. 
4.3 Experimental 
4.3.1 General 
All starting materials and reagents for the synthetic procedures were purchased 
from the commercial vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless 
otherwise noted. They were of high purity and were used without further purification 
unless noted in the procedure. The compound used for synthesis of the ligands, 2,2′-
bipyridine-4,4′-diol, was synthesized as described in Chapter 2.12,13 Minimum essential 
medium (MEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsin-
EDTA, and penicillin-streptomycin were purchased from Life Technologies (Carlsbad, 
CA). The RPMI 1640 medium was purchased from ATCC (Manassas, VA). Cisplatin, 
carboplatin, HEPES, albumin from bovine serum (BSA), propidium iodide, Hoechst 
33342, methanol, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. 
All reagents and enzymes used for flow cytometry were of analytical grade qualities and 
were purchased from Sigma-Aldrich, unless otherwise noted. 
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4.3.2 Chemical characterization instrumentation 
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or 
the indicated temperature using deuterated dimethyl sulfoxide (DMSO-d6) or chloroform 
(CDCl3) as the solvents: 
1
H NMR, 400 MHz; and 
13
C NMR, 100 MHz. Either residual 
solvent or tetramethylsilane (TMS) were used as the internal chemical shift reference. 
Thermal transitions were determined by using a TA Instruments DSC 2010 differential 
scanning calorimeter in nitrogen at heating and cooling rates of 10 °C min
-1
. The 
temperature axis of the DSC thermogram was calibrated with reference standards of high 
purity indium and tin before use. An amount of 2-3 mg of compound was used in this 
measurement. The Tonset and Tmax temperatures of a melting endotherm of a compound 
were recorded from the DSC thermogram as Mp (Tonset-Tmax). Elemental analysis (EA) 
was determined by NuMega Resonance Labs Inc. (San Diego, CA) using a Perkin Elmer 
PE2400-Series II with a CHNS/O analyzer.  
4.3.3 Preparation of monoalkoxy glycol tosylate compounds 
4.3.3.1 Procedure A  
The tosylate was synthesized following the procedure of Keddie et al.
14
 with a 
slight modification of the reaction condition. The desired glycol (1.1 equiv.) was 
dissolved in CH2Cl2 and cooled to 0 °C. After addition of KOH (4 equiv.), a solution of 
p-toluenesulfonyl chloride (1 equiv.) in CH2Cl2 was slowly added while maintaining the 
temperature at 0 °C. When all of the p-toluenesulfonyl chloride was added, the mixture 
was further stirred at 4 °C for 24 h. The resulting white suspension was filtered to remove 
salt and water was added to the filtrate. The product was isolated by extraction with 
CH2Cl2 and dried over Na2SO4. The solvent was removed using a rotary evaporator 
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resulting in a colorless oily liquid. The final product was dried in vacuo overnight at 50 
°C. 
4.3.3.2 Procedure B  
The tosylate was synthesized following the procedure of Lenz et al.
15
 with a slight 
modification of the reaction condition. The desired glycol (1.1 equiv.) was added to a 
solution of 7 M KOH (40-60 ml) and cooled to 0 °C. To the reaction flask, p-
toluenesulfonyl chloride (1 equiv.) was slowly added and the mixture was stirred at 0 °C 
for 3 h. The product was isolated by extraction with CH2Cl2 and dried over Na2SO4. The 
solvent was removed using a rotary evaporator and the colorless oily liquid was washed 
with hexane. The final product was dried in vacuo overnight at 50 °C. 
 OTs-2O,1C. Yield: 73% (prepared by procedure A). 
1
H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) = 7.81 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 4.16 (t, J = 4.7 Hz, 
2H), 3.58 (t, J = 4.8 Hz, 2H), 3.31 (s, 3H), 2.45 (s, 3H). 
 OTs-3O,2C. Yield: 81% (prepared by procedure B). 
1
H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) = 7.80 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.17 (t, J = 4.9 Hz, 
2H), 3.70 (t, J = 4.9 Hz, 2H), 3.61 – 3.55 (m, 2H), 3.54 – 3.45 (m, 4H), 2.45 (s, 3H), 1.19 
(t, J = 7.0 Hz, 3H). 
OTs-4O,2C. Yield: 91% (prepared by procedure B). 
1
H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) =  7.78 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.14 (t, J = 4.8, 
2H), 3.66 (t, J = 4.9, 2H), 3.61 – 3.52 (m, 8H), 3.49 (m, 2H), 2.42 (s, 3H), 1.18 (t, J = 7.0 
Hz, 3H). 
OTs-4O,4C. Yield: 76% (prepared by procedure B). 
1
H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) = 7.79 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.15 (t, J = 4.9 Hz, 
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2H), 3.68 (t, J = 4.9 Hz, 2H), 3.63 – 3.51 (m, 8H), 3.44 (t, J = 6.7 Hz, 2H), 2.44 (s, 3H), 
1.60 – 1.49 (m, 2H), 1.41 – 1.27 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
 OTs-5O,1C. Yield: 86% (prepared by procedure B). 
1
H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) = 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.13 (t, J = 4.7 Hz, 
2H), 3.66 (t, J = 4.9 Hz, 2H), 3.63 – 3.49 (m, 12H), 3.34 (s, 3H), 2.42 (s, 3H). 
4.3.4 Preparation of 4,4′-dioligooxyethylene-2,2′-bipyridine 
The appropriate tosylate (2.1 equiv.) was slowly added to a mixture of 2,2′-
bipyridine-4,4′-diol (1 equiv.) and Cs2CO3 (2.3 equiv.) in DMF, and the suspension was 
heated to reflux for 48 h. The salt was removed by vacuum filtration and washed with 
CH2Cl2. A rotary evaporator was used to remove the solvents from the solution. The 
crude product was dissolved in CH2Cl2, filtered to remove any remaining salt, and 
washed with hexane. The product was further purified by recrystallization in the noted 
solvent or by extraction with CH2Cl2, dried over Na2SO4, and the solvent removed by a 
rotary evaporator. The final product was dried in vacuo for 48 h. 
L-2O,1C. Yield: 77%, white crystals (by recrystallization in acetone-hexane). Mp 
99-101 °C. 
1
H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 8.44 (d, J = 5.6 Hz, 1H), 
7.88 (s, 1H), 7.00 (d, J = 5.5 Hz, 1H), 4.24 (d, J = 4.2 Hz, 2H), 3.67 (t, J = 4.2 Hz, 2H), 
3.29 (s, 3H). 
13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 165.85, 157.27, 150.94, 
111.55, 106.79, 70.44, 67.58, 58.63. Anal. Calcd for C16H20N2O4 (304.35 g mol
-1
): C, 
63.14; H, 6.62; N, 9.20%; found: C, 63.26; H, 6.85; N, 9.32%. 
L-3O,2C. Yield: 79%, white solid. Mp 43–45 °C. 1H NMR (298 K, 400 MHz, 
CDCl3): δ (ppm) = 8.45 (d, J = 5.6 Hz, 1H), 7.97 (d, J = 2.6 Hz, 1H), 6.86 (dd, J = 5.7, 
2.6 Hz, 1H), 4.30 (t, J = 4.8 Hz, 2H), 3.90 (t, J = 4.7 Hz, 2H), 3.72 (t, J = 4.7 Hz, 2H), 
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3.61 (t, J = 4.7 Hz, 2H), 3.58–3.46 (m, 2H), 1.21 (t, J = 7.0, 3H). 13C NMR (298 K, 100 
MHz, CDCl3): δ (ppm) = 165.84, 157.81, 150.12, 111.47, 106.66, 71.00, 69.87, 69.39, 
67.47, 66.71, 15.16. Anal. Calcd for C22H32N2O6 (420.50 g mol
-1
): C, 62.87; H, 7.67; N, 
6.66%; found: C, 61.87; H, 7.45; N, 6.75%. EA results showed a possibility of the 
hydrated form C22H32N2O6 • 0.5 H2O. Anal. Calcd for C22H32N2O6 • 0.5 H2O (429.51 g 
mol
-1
): C, 61.52; H, 7.74; N, 6.52%; found: C, 61.67; H, 7.45; N, 6.75%. 
L-4O,2C. Yield: 83%, pale yellow oil. 
1
H NMR (298 K, 400 MHz, CDCl3): δ 
(ppm) = 8.44 (d, J = 5.6 Hz, 1H), 7.96 (d, J = 2.5 Hz, 1H), 6.85 (dd, J = 5.7, 2.6 Hz, 1H), 
4.35–4.25 (m, 2H), 3.92–3.87 (m, 2H), 3.75–3.71 (m, 2H), 3.70–3.62 (m, 4H), 3.60–3.55 
(m, 2H), 3.54–3.47 (m, 2H), 1.19 (t, J = 7.0 Hz, 3H). 13C NMR (298 K, 100 MHz, 
CDCl3): δ (ppm) = 165.85, 157.82, 150.12, 111.49, 106.63, 70.94, 70.75, 70.67, 69.82, 
69.38, 67.48, 66.63, 15.17. Anal. Calcd for C26H40N2O8 (508.60 g mol
-1
): C, 61.40; H, 
7.93; N, 5.51%; found: C, 60.33; H, 8.63; N, 5.71%. EA results showed a possibility of 
the hydrated form C26H40N2O8 • 0.5 H2O. Anal. Calcd for C26H40N2O8 • 0.5 H2O (517.61 
g mol
-1
): C, 60.33; H, 7.98; N, 5.41%; found: C, 60.33; H, 8.63; N, 5.71%. 
L-4O,4C. Yield: 70%, pale yellow oil. 
1
H NMR (298 K, 400 MHz, CDCl3): δ 
(ppm) = 8.44 (d, J = 5.7 Hz, 1H), 7.96 (d, J = 2.6 Hz, 1H), 6.85 (dd, J = 5.6, 2.5 Hz, 1H), 
4.29 (t, J = 4.7 Hz, 2H), 3.89 (t, J = 4.9 Hz, 2H), 3.75–3.54 (m, 8H), 3.44 (t, J = 6.7 Hz, 
2H), 1.62–1.50 (m, 2H), 1.41–1.27 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (298 K, 
100 MHz, CDCl3): δ (ppm) = 165.87, 157.75, 150.09, 111.49, 106.69, 71.20, 70.94, 
70.71, 70.67, 70.07, 69.36, 67.49, 31.71, 19.27, 13.93. Anal. Calcd for C30H48N2O8 
(564.71 g mol
-1
): C, 63.81; H, 8.57; N, 4.96%; found: C, 62.09; H, 8.87; N, 4.91%. EA 
results showed a possibility of the monohydrated form C30H48N2O8 • H2O. Anal. Calcd 
103 
 
for C30H48N2O8 • H2O (582.73 g mol
-1
): C, 61.83; H, 8.65; N, 4.81%; found: C, 62.09; H, 
8.87; N, 4.91%. 
L-5O,1C. Yield: 84%, pale yellow oil. 
1
H NMR (298 K, 400 MHz, CDCl3): δ 
(ppm) = 8.44 (d, J = 5.7 Hz, 1H), 7.96 (d, J = 2.5 Hz, 1H), 6.86 (dd, J = 5.6, 2.5 Hz, 1H), 
4.29 (t, J = 4.8 Hz, 2H), 3.89 (t, J = 4.8 Hz, 2H), 3.77 – 3.59 (m, 10H), 3.57 – 3.49 (m, 
2H), 3.36 (s, 3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 165.96, 157.91, 
150.23, 111.60, 106.76, 72.05, 71.03, 70.77, 70.76, 70.73, 70.63, 69.48, 67.59, 59.15. 
Anal. Calcd for C28H44N2O10 (568.66 g mol
-1
): C, 59.14; H, 7.80; N, 4.99%; found: C, 
58.75; H, 7.93; N, 5.31%. 
4.3.5 Preparation of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes 
A concentrated solution of K2[PtCl4] (1.0 equiv.) in H2O (1–2 mL) was added to a 
solution of 4,4′-dioligooxyethylene-2,2′-bipyridine (1.0 equiv.) in acetone. The mixture 
was then heated to reflux for 24 h and the acetone was removed by using a rotary 
evaporator resulting in either a yellow suspension or a yellow wax-like solid. For 
reactions resulting in a yellow suspension, the crude product was collected by vacuum 
filtration and the final product was obtained by recrystallization in the noted solvent and 
dried in vacuo at 70 °C for 24 h. For reactions resulting in a yellow wax-like solid, the 
product was purified by extraction with CH2Cl2 and dried over Na2SO4. The solvent was 
removed using a rotary evaporator and the solid residue was washed with hexane. The 
final product was collected and dried in vacuo for 24 h. 
Pt(II)-2O,1C. Yield: 86%, bright yellow solid (by recrystallization in CHCl3). 
Mp 206–207 °C. 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.10 (d, J = 6.7 Hz, 
1H), 8.21 (s, 1H), 7.39 (d, J = 6.6 Hz, 1H), 4.43 (t, J = 4.3 Hz, 2H), 3.74 (t, J = 4.2 Hz, 
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2H), 3.33 (s, 3H). 
13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 167.45, 158.46, 
149.46, 113.55, 111.32, 70.13, 69.28, 58.64. Anal. Calcd for C16H20Cl2N2O4Pt (570.25 g 
mol
-1
): C, 33.69; H, 3.53; N, 4.91%; found: C, 33.76; H, 3.70; N, 4.93%. 
Pt(II)-3O,2C. Yield: 78%, bright yellow solid (by extraction, then 
recrystallization in isopropanol). Mp 126–130 °C. 1H NMR (298 K, 400 MHz, CDCl3): δ 
(ppm) = 8.86 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 2.8 Hz, 1H), 6.85 (dd, J = 6.8, 2.7 Hz, 1H), 
4.53–4.46 (m, 2H), 4.00–3.93 (m, 2H), 3.78–3.71 (m, 2H), 3.67– 3.59 (m, 2H), 3.57–3.50 
(m, 2H), 1.21 (t, J = 7.0 Hz, 3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 166.94, 
157.77, 149.03, 113.20, 110.19, 70.94, 69.81, 69.24, 69.15, 66.71, 15.19. Anal. Calcd for 
C22H32Cl2N2O6Pt (686.47 g mol
-1
): C, 38.49; H, 4.70; N, 4.08%; found: C, 38.26; H, 
5.01; N, 4.10%. 
Pt(II)-4O,2C. Yield: 72%, bright yellow solid (by extraction). Mp 94–98 °C. 1H 
NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.84 (d, J = 6.8 Hz, 1H), 7.47 (d, J = 2.8 Hz, 
1H), 6.86 (dd, J = 6.8, 2.7 Hz, 1H), 4.49 (t, J = 4.4 Hz, 2H), 3.95 (t, J = 4.5 Hz, 2H), 
3.79–3.49 (m, 10H), 1.20 (t, J = 7.0 Hz, 3H). 13C NMR (298 K, 100 MHz, CDCl3): δ 
(ppm) = 166.93, 157.69, 148.99, 113.24, 110.21, 70.82, 70.69, 70.60, 69.79, 69.27, 
69.13, 66.65, 15.18. Anal. Calcd for C26H40Cl2N2O8Pt (774.59 g mol
-1
): C, 40.32; H, 
5.21; N, 3.62%; found: C, 39.91; H, 5.61; N, 3.77.  
Pt(II)-4O,4C. Yield: 93%, bright yellow solid (by extraction). Mp 109–114°C.  
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 9.04 (d, J = 6.8 Hz, 1H), 7.42 (d, J = 2.8 
Hz, 1H), 6.87 (dd, J = 6.8, 2.7 Hz, 1H), 4.39 (t, J = 4.5 Hz, 2H), 3.89 (t, J = 4.5 Hz, 2H), 
3.70–3.48 (m, 8H), 3.38 (t, J = 6.7 Hz, 2H), 1.51–1.43 (m, 2H), 1.34–1.22 (m, 2H), 0.83 
(t, J = 7.4 Hz, 3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 166.64, 157.33, 
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148.13, 113.36, 110.18, 71.07, 70.62, 70.55, 70.48, 69.95, 69.12, 68.98, 31.60, 19.17, 
13.86. Anal. Calcd for C30H48Cl2N2O8Pt (830.69  g mol
-1
): C, 43.38; H, 5.82; N, 3.37%; 
found: C, 43.34; H, 6.30; N, 3.65%. 
Pt(II)-5O,1C. Yield: 85%, wax-like yellow solid (by extraction). Mp 48–58 °C. 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 8.79 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 2.8 
Hz, 1H), 6.84 (d, J = 6.8 Hz, 1H), 4.48 (t, J = 4.5 Hz, 2H), 3.94 (t, J = 4.4 Hz, 2H), 3.77 – 
3.59 (m, 10H), 3.56 – 3.49 (m, 2H), 3.35 (s, 3H). 13C NMR (298 K, 100 MHz, CDCl3): δ 
(ppm) = 167.06, 157.87, 149.11, 113.33, 110.36, 72.05, 70.94, 70.72 (3C overlapped), 
70.64, 69.40, 69.25, 59.16.  Anal. Calcd for C28H44Cl2N2O10Pt (834.65  g mol
-1
): C, 
40.29; H, 5.31; N, 3.36%; found: C, 40.50; H, 5.51; N, 3.64%. 
4.3.6 Cell culture 
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1), 
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained 
from American Culture Type Collection (ATCC). The A549, HCC38, MCF-7, MDA-
MB-231, SK-BR-3, T-47D, and ZR-75-1 cells were grown in MEM supplemented with 
10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) and streptomycin 
(100 µg mL
-1
). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640 
supplemented with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) 
and streptomycin (100 µg mL
-1
). All cell lines were maintained at 37 °C in a humidified, 
5% CO2 atmosphere. 
4.3.7 Cell viability assay 
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96-
well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50% 
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confluence. The cells were then treated with solvent or the appropriate drugs (CDDP 
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose, 
synthesized Pt(II) complexes were dissolved in DMSO) for 1 h, washed three times with 
100 µL PBS, and incubated in 100 µL of fresh medium.  After 2 d, the medium was 
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent 
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and 
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan 
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method, 
except the cells were not washed after treatment and the MTS reagent was immediately 
added. Viability of treated groups was calculated as a percent of control and graphed with 
GraphPad Prism. 
4.3.8 Flow cytometry 
4.3.8.1 Propidium iodide (PI) staining 
Cells (~50-60% confluent in 60 mm dishes) were treated as indicated with the 
platinum compound. After the treatment duration, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated. The cells were harvested (both the floating 
and attached cells were collected), counted, and pelleted. The cells were then washed two 
times with 5 mL PBS, fixed by resuspending in 0.1 mL of PBS and 1 mL of ice-cold 95% 
ethanol with gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis, 
fixed cells were washed once with 1–2 mL of PBS and centrifuged at 500 × g for 5 
minutes. The cell pellet was resuspended in 100 µL of a 1.0% Triton X-100 buffer 
solution, and 100 µL of a 1.0 mg mL
-1 
RNAse solution was added and allowed to stand at 
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room temperature for 10–15 min. While in the dark, 200 µL of a 100 µg mL-1 PI stain 
was added to make a final concentration of 50 µg mL
-1
 and gently vortexed. The cell 
mixture was incubated at room temperature for 30 min and flow cytometry acquisition 
was done on a Becton Dickinson FACS Calibur with the argon laser set at 488 nm on the 
linear Flow Channel 2 (FL-2) with Doublet Discriminatory Module (DDM) and threshold 
set on FL-2. 
4.3.8.2 Annexin V-FITC/PI staining 
Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the 
platinum compound. After the treatment duration, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated. The cells were harvested (both the floating 
and attached cells were collected), counted, and pelleted. The cells were then washed two 
times with 5 mL of Ca
2+
 and Mg
2+
 free PBS. The pellets were then washed in 2.0 mL of 
1X Annexin-V Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g 
for 5 min. The pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San 
Jose, CA) and incubated in the dark for 15 min. Just before acquisition, the volume of 
cells-conjugate mixture was adjusted by addition of 1X Annexin-V binding buffer.  
Acquisition to discriminate between apoptotic and necrotic cells was done by staining the 
cell-conjugate mixture with 10 µL of PI (50 µg mL
-1
) solution (BD Bioscience, San Jose, 
CA). Acquisitions were done on a FACS Calibur Cytometer on the FL1 (Annexin) and 
FL3 (PI) channels with threshold and Duplet Discriminating Module (DDM) set at FL1. 
The level of shift in events distribution in the Annexin-V only and Annexin-V-PI 
populations in comparison to control is indicative of degree of effectiveness of the 
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treatment agents. A quantitative measure of these event shifts was accomplished by 
gating. 
4.3.8.3 Flow cytometric immunofluorescence 
 Cells (200,000–250,000) were seeded in 60 mm dishes and incubated at 37 °C in 
a humidified, 5% CO2 atmosphere for 2 d to reach ~50–60% confluence.  The cells were 
treated with the platinum complexes as indicated, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated.  After incubation, both the floating and 
attached cells were collected and fixed by incubation in 4% formaldehyde for 10 min at 
room temperature. The fixed cells were pelleted and permeabilized by incubation in 500 
µL of ice-cold methanol at 4 °C for 10 min.  The samples were stored at -20 °C until 
analysis.  For analysis, the cells were pelleted and washed 2X with 1% BSA in PBS. The 
cells were resuspended in BD Stain Buffer (BS Biosciences #554656) containing the 
appropriate conjugated primary antibody [PE Mouse Anti-Cleaved PARP (Asp214) and 
Alexa Fluor 647 Mouse Anti-H2AX (pS139) antibodies were purchased as a part of a 
Cell Proliferation Kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After 
washing 2X with 1% BSA, the cells were resuspended in PBS and analyzed on a Becton 
Dickinson FACS Calibur. 
4.3.9 Confocal microscopy 
Cells (100,000–125,000) were seeded into 35 mm dishes and incubated for 48 h at 
37 °C.  The cells were treated as indicated, and while in the dark, the cells were washed 
twice with 1 mL PBS. After washing, 1 mL of a 2 µg mL
-1
 Hoechst 33342 and 10 µg mL
-
1
 PI solution (in PBS) was added and the cells were incubated for 15 min at room 
109 
 
temperature. Images were acquired within 5 min with a Nikon A1R confocal laser 
scanning microscopy system (CLSM) mounted on a Nikon Eclipse Ti. At least three 
random areas on each dish were imaged. 
4.3.10 Statistical analysis 
GraphPad Prism was used to graph viability curves. ModFit version 3.0 was used 
for the flow cytometry analysis. Microsoft Office Excel was used to perform unpaired 
Student’s t-test; values with p < 0.05 were considered significant. Student’s t-tests were 
used to verify significant differences among the EC50 values. 
4.4 Results and discussion 
4.4.1 Synthesis and characterization 
 A method similar to the synthesis of the [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] 
complexes was used to synthesize the [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′- 
bipyridine)] complexes (Scheme 4-1), except the ligands were synthesized using tosylate 
compounds as alkylating agents instead of alkylhalides. The tosylates were prepared from 
the desired glycols (containing increasing number of oxyethylene linkages and varying 
terminal carbon number) by following previously described procedures.
14,15
 All of the 
tosylate compounds were colorless liquids and the yields were moderate to high (73– 
 
 
Scheme 4 – 1. Synthesis of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] 
complexes. 
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Figure 4 – 1. Structures of monoalkoxy glycol tosylate compounds.  
 
 
91%).  The structures of these tosylate compounds (Figure 4-1) were confirmed by proton 
NMR and used for the preparation of the ligands without further analysis. 
 The ligands were synthesized by reacting the respective tosylate compound with a 
mixture of 2,2′-bipyridine-4,4′-diol and Cs2CO3 in DMF on heating to reflux for 48 h.  
The yields for the ligands range from 70-84%. The platinum complexes were prepared by 
reacting the ligands with K2[PtCl4] for 24 h on reflux.  As was observed for the 
previously synthesized Pt(II) complexes, the formation of the product was monitored by 
the appearance of a yellow solid or solution. The structures of the synthesized platinum 
complexes are shown in Figure 4-2.  The yields of the platinum complexes were in the 
range of 72–93%.  All of the ligands and platinum complexes were characterized by 1H 
and 
13
C NMR spectroscopy, EA, and DSC measurements. 
1
H and 
13
C NMR spectra of the ligands and platinum complexes displayed the 
expected resonances.  Formation of the ligand was marked by the disappearance of the 
tosylate characteristic aromatic peaks and appearance of the bipyridyl aromatic peaks in  
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Figure 4 – 2. Chemical structures of the synthesized [Pt(II)Cl2(4,4′-dioligooxyethylene-
2,2′-bipyridine)] complexes. 
 
the 
1
H NMR spectra. Coordination of the ligands to the Pt was confirmed by observing 
the shifting of the bipyridyl aromatic peaks towards downfield. 
Elemental analysis of the ligands, L-2O,1C and L-5O,1C, matched with that of 
the calculated values (within 0.5%); however, the carbon values for L-3O,2C and L-
4O,2C, were 1% less than the calculated values. When considering the possibility of 
having hydration due to the many oxygen atoms in their structures, the EA results 
matched the calculated values for a hydrated form of L-3O,2C and L-4O,2C with 0.5 
mol of H2O. Further purification of L-4O,2C or re-synthesis did not improve the carbon 
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result. The carbon for L-4O,4C was also less than the calculated value; however, the EA 
result matched the calculated value for a monohydrated form of L-4O,4C. Elemental 
analysis of all the platinum complexes matched well with the calculated values (within 
0.5%).  
The melting point of the ligands decreased as the oxygen number increased. The 
DSC thermogram of L-2O,1C (contains two oxygens in each substituent) showed an 
endothermic transition at 99–100 °C, which is an indication of a melting transition. This 
melting transition was observed in the L-3O,2C (three oxygens in each substituent) DSC 
thermogram at 43–45 °C.  L-4O,2C, L-4O,4C, and L-5O,1C were all liquid compounds 
and thus DSC analysis was not performed. Coordination to platinum caused an increase 
in the melting temperature and, similar to the ligands, the melting points of the platinum 
complexes decreased as the oxygen number increased. Pt(II)-2O,1C has the highest 
melting temperature with a sharp endothermic transition at 206–207 °C. Pt(II)-5O,1C, 
with the most oxygen in its structure, has a broad melting point at 48–58 °C. Pt(II)-
4O,2C and Pt(II)-4O,4C have the same number of oxygen atoms, but Pt(II)-4O,4C has 
two more carbons on each end of the substituents than Pt(II)-4O,2C, which resulted in a 
higher melting temperature. 
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Figure 4 – 3. DSC thermograms of the [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-
bipyridine)] complexes. The thermograms were obtained in the first heating cycles in 
nitrogen at heating and cooling rates of 10 °C/min. 
114 
 
 The structure of Pt(II)-2O,1C is similar to Pt(II)-4C, except one of the carbons 
in each chain of the alkoxy substituent is replaced by an oxygen. Although the solubility 
of Pt(II)-2O,1C in common organic solvents is slightly improved, it was still poorly 
soluble in water. Pt(II)-3O,2C, which  has an additional oxygen on each substituent by 
the addition of another oxyethylene linkage, is also poorly soluble in water. Pt(II)-4O,4C 
is also poorly soluble, but Pt(II)-4O,2C and Pt(II)-5O,1C both have some solubility in 
water (a 5 mM solution can be made). 
4.4.2 Biological properties 
4.4.2.1 In vitro cytotoxic activity 
 Three of the most commonly diagnosed cancers are breast, lung and prostate; 
thus, the anti-proliferative activities of the synthesized complexes were examined in 
human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1), lung 
(A549 and H520), and prostate (DU145 and PC-3) cancer cell lines using the MTS cell 
proliferation assay. The graphs of the results for a representative cell line from each type 
of cancer treated for 1 or 48 h with cisplatin, carboplatin, or the synthesized platinum 
complexes are shown in Figure 4-4 (DU145 cells), Figure 4-5 (MCF-7 cells), and Figure 
4-6 (A549 cells). As shown in Figure 4-4, the viability of DU145 cells treated with the 
highest concentration of cisplatin (1 mM) was reduced by about 60%, while carboplatin 
had negligible effects. Pt(II)-2O,1C and Pt(II)-3O,2C were only tested up to a 
concentration of 100 µM due to limited solubility and had about the same effect as 
cisplatin at the concentrations tested. However, they were more effective than 
carboplatin.  It is interesting to note that, with only a change of one carbon to an oxygen, 
the anti-proliferative activity of Pt(II)-2O,1C (EC50 for the 1 h treatment is 80 ± 20 ) is 
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greatly reduced compared to Pt(II)-4C (EC50 for the 1 h treatment is 12 ± 8, Chapters 2 
and 3). While Pt(II)-4O,2C and Pt(II)-5O,1C have water solubility, Pt(II)-4O,2C had 
similar activity to cisplatin and Pt(II)-5O,1C was not as active. However, it is worth 
noting that Pt(II)-4O,2C is more effective than carboplatin. Pt(II)-4O,4C was the most 
effective; however, poor water solubility remains an issue. Similar results were observed 
for the 48 h treatment. All of the complexes were more effective than carboplatin, except 
Pt(II)-5O,1C, which had similar activity. Cisplatin was slightly more effective than 
Pt(II)-2O,1C, Pt(II)-3O,2C, and Pt(II)-4O,2C. 
 Similar results were obtained for A549 and MCF-7. It should be noted that, 
compared to DU145 cells, these cell lines are more resistant to cisplatin and all the other 
platinum complexes. The EC50 values obtained from the MTS data for all the tested cell 
lines are given in Tables 4-1 to 4-4. Comparison of the EC50 values indicates varying 
degrees of activity across the different cell lines. A549 and MCF-7 are the most resistant 
to treatment and SK-BR-3, ZR-75-1, and T-47D are generally more sensitive to the 
synthesized platinum complexes than to cisplatin for the 1 h treatment. 
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Figure 4 – 4. DU145 cell viability from MTS cell proliferation assays post (A) 1 h or (B) 
48 h treatment. 
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Figure 4 – 5. MCF-7 cell viability from MTS cell proliferation assays post (A) 1 h or (B) 
48 h treatment. 
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Figure 4 – 6. A549 cell viability from MTS cell proliferation assays post (A) 1 h or (B) 
48 h treatment. 
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Table 4 – 1. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in 
A549 and H520 post 1 or 48 h treatment 
 
Lung cancer 
 
A549 
 
H520 
 
 
1 h 48 h 1 h 48 h 
CDDP 900 ± 200 500 ± 100 200 ± 17 24 ± 2 
Carboplatin >1000 300 ± 30 ND ND 
Pt(II)-2O,1C >100 >100 >100 36 ± 3
a
 
Pt(II)-3O,2C >100 >100 >100 60 ± 10 
Pt(II)-4O,2C >1000 330 ± 5 150 ± 100 197 ± 0
a
 
Pt(II)-4O,4C 17 ± 4
a
 17 ± 3
a,b
 13.1 ± 0.9
 a
 12.1 ±0.5 
Pt(II)-5O,1C >1000 >1000 >1000 400 ± 100 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
 
 
Table 4 – 2. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes 
in DU145 and PC-3 post 1 or 48 h treatment 
 Prostate cancer 
 
DU145 
 
PC-3 
 
 
1 h 48 h 1 h 48 h 
CDDP 400 ± 100 64 ± 8 200 ± 20 30 ± 1 
Carboplatin >1000 400 ± 100
a
 ND ND 
Pt(II)-2O,1C 80 ± 20 60 ± 20
b
 90 ± 20
a
 70 ± 10
a
 
Pt(II)-3O,2C >100 100 ± 6
a,b
 >100 80 ± 8 
Pt(II)-4O,2C 300 ± 60 250 ± 40
a,b
 300 ± 30
a
 310 ± 6
a
 
Pt(II)-4O,4C 13 ± 2
a
 14.3 ± 0.2
a,b
 13 ± 1
a
 12 ± 1
a
 
Pt(II)-5O,1C >1000 800 ± 100 >1000 400 ± 70
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
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Table 4 – 3. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in 
various breast cancer cells post 1 h treatment 
 
HCC38 MCF-7 MDA-MB-231 SK-BR-3 T-47D ZR-75-1 
CDDP 300 ± 30 900 ± 100  50 ± 4 420 ± 80 900 ± 100 260 ± 10 
Carboplatin ND >1000 ND ND ND ND 
Pt(II)-2O,1C 80 ± 6
a
 >100 >100 40 ± 10
a
 24 ± 6
a
 70 ± 20
a
 
Pt(II)-3O,2C >100 >100 >100 50 ± 20
a
 40 ± 9
a
 >100 
Pt(II)-4O,2C 240  ± 30 >1000 210 ± 20
a
 240 ± 20
a
 190 ± 20
a
 345 ± 6
a
 
Pt(II)-4O,4C 13 ± 1
a
 30 ± 2
a
 14.4 ± 0.4
a
 8 ± 6
a
 12.1 ±0.3
a
 19 ± 1
a
 
Pt(II)-5O,1C >1000 >1000 >1000 800 ± 200 1000 ± 30 >1000 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
 
 
 
 
Table 4 – 4. EC50 (µM) of [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-bipyridine)] complexes in 
various breast cancer cells post 48 h treatment 
 
HCC38 MCF-7 
MDA-
MB-231 
SK-BR-3 T-47D ZR-75-1 
CDDP 30 ± 8 34 ± 1 21 ± 3 23 ± 6 35 ± 6 30 ± 8 
Carboplatin ND 800 ± 100
a
 ND ND ND ND 
Pt(II)-2O,1C 70 ± 10
a
 >100 65 ± 3
a
 25 ± 5 25 ± 2 50 ± 20 
Pt(II)-3O,2C 80 ± 20
a
 >100 >100 60 ± 10
a
 50 ± 8 90 ± 6
a
 
Pt(II)-4O,2C 20  ± 6 500 ±100
a,b
 170 ± 7
a
 230 ± 70
a
 170 ± 10
a
 260 ± 50
a
 
Pt(II)-4O,4C 12.5 ±0.4
a
 18 ± 4
a,b
 14.5 ±0.1
a
 8 ± 6
a
 12.2 ± 0.4
a
 18.2 ± 0.6 
Pt(II)-5O,1C 100 ± 100 900 ± 100
a
 500 ± 90
a
 340 ± 20
a
 400 ± 50
a
 400 ± 100
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
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Figure 4 – 7. Pt(II)-4O,2C induced phosphorylation of H2AX in A549 and DU145 cells. 
(A) A549 cells were treated for 6 h with 1000 µM Pt(II)-4O,2C and analyzed 12 h post 
treatment, (B) DU145 cells were treated for 2 h with 250 µM Pt(II)-4O,2C  and analyzed 
7 h post treatment. Data are representative of three independent experiments. 
 
 
4.4.2.2 Detection of DNA damage 
 The MTS results indicate that these dioligooxyethylene bipyridyl Pt(II) 
complexes have anti-proliferative effects in various cancer cells; thus, it is necessary to 
determine the type of cell death. Cisplatin treatment is often associated with apoptosis, a 
type of programmed cell death in which the cells go through various signaling cascades 
resulting in characteristic features such as externalization of phosphatidylserine to the 
membrane surface, activation of apoptotic proteins, membrane damage, cell shrinkage, 
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and chromatin condensation and fragmentation. These types of events can be measured 
by flow cytometry and fluorescence microscopy. 
The cytotoxic effects of cisplatin result from the formation of DNA adducts, 
which stimulate multiple events such as cell cycle arrest, DNA damage repair, various 
stress response pathways, and death pathways. DNA damage by cisplatin induces 
phosphorylation of histone H2AX, which recognizes the damage and recruits proteins to 
repair the damage or to regulate the apoptotic pathway. Flow cytometry was used to 
analyze levels of phosphorylated H2AX (γH2AX) in A549 and DU145 cells treated with 
Pt(II)-4O,2C. Although the Pt(II)-4O,4C complex was the most effective, it was not 
selected for further analysis due to its low solubility when diluted in medium; thus,  
Pt(II)-4C,2C was selected due to its water solubility and comparable activity to cisplatin 
in some of the cell lines tested. As shown in Figure 4-7, treatment with Pt(II)-4O,2C 
resulted in an increase of phopho-H2AX in both A549 and DU145 cells. This indicates 
that Pt(II)-4O,2C may cause DNA damage in A549 and DU145 cells. 
4.4.2.3 Evaluation of apoptosis 
 The increased level of γH2AX induced by Pt(II)-4O,2C is an indication of DNA 
damage; thus, the effects on the cell cycle was analyzed by measurement of PI 
fluorescence using flow cytometry. PI is a membrane impermeable molecule that can 
bind to DNA of cells with membrane damage, an event that occurs during late stage 
apoptosis or necrosis. Measurement of the PI fluorescence by the flow cytometer will 
give an indication of the DNA content in the cells. Different stages of the cell cycle are 
correlated with the amount of DNA in the cell and the PI fluorescence intensity is 
proportional to DNA content. A sub-G1 peak occurs when the cells have less DNA than 
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cells in the G1 phase, which has been attributed to cells undergoing apoptosis. 
 As shown in Figure 4-8, the flow histogram of the DNA contents in the different 
phases of the cell cycle did not show any significant changes in the cell cycle of both 
A549 and DU145 cells after treatment with Pt(II)-4O,2C, except for a small increase in 
the sub-G1 peak. This indicates that Pt(II)-4O,2C does not cause cell cycle arrest and 
may induce apoptosis in A549 and DU145 cells.  
 
 
Figure 4 – 8. Cell cycle analysis of A549 and DU145 cells treated with Pt(II)-4O,2C. 
(A) A549 cells were treated for 6 h with 1000 µM of Pt(II)-4O,2C and analyzed 12 h 
post treatment, (B) DU145 cells were treated with 250 µM of Pt(II)-4O,2C  for 1 h and 
analyzed 12 h post treatment. Data are representative of three independent experiments. 
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Figure 4 – 9. A549 and DU145 flow cytometry analysis of Annexin V/PI staining. 
(A) A549 cells were treated for 5 h with 1000 µM of Pt(II)-4O,2C and analyzed 12 h 
post treatment, (B) DU145 cells were analyzed after treatment with 250 µM of Pt(II)-
4O,2C  for 1 h. Q1 = PI+, represents necrotic cells; Q2 = Annexin V/PI+, representing 
late apoptotic/necrotic cells; Q3 =  Annexin V+, representing early apoptotic cells; Q4 = 
AnnexinV/PI-, representing live cells. Data are representative of three independent 
experiments. 
 
To confirm that Pt(II)-4O,2C induces apoptosis, flow cytometry was used to 
detect for signs of early apoptosis by analysis of Annexin V, which binds to exposed 
phosphatidylserine (occurs in early apoptosis). The flow scatter plot of A549 cells treated 
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with Pt(II)-4O,2C showed an increase in early apoptotic cells (Q3) and late 
apoptotic/necrotic cells (Q2), and a corresponding decrease in live cells (Q4) (Figure 4-9 
A). Similar results were observed for DU145 cells, except, the plot of DU145 cells 
showed a 17% increase in necrotic cells (Q1) (Figure 4-9 A). These results indicate that 
Pt(II)-4O,2C induced DNA damage leads to apoptosis. 
 
 
Figure 4 – 10. Microscopy analysis of PI and Ho uptake. (A) A549 were treated for 5 h 
with 1000 µM Pt(II)-4O,2C and (B) DU145 treated for 3.5 h with 250 µM Pt(II)-4O,2C 
were stained with Ho and PI and images were capture with a confocal microscope. 
Images are from one trial. 
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 To further analyze for cell death, A549 and DU145 cells treated with Pt(II)-
4O,2C were stained with Hoechst (Ho) and PI. Ho is membrane permeable and can stain 
both live cells and cells undergoing apoptosis; cells with intense bright fluorescence 
indicate apoptotic cells. PI, as mentioned earlier, is membrane impermeable and only 
stains cells with membrane damage. As shown in Figure 4-10, an increase of both Ho and 
PI positive cells were detected in A549 and DU145 cells treated with Pt(II)-4O,2C. Ho 
positive indicates cells undergoing apoptosis, while, PI positive indicates that the cells 
have membrane damage so they are either at late stage apoptosis or necrosis. 
 
 
Figure 4 – 11. Pt(II)-4O,2C induced cleavage of PARP. (A) A549 were treated for 6 h 
with 1000 µM Pt(II)-4O,2C and analyzed 12 h treatment and (B) DU145 treated with 
250 µM Pt(II)-4O,2C  for 2 h analyzed 7 h post treatment. Data are representative of 
three independent experiments. 
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 The last method used for analysis of apoptosis is measurement of cleaved-PARP 
by flow cytometry. PARP is a nuclear poly (ADP-ribose) polymerase that has been 
associated with DNA repair. During apoptosis, PARP is cleaved by caspase-3; thus, 
cleaved-PARP is an indication of apoptosis.
16
 As shown in Figure 4-11, both A549 and 
DU145 cells treated with Pt(II)-4O,2C had increased levels of cleaved-PARP, 
suggesting that Pt(II)-4O,2C induced apoptosis in these two cell lines.  
4.5 Conclusions 
 A series of Pt(II) complexes containing 4,4′-dioligooxyethylene-2,2′-bipyridyl 
ligands have been prepared and two of the complexes have some water solubility. Their 
anti-proliferative activities were investigated in a panel of human lung, breast, and 
prostate cancer cell lines. The results showed varying degrees of activity in the cell lines 
tested.  In some cell lines, the synthesized complexes were as effective as cisplatin or less 
effective, while in others, the synthesized complexes were more potent than cisplatin.  
The breast cancer cell lines, SK-BR-3, T-47D, and ZR-75-1 were the most sensitive to 
the new platinum complexes, whereas, A549 and MCF-7 were most resistant, even to 
cisplatin. Results from confocal microscopy and flow cytometry, revealed that Pt(II)-
4O,2C causes DNA damage in A549 and DU145 cancer cells and induced apoptosis. 
 It should be noted that there was no observable difference in the activity of 
Pt(II)-4O,2C, which is water soluble, whether the stock solution used was dissolved in 
DMSO or in 0.15 M NaCl. However, the activity of cisplatin was attenuated when the 
tested stock solution was made in DMSO instead of NaCl due to inactivation of cisplatin 
through displacement of the chloride leaving groups by DMSO (data not shown). This 
indicates that Pt(II)-4O,2C is more stable than cisplatin. Even though Pt(II)-4O,2C is 
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only as effective or less effective than cisplatin in some of the cell lines tested, it is still 
more effective than carboplatin in some cases; thus, it could still be potentially useful for 
clinical applications due to its increased solubility and stability which might result in less 
side effects. 
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CHAPTER 5 
SYNTHESIS AND CHARACTERIZATION OF PT(IV) COMPLEXES CONTAINING 
4,4′-DIALKOXY-2,2′-BIPYRIDINE LIGANDS FOR CANCER TREATMENT 
 
5.1 Abstract 
 Seven [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes have been 
synthesized and characterized by 
1
H NMR, 
13
C NMR spectroscopy, elemental analysis, 
and differential scanning calorimetry (DSC) measurements. The in vitro anti-proliferative 
activities of these Pt(IV) complexes were examined in a panel of human breast, prostate, 
and lung cancer cell lines. Comparison of the EC50 values showed varying degrees of 
activities in the 10 cell lines tested; however, the Pt(IV) complexes are generally more 
effective than cisplatin. A structure activity relationship was observed in which 
complexes with increasing carbon number on the alkoxy substituents had increasing anti-
proliferative activity. These Pt(IV) complexes exhibited improved solubility in organic 
solvents compared to the Pt(II) precursors. 
 Analysis of the cell death pathways by confocal microscopy and various staining 
with flow cytometry showed an increase of phosphorylated H2AX in A549 and DU145 
cells treated with Pt(IV)-4C and Pt(IV)-5C. This indicates that these complexes cause 
DNA damage leading to activation of apoptosis, although some necrosis might be 
involved. 
5.2 Introduction 
In 2012, there were 8.2 million cancer-related deaths and 14.1 million new cancer 
cases worldwide.
1
 Furthermore, these values are projected to continue increasing to an 
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estimated 22.2 million new cases and 13.2 million cancer-related deaths by 2030.
2
 
Although new treatment techniques such as targeted therapy and immunotherapy are 
being explored,
3,4
 the use of chemotherapeutic drugs has remained a mainstream.  
In the 1960s, the accidental discovery of the anticancer activity of cisplatin 
(CDDP), a platinum(II) [Pt(II)] complex, opened up a new area of research on metal-
based drug discovery.
5
 Although numerous platinum complexes have been synthesized, 
only a few have been approved for clinical use. Along with cisplatin, two other Pt(II) 
complexes, carboplatin and oxaliplatin, are approved for use worldwide.
6
 Additionally, 
five other Pt(II) complexes are used in China (lobaplatin and dicycloplatin), Japan 
(nedaplatin and miriplatin), and Korea (heptaplatin).
7–10
 Currently, about 50% of cancer 
chemotherapeutic regimens consist of platinum-based drugs.
10,11
 However, clinical 
application of these platinum drugs is hindered due to toxic side effects and intrinsic or 
acquired resistance.
12
 Consequently, new strategies to improved platinum compounds are 
continually being introduced in hope of discovering compounds with greater efficacy and 
reduced toxicity.  
While many researchers remain focused on improving Pt(II) complexes, some are 
expanding into the development of Pt(IV) complexes to act as prodrugs, which are 
activated by intracellular enzymatic reduction to Pt(II). The general structure of Pt(IV) 
complexes offers some advantages over their Pt(II) counterparts such as being more inert 
to substitution reactions owing to their low-spin d
6
 electronic configuration and 
octahedral geometry; reduction of side effects and the potential for oral administration; 
and greater flexibility in strategies that improve solubility and target selectivity through 
modification of the additional axial ligands.
12–14
 Additionally, Pt(IV) complexes could be 
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used to selectively target tumor cells since tumors are known to be hypoxic, which leads 
to a more reductive intracellular environment that favors the reduction of Pt(IV) to 
Pt(II).
12,15
  
Along with cisplatin, several Pt(IV) complexes (cis-[Pt(NH3)2Cl4], trans-
[Pt(NH3)2Cl4] and [Pt(en)Cl4]) were described by Rosenberg et al.; however they were 
less effective than cisplatin.
14
 Since then, iproplatin, tetraplatin, and satraplatin (Figure 5-
1) are several other Pt(IV) complexes which have entered clinical trials.
10,13,14,16,17
 
Satraplatin, which can be administered orally, is the most successful example of Pt(IV) 
complexes, but failed Phase III clinical trials. However, it is still undergoing clinical trials 
in combination with other chemotherapeutic agents.
10
  
 
Figure 5 – 1. Structures of some platinum(IV) complexes that have entered clinical trials. 
 
 
We have previously reported on the synthesis of a series of Pt(II) complexes 
containing 4,4′-dialkoxy-2,2′-bipyridine ligands (with the dialkoxy having one to six 
carbons) and their anti-proliferative activities against the A549 lung cancer cell line 
(Chapter 2).
18
 The improved anti-proliferative activity of these complexes compared to 
cisplatin warrant further investigation of these compounds.  However, these complexes 
have poor solubility in water and only moderate solubility in common organic solvents 
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and solubilizing agents. To increase solubility, the structures of these 4,4′-dialkoxy-2,2′-
bipyridy Pt(II) complexes were modified by introducing increasing oxygen atoms into the 
dialkoxyl substituents.  Although increased solubility was observed, the anti-proliferative 
activities of these complexes were decreased (by comparison of the EC50 values in 
Chapters 3 and 4). Thus, an alternative strategy to improve these [Pt(II)Cl2(4,4′-dialkoxy-
2,2′-bipyridine)] complexes was to convert them to Pt(IV) complexes owing to the 
attractive advantages of Pt(IV) complexes. 
Herein, we describe the synthesis and characterization by 
1
H NMR, 
13
C NMR 
spectroscopy, elemental analysis, and differential scanning calorimetry (DSC) 
measurements of a series of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes. 
Additionally, the anti-proliferative activities of these complexes in a panel of human 
lung, prostate, and breast cancers will be discussed.  
5.3 Experimental 
5.3.1 General 
All starting materials and reagents for the synthetic procedures were purchased 
from commercial vendors (Sigma-Aldrich, TCI, Alfa-Aesar, or Acros) unless otherwise 
noted. They were of high purity and were used without further purification unless noted 
in the procedure. [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes were synthesized 
as described in Chapter 2.
18
  Minimum essential medium (MEM), fetal bovine serum 
(FBS), phosphate buffered saline (PBS), trypsin-EDTA, and penicillin-streptomycin were 
purchased from Life Technologies (Carlsbad, CA). The RPMI 1640 medium was 
purchased from ATCC (Manassas, VA).  CDDP, carboplatin, HEPES, albumin from 
bovine serum (BSA), propidium iodide, Hoechst 33342, methanol, and dimethyl 
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sulfoxide (DMSO) were purchased from Sigma-Aldrich. All reagents and enzymes used 
for flow cytometry were of analytical grade qualities and were purchased from Sigma-
Aldrich, unless otherwise noted. 
5.3.2 Chemical characterization instrumentation 
All of the NMR spectra were obtained utilizing a Varian spectrometer at 298 K or 
the indicated temperature using deuterated DMSO (DMSO-d6) or chloroform (CDCl3) as 
the solvents: 
1
H NMR, 400 MHz; and 
13
C NMR, 100 MHz. Either residual solvent or 
tetramethylsilane (TMS) were used as the internal chemical shift reference. Thermal 
transitions were determined by using a TA Instruments DSC 2010 differential scanning 
calorimeter in nitrogen at heating and cooling rates of 10 °C min
-1
. The temperature axis 
of the DSC thermogram was calibrated with reference standards of high purity indium 
and tin before use. An amount of 2–3 mg of the compounds was used for measurements. 
The Tonset and Tmax temperatures of a melting endotherm of a compound were recorded 
from the DSC thermogram as Mp (Tonset–Tmax). Elemental analysis was determined by 
NuMega Resonance Labs Inc. (San Diego, CA) by using a Perkin Elmer PE2400-Series 
II with a CHNS/O analyzer.  
5.3.3 Preparation of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes 
The Pt(IV) complexes were prepared from the corresponding Pt(II) complexes 
using a previously published procedure with slight modifications of the reaction 
condition.
19
 [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] (1 equiv.) was suspended in 40 mL 
of glacial acetic acid (>99%) and H2O2 (30%, 33 equiv.) was added. The bright yellow 
suspension was protected from light and stirred at 298 K for 24 h to obtain a light yellow 
solution. The solvent was removed completely and 30 mL of acetic anhydride was added 
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to the pale yellow residue. A pale yellow suspension was obtained after stirring for 1–2 d 
at 298 K. The solvent was removed and ice-cold H2O was added. The crude product (pale 
yellow solid) was collected by vacuum filtration.  Unless otherwise noted, the product 
was purified by extraction with CHCl3, dried over Na2SO4, removal of the solvent with a 
rotary evaporator, and then dried in vacuo at 80 °C. 
[Pt(IV)Cl2(OAc)2(4,4′-dimethoxy-2,2′-bipyridine)] (Pt(IV)-1C). Yield: 87%, 
pale yellow powder (obtained by washing the crude product with water without further 
purification). Mp 249 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) 
= 9.30 (d, 1H, J = 6.9 Hz), 8.37 (s, 1H), 7.58 (d, 1H, J = 7.0 Hz), 4.14 (s, 3H), 1.60 (s, 
3H). 
13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.66, 170.03, 158.03, 149.74, 
113.24, 111.20, 58.12, 22.38.  Anal. Calcd for C16H18Cl2N2O6Pt (600.31 g mol
-1
): C, 
32.01; H, 3.02; N, 4.67%; found: C, 32.07; H, 3.11; N, 4.61%. 
[Pt(IV)Cl2(OAc)2(4,4′-diethoxy-2,2′-bipyridine)] (Pt(IV)-2C). Yield: 90%, pale 
yellow powder. Mp 260 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): δ 
(ppm) = 9.27 (d, J = 6.9 Hz, 1H), 8.35 (d, J = 2.9 Hz, 1H), 7.54 (dd, J = 7.0, 2.8 Hz, 1H), 
4.43 (q, J = 6.8 Hz, 2H), 1.59 (s, 3H), 1.44 (t, J = 6.5 Hz, 3H). 
13
C NMR (298 K, 100 
MHz, DMSO-d6): δ (ppm) = 173.79, 168.41, 157.23, 148.83, 112.59, 110.47, 65.85, 
21.54, 13.69.  Anal. Calcd for C18H22Cl2N2O6Pt (628.37 g mol
-1
): C, 34.41; H, 3.53; N, 
4.46%; found: C, 34.58; H, 3.89; N, 4.59%. 
[Pt(IV)Cl2(OAc)2(4,4′-dipropoxy-2,2′-bipyridine)] (Pt(IV)-3C). Yield: 64%, 
pale yellow powder. Mp 243 C (decomposed). 1H NMR (298 K, 400 MHz, DMSO-d6): 
δ (ppm) = 9.27 (d, J = 7.0 Hz, 1H), 8.37 (d, J = 2.9 Hz, 1H), 7.55 (dd, J = 7.1, 2.9 Hz, 
1H), 4.34 (t, J = 6.5 Hz, 2H), 1.90–1.81 (m, 2H), 1.60 (s, 3H), 1.05 (t, J = 7.4 Hz, 3H). 
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13
C NMR (298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.66, 169.42, 158.09, 149.69, 
113.44, 111.38, 72.12, 22.39, 22.04, 10.62.  Anal. Calcd for C20H26Cl2N2O6Pt (656.42 g 
mol
-1
): C, 36.59; H, 3.99; N, 4.27%; found: C, 36.47; H, 4.08; N, 4.60%. 
[Pt(IV)Cl2(OAc)2(4,4′-dibutoxy-2,2′-bipyridine)] (Pt(IV)-4C). Yield: 67%, 
pale yellow powder (further purified by recrystallization in CHCl3-hexane). Mp 219 C 
(decomposed). 
1
H NMR (298 K, 400 MHz, DMSO-d6): δ (ppm) = 9.25 (d, J = 7.0 Hz, 
1H), 8.34 (d, J = 3.0 Hz, 1H), 7.54 (dd, J = 7.2, 2.8 Hz, 1H), 4.36 (t, J = 6.4 Hz, 2H), 
1.83–1.76 (m, 2H), 1.58 (s, 3H), 1.53–1.44 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H). 13C NMR 
(298 K, 100 MHz, DMSO-d6): δ (ppm) = 174.67, 169.43, 158.09, 149.69, 113.46, 
111.40, 70.45, 30.64, 22.41, 18.99, 14.06.  Anal. Calcd for C22H30Cl2N2O6Pt (684.47 g 
mol
-1
): C, 38.60; H, 4.42; N, 4.09%; found: C, 38.48; H, 4.75; N, 4.10%. 
[Pt(IV)Cl2(OAc)2(4,4′-dipentoxy-2,2′-bipyridine)] (Pt(IV)-5C). Yield: 92%, 
pale yellow powder. Mp 222 C (decomposed). 1H NMR (298 K, 400 MHz, CDCl3): δ 
(ppm) = 9.57 (d, J = 6.9 Hz, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.16 (dd, J = 7.0, 2.7 Hz, 1H), 
4.20 (t, J = 6.4 Hz, 2H), 1.91–1.84 (m, 2H), 1.82 (s, 3H), 1.54–1.34 (m, 4H), 0.96 (t, J = 
7.1 Hz, 3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.23, 169.18, 158.72, 
150.21, 111.62, 110.01, 70.49, 28.46, 28.03, 22.90, 22.43, 14.05. Anal. Calcd for 
C24H34Cl2N2O6Pt (712.53 g mol
-1
): C, 40.46; H, 4.81; N, 3.93%; found: C, 40.46; H, 
5.12; N, 4.05%. 
[Pt(IV)Cl2(OAc)2(4,4′-dihexyloxy-2,2′-bipyridine)] (Pt(IV)-6C). Yield: 74%, 
pale yellow powder (further purified by recrystallization in acetone-hexane). Mp 219 C 
(decomposed). 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) = 9.58 (d, J = 6.9 Hz, 1H), 
7.45 (d, J = 2.9 Hz, 1H), 7.15 (dd, J = 7.1, 2.9 Hz, 1H), 4.21 (t, J = 6.4 Hz, 2H), 1.92–
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1.85 (m, 2H), 1.83 (s, 3H), 1.56–1.43 (m, 2H), 1.42–1.32 (m, 4H), 0.93 (t, J = 6.7 Hz, 
3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.12, 169.04, 158.54, 150.09, 
111.44, 109.88, 77.32, 77.00, 76.69, 70.35, 31.33, 28.59, 25.46, 22.75, 22.50, 13.96.  
Anal. Calcd for C26H38Cl2N2O6Pt (740.58 g mol
-1
): C, 42.17; H, 5.17; N, 3.78%; found: 
C, 42.08; H, 5.44; N, 3.80%. 
[Pt(IV)Cl2(OAc)2(4,4′-dioctyloxy-2,2′-bipyridine)] (Pt(IV)-8C). Yield: 85%, 
pale yellow powder (further purified by recrystallization in acetone-hexane). Mp 203 C 
(decomposed). 
1
H NMR (298 K, 400 MHz, CDCl3): δ (ppm) 9.57 (d, J = 6.9 Hz, 1H), 
7.46 (d, J = 2.7 Hz, 1H), 7.15 (dd, J = 7.0, 2.7 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 1.93–
1.84 (m, 2H), 1.82 (s, 3H), 1.54–1.43 (m, 2H), 1.43–1.25 (m, 8H), 0.90 (t, J= 6.6 Hz, 
3H). 
13
C NMR (298 K, 100 MHz, CDCl3): δ (ppm) = 177.07, 169.04, 158.58, 150.07, 
111.47, 109.86, 70.36, 31.73, 29.15, 29.11, 28.63, 25.78, 22.75, 22.61, 14.07. Anal. 
Calcd for C30H46Cl2N2O6Pt (796.69 g mol
-1
): C, 45.23; H, 5.82; N, 3.52%; found: C, 
45.07; H, 6.10; N, 3.55%. 
5.3.4 Cell culture 
Human breast (HCC38, MCF-7, MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1), 
lung (A549 and H520), and prostate (DU145 and PC-3) cancer cell lines were obtained 
from American Culture Type Collection (ATCC). The  HCC38, MCF-7, MDA-MB-231, 
SK-BR-3, T-47D, ZR-75-1, and A549 cells were grown in MEM supplemented with 10% 
FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) and streptomycin (100 µg 
mL
-1
). The H520, DU145, and PC-3 cell lines were grown in RPMI-1640 supplemented 
with 10% FBS, 25 mM HEPES buffer (pH 7.4), penicillin (100 U mL
-1
) and streptomycin 
(100 µg mL
-1
). All cell lines were maintained at 37 °C in a humidified, 5% CO2 
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atmosphere. 
5.3.5 Cell viability assay 
Cells were cultured at a density of 2–3.5 x 103 cells per well in flat bottomed 96-
well plates in 100 µL of complete growth medium and incubated for 2 d to reach ~ 50% 
confluence. The cells were then treated with solvent or the appropriate drugs (CDDP 
stock was dissolved in 0.15 M NaCl, carboplatin stock was dissolved in 5% glucose, 
synthesized Pt(IV) complexes were dissolved in DMSO) for 1 h, washed three times with 
100 µL PBS, and incubated in 100 µL of fresh medium.  After 2 d, the medium was 
replaced with 120 µL of medium containing CellTiter 96® Aqueous One Solution Reagent 
(MTS reagent) (Promega, Madison, WI). The cells were incubated at 37 °C for 4 h and 
the cell viability was determined by measuring the absorbance at 490 nm using a Tecan 
Infinite M1000 microplate reader. The 48 h treatment was done in a similar method, 
except the cells were not washed after treatment and the MTS reagent was immediately 
added. Viability of treated groups was calculated as a percent of control and graphed with 
GraphPad Prism. 
5.3.6 Flow cytometry 
5.3.6.1 Propidium iodide (PI) staining 
 Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the 
platinum compound. After the treatment duration, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated. The cells were harvested (both the floating 
and attached cells were collected), counted, and pelleted. The cells were then washed two 
times with 5 mL PBS, fixed by resuspending in 0.1 mL of PBS and 1 mL of ice-cold 95% 
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ethanol with gentle vortexing. Fixed cells were stored at 4 °C until analysis. For analysis, 
fixed cells were washed once with 1–2 mL of PBS and centrifuged at 500 × g for 5 
minutes. The cell pellet was resuspended in 100 µL of a 1.0% Triton X-100 buffer 
solution, and 100 µL of a 1.0 mg mL
-1 
RNAse solution was added and allowed to stand at 
room temperature for 10–15 min. While in the dark, 200 µL of a 100 µg mL-1 PI stain 
was added to make a final concentration of 50 µg mL
-1
 and gently vortexed. The cell 
mixture was incubated at room temperature for 30 min and flow cytometry acquisition 
was done on a Becton Dickinson FACS Calibur with the argon laser set at 488 nm on the 
linear Flow Channel 2 (FL-2) with Doublet Discriminatory Module (DDM) and threshold 
set on FL-2. 
5.3.6.2 Annexin V-FITC/PI staining 
Cells (~50–60% confluent in 60 mm dishes) were treated as indicated with the 
platinum compound. After the treatment duration, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated. The cells were harvested (both the floating 
and attached cells were collected), counted, and pelleted. The cells were then washed two 
times with 5 mL of Ca
2+
 and Mg
2+
 free PBS. The pellets were then washed in 2.0 mL of 
1X Annexin-V Binding buffer (BD Bioscience, San Jose, CA) and centrifuged at 500 × g 
for 5 min. The pellets were treated with Annexin-V-FITC conjugate (BD Bioscience, San 
Jose, CA) and incubated in the dark for 15 min. Just before acquisition, the volume of 
cells-conjugate mixture was adjusted by addition of 1X Annexin-V binding buffer.  
Acquisition to discriminate between apoptotic and necrotic cells was done by staining the 
cell-conjugate mixture with 10 µL of PI (50 µg mL
-1
) solution (BD Bioscience, San Jose, 
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CA). Acquisitions were done on a FACS Calibur Cytometer on the FL1 (Annexin) and 
FL3 (PI) channels with threshold and Duplet Discriminating Module (DDM) set at FL1. 
The level of shift in events distribution in the Annexin-V only and Annexin-V-PI 
populations in comparison to control is indicative of degree of effectiveness of the 
treatment agents. A quantitative measure of these event shifts was accomplished by 
gating. 
5.3.6.3 Flow cytometric immunofluorescence 
 Cells (200,000–250,000) were seeded in 60 mm dishes and incubated at 37 °C in 
a humidified, 5% CO2 atmosphere for 2 d to reach ~50–60% confluence.  The cells were 
treated with the platinum complexes as indicated, the floating cells were collected, and 
both attached and floating cells were washed 2X with PBS. The cells were resuspended 
in fresh medium and incubated as indicated.  After incubation, both the floating and 
attached cells were collected and fixed by incubation in 4% formaldehyde for 10 min at 
room temperature. The fixed cells were pelleted and permeabilized by incubation in 500 
µL of ice-cold methanol at 4 °C for 10 min.  The samples were stored at -20 °C until 
analysis.  For analysis, the cells were pelleted and washed 2X with 1% BSA in PBS. The 
cells were resuspended in BD Stain Buffer (BS Biosciences #554656) containing the 
appropriate conjugated primary antibody [PE Mouse Anti-Cleaved PARP (Asp214) and 
Alexa Fluor 647 Mouse Anti-H2AX (pS139) antibodies were purchased as a part of a 
Cell Proliferation Kit (BD Biosciences #562253)], and incubated at 4 °C overnight. After 
washing 2X with 1% BSA, the cells were resuspended in PBS and analyzed on a Becton 
Dickinson FACS Calibur. 
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5.3.7 Confocal microscopy 
Cells (100,000–125,000) were seeded into 35 mm dishes and incubated for 48 h at 
37 °C.  The cells were treated as indicated, and while in the dark, the cells were washed 
2X with 1 mL PBS. After washing, 1 mL of a 2 µg mL
-1
 Hoechst 33342 and 10 µg mL
-1
 
PI solution (in PBS) was added and the cells were incubated for 15 min at room 
temperature. Images were acquired within 5 min with a Nikon A1R confocal laser 
scanning microscopy system (CLSM) mounted on a Nikon Eclipse Ti. At least three 
random areas on each dish were imaged. 
5.3.8 Statistical analysis 
GraphPad Prism was used to graph viability curves. ModFit version 3.0 was used 
for the flow cytometry analysis. Microsoft Office Excel was used to perform unpaired 
Student’s t-test; values with p < 0.05 were considered significant. Student’s t-tests were 
used to verify significant differences among the EC50 values. 
5.4 Results and discussion 
5.4.1 Synthesis and characterization 
 The activity of Pt(IV) complexes are believed to be due to activation by 
intracellular enzymatic reduction to Pt(II); thus, the reduction potential of the Pt(IV) 
compound is important. This is governed by the axial ligands; chlorido ligands are most 
easily reduced, followed by acetato ligands, and hydroxido ligands are the most difficult 
to reduce.
12
 With this guideline taken into consideration and in combination with the fact 
that satraplatin, the most successful Pt(IV) to date, has acetato axial ligands, acetato axial 
ligands were selected for modification of the [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)]. 
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[Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes were synthesized as 
previously described (Chapter 2)
18
 and used as precursors for the synthesis of the Pt(IV) 
complexes. Pt(IV) complexes of the formula [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-
bipyridine)] (where R = –(CH2)n–1CH3, n = 2–6, 8) were synthesized with yields ranging 
from 64–92% by following the procedure (Scheme 5-1) of Mackay et al.19 with slight 
modification of the reaction condition. The Pt(II) precursors were first converted to 
unsymmetrical Pt(IV) complexes containing a mixture of OH and OAc axial ligands by 
an oxidation reaction with H2O2 in acetic acid. The progress of the reaction was visually 
monitored by the disappearance of the insoluble bright yellow solid of the Pt(II) 
compounds into a light yellow solution. After removal of the solvent, the  
[Pt(IV)Cl2(OAc)(OH)(4,4′-bis(RO)-2,2′-bipyridine)] complexes were then reacted with 
acetic anhydride to form the desired [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-bipyridine)] 
complexes. This step in the reaction was visually monitored by the appearance of a pale 
yellow suspension. Seven complexes were successfully synthesized and their chemical 
structures are shown in Figure 5-2; these Pt(IV) complexes have not been reported in the 
literature. 
 
Scheme 5 – 1. Synthetic route for the preparation of [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-
bipyridine)] complexes. 
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Figure 5 – 2. Chemical structures of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-
2,2′-bipyridine)] complexes. 
 
 All of the compounds were characterized by 
1
H and 
13
C NMR spectroscopy, 
elemental analysis, and DSC measurements. Elemental analyses of the complexes were in 
excellent agreement (within 0.5%) with the expected values; thus, validating the 
molecular formulae of these compounds.  To compare the NMR chemical shifts of the 
Pt(IV) complexes to that of the Pt(II) complexes, the Pt(IV) samples were prepared in the 
same deuterated solvent as the corresponding Pt(II) precursors.  The 
1
H and 
13
C NMR 
spectra of Pt(IV)-1C–Pt(IV)-4C were recorded in DMSO-d6, whereas those of Pt(IV)-
5C–Pt(IV)-8C were recorded in CDCl3. The spectra of all of the complexes displayed the 
expected proton and carbon resonances; the 
1
H NMR chemical shifts of the Pt(II) and 
Pt(IV) complexes are depicted in Figure 5-3. The appearance of a singlet peak between 
1.6–1.8 ppm in the 1H spectra (peak e) and two additional peaks in the 13C spectra  
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Figure 5 – 3. 1H NMR spectra of Pt(II) and Pt(IV) complexes recorded in (A) DMSO-d6 
or (B) CDCl3 at room temperature. 
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indicate the presence of the diacetato ligands attached to the Pt center. While the 
chemical shifts of the protons in the alkyl region remained relatively the same between 
the Pt(II) and Pt(IV) complexes, the chemical shifts of the aromatic protons (peaks a–c) 
and the methylene protons next to the oxygen attached to the bipyridine ring (peak d) are 
slightly shifted. All of the aromatic proton peaks (Figure 5-3 A, peaks a–c) and the 
methylene protons peak (Figure 5-3 A, peak d) of the Pt(IV) complexes in DMSO-d6 are 
shifted downfield compared to Pt(II); however, the methylene proton signal (Figure 5-3 
B, peak d) of the Pt(IV) complexes recorded in CDCl3 is slightly shifted upfield and only 
the peaks corresponding to the protons at the 6,6′ (peak c) and 5,5′ (peak b) positions are 
shifted downfield. Similar to the proton signals, carbon signals of the Pt(IV) complexes 
are shifted to varying degrees compared to Pt(II) complexes (the chemical shifts of the 
Pt(II) complexes are given in the experimental section of Chapter 2 and the shifts for the 
Pt(IV) complexes are given in the experimental section of this chapter). 
The thermal characteristics of the synthesized Pt(IV) compounds were studied by 
using DSC analysis. As depicted in the DSC thermogram (Figure 5-4), the thermal 
transitions of all the synthesized Pt(IV) complexes had a similar trend, but there are slight 
variations. Although all of the complexes had an exothermic peak indicating 
decomposition, the Tonset–Tmax ranges for the decomposition temperatures of Pt(IV)-1C–
Pt(IV)-4C  were lower than the melting ranges of the Pt(II) counterparts and the ranges 
for  Pt(IV)-5C–Pt(IV)-8C  were higher than the melting ranges of the Pt(II) (Table 5-1).  
All of the Pt(IV) complexes also had an endotherm at varying temperatures after 
decomposition. Additionally, the DSC thermogram of Pt(IV)-1C displayed an endotherm 
about 10 °C before the Tonset of decomposition, and Pt(IV)-5C and Pt(IV)-8C each had 
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an endotherm immediately before Tonset of decomposition.  Pt(IV)-6C also had a broad 
low energy endotherm between 150–160 °C. The endotherms occurring before the 
decomposition temperature may be due to crystal-to-crystal transitions. Since the 
compounds decompose, only one heating cycle was done instead of performing both 
heating and cooling cycles. 
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Figure 5 – 4. DSC thermograms of [Pt(IV)Cl2(OAc)2(4,4′-bis(RO)-2,2′-bipyridine)] 
complexes obtained in the first heating cycles in nitrogen at a heating rate of 10 °C/min. 
 
 
Table 5 – 1. Tonset–Tmax (°C) of the Pt(II) melting temperatures vs. the Pt(IV) decomposition 
temperatures 
Complex Pt-1C Pt-2C Pt-3C Pt-4C Pt-5C Pt-6C Pt-8C 
Pt(II) 311–316 318–322 269–272 229–230 173–175 176–179 169–172 
Pt(IV) 239–249 256–259 242–243 215–219 220–222 217–219 197–203 
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Coordination of the axial ligands to the Pt center improved the solubility of the 
complexes in common organic solvents. DMSO solutions of the Pt(IV) complexes with 
concentrations of 10 mM or higher were obtainable, whereas, the Pt(II) can only be made 
at the highest concentration of 5 mM. The solubility of Pt(IV)-8C was markedly 
improved compared to Pt(II)-8C, which was not evaluated for anti-proliferative activities 
due to poor solubility in DMSO and other common organic solvents that could be used 
for in vitro testing.   
5.4.2 Biological properties 
5.4.2.1 In vitro cytotoxic activity 
 The anti-proliferative activities of all the Pt(IV) complexes were determined in 
two lung (H520), two prostate (DU145 and PC-3), and six breast (HCC38, MCF-7, 
MDA-MB-231, SK-BR-3, T-47D, and ZR-75-1) cancer cell lines.  The cells were treated 
with increasing concentrations of cisplatin, carboplatin, or the Pt(IV) complexes for 1 or 
48 h and the viability was measured using an MTS colorimetric cell proliferation assay. 
The graphs of the results for DU145 (Figure 5-5), A549 (Figure 5-6), and MCF-7 (Figure 
5-7) are shown to represent each type of cancer.  
For the 1 h treatment in DU145 cells (Figure 5-5 A), cisplatin caused a 
concentration dependent decrease in cell viability (a 60% reduction by the highest 
concentration of 1 mM) and carboplatin had no effect even up to 1 mM. The two 
complexes with short alkoxy substituents, Pt(IV)-1C (one carbon) and Pt(IV)-2C (two 
carbons), also did not have any effects at the concentrations tested (up to 100 µM for 
Pt(IV)-1C and 50 µM for Pt(IV)-2C). Complexes Pt(IV)-3C–Pt(IV)-8C all caused a 
concentration dependent decrease in DU145 cell viability and were more effective than 
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cisplatin. Pt(IV)-3C was the least effective among the five active compounds, followed 
by Pt(IV)-4C, with Pt(IV)-5C–Pt(IV)-8C having similar activities. When the treatment 
time was extended to 48 h (Figure 5-5 B), the activities of all the platinum compounds 
were increased. However, all of the Pt(IV) complexes were still more effective than 
cisplatin except for Pt(IV)-1C, which was more effective than carboplatin. 
Similar trends were observed for A549 (Figure 5-6) and MCF-7 (Figure 5-7) 
cells, except these cells were not as sensitive to treatment with the platinum complexes as 
DU145 cells. Also, Pt(IV)-3C and Pt(IV)-4C did not have any effects on A549 and 
MCF-7 cells at the concentrations tested for the 1 h treatment, and Pt(IV)-1C and 
Pt(IV)-2C had no effects for the 48 h treatment. The dramatic increased activities of 
Pt(IV)-3C and Pt(IV)-4C for the 48 h treatment compared to the 1 h treatment is an 
indication that the anti-proliferative activities of the platinum complexes are not due to a 
surfactant effect since interactions of the hydrophobic alkyl chain with the cell membrane 
would result in a faster response. 
It should be noted that while the solubility of these Pt(IV) complexes in organic 
solvents are increased compared to their Pt(II) precursors, they were still poorly soluble 
in water; thus, Pt(IV)-1C–Pt(IV)-3C were limited to a highest concentration of 100 µM. 
Interestingly, Pt(IV)-4C precipitates out of solution at concentrations of 30 µM or higher 
when the stock DMSO solution was diluted in the culture medium; thus, testing of 
Pt(IV)4C was limited to 25 µM. Pt(IV)-8C gave similar results regardless of whether the 
stock solution was made in DMSO or ethanol, which suggests that the chloride leaving 
groups were not displaced by DMSO and indicates that the Pt(IV)-8C structure is stable.  
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The effective concentration that resulted in 50% cell viability (EC50) for all the 
cell lines tested are given in Tables 5-2–5-5. Comparison of the EC50 values indicate that 
the Pt(IV) complexes are generally more effective than cisplatin. A549 and MCF-7 are 
the most resistant cell lines, while SK-BR-3 and T-47D are the most sensitive. Similar to 
Pt(II) complexes (Chapters 2 and 3), the activity of the Pt(IV) complexes increases as the 
carbon number on the alkoxy substituent increases.  Pt(IV) complexes with short carbon 
chains (1–3 carbons) are not as effective as their Pt(II) precursors and Pt(IV) complexes 
with long carbon chains (5–8) are more effective than their Pt(II) precursors.  Pt(II)-4C 
and Pt(IV)-4C (four carbon chain) have similar activities. 
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Figure 5 – 5. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-
bipyridine)] complexes vs. CDDP and carboplatin against DU145 cells. Cells were 
treated with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B) 
48 h and the viability was determined using the MTS assay. Data points represent mean ± 
SD of at least two independent experiments done in quadruplicates. 
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Figure 5 – 6. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-
bipyridine)] complexes vs. CDDP and carboplatin against A549 cells. Cells were treated 
with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B) 48 h and 
the viability was determined using the MTS assay. Data points represent mean ± SD of at 
least two independent experiments done in quadruplicates. 
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Figure 5 – 7. Cytotoxic activity of the synthesized [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-
bipyridine)] complexes vs. CDDP and carboplatin against MCF-7 cells. Cells were 
treated with CDDP or the platinum analogs at various concentrations for (A) 1 h or (B) 
48 h and the viability was determined using the MTS assay. Data points represent mean ± 
SD of at least two independent experiments done in quadruplicates. 
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Table 5 – 2. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] 
complexes in A549 and H520 post 1 or 48 h treatment  
 Lung cancer 
 A549 H520 
 
1 h 48 h 1 h 48 h 
CDDP 900 ± 200 500 ± 100 200 ± 17 24 ± 2 
Carboplatin >1000 300 ± 30 ND ND 
Pt(IV)-1C >100 >100 >100 >100 
Pt(IV)-2C >50 >50 >100 61 ± 2
a
 
Pt(IV)-3C >50 23 ± 1
a,b
 80 ± 20
a
 8 ± 6
a
 
Pt(IV)-4C >25 14  ± 1
a,b
 13  ± 5
a
 2.2  ± 0.1
a
 
Pt(IV)-5C 6.6 ± 0.3
a
 2.2 ± 0.1
a,b
 3 ± 1
a
 1.0 ± 0.3
a
 
Pt(IV)-6C 2.5 ± 0.2
a
 2.2 ± 0.1
a,b
 2.1 ± 0.2
a
 1.0 ± 0.4
a
 
Pt(IV)-8C 7.0 ± 0.4
a
 3.0 ± 0.5
a,b
 7 ± 5
a
 1.2 ± 0.6
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
 
 
 
Table 5 – 3. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes 
in DU145 and PC-3 post 1 or 48 h treatment 
 
Prostate cancer 
 
DU145 PC-3 
 
1 h 48 h 1 h 48 h 
CDDP 400 ± 100 64 ± 8 200 ± 20 30 ± 1 
Carboplatin >1000 400 ± 100
a
 ND ND 
Pt(IV)-1C >100 80 ± 20
b
 >100 >100 
Pt(IV)-2C >50 10 ± 4
a,b
 >50 20 ± 2
a
 
Pt(IV)-3C 24 ± 7
a
 1 ± 1
a,b
 23.0 ± 0.3
a
 1.1 ± 0.4
a
 
Pt(IV)-4C 8 ± 7
a
 0.9 ± 0.2
a,b
 5 ± 3
a
 1.1 ± 0.4
a
 
Pt(IV)-5C 1 ± 1
a
 0.34 ± 0.02
a,b
 1.7 ± 0.2
a
 0.5 ± 0.2
a
 
Pt(IV)-6C 1.3 ± 0.2
a
 0.5 ± 0.3
a,b
 2.0 ± 0.3
a
 0.33 ± 0.04
a
 
Pt(IV)-8C 0.7 ± 0.3
a
 0.2 ± 0.1
a,b
 1.2 ± 0.5
a
 0.11 ± 0.02
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
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Table 5 – 4. EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in 
various breast cancer cells post 1 h treatment 
 
HCC38 MCF-7 
MDA- 
MB-231 
SK-BR-3 T-47D ZR-75-1 
CDDP 300 ± 30 900 ± 100  50 ± 4 420 ± 80 900 ± 100 260 ± 10 
Carboplatin ND >1000 ND ND ND ND 
Pt(IV)-1C >100 >100 >100 >100 >100 >100 
Pt(IV)-2C 93 ± 10
a
 >100 >100 40 ± 10
a
 46 ± 8
a
 >50 
Pt(IV)-3C 26 ± 6
a
 >100 34 ± 7
a
 19 ± 2
a
 24 ± 3
a
 24 ± 3
a
 
Pt(IV)-4C 17  ± 3
a
 >25 2.8 ± 0.1
a
 4.0 ± 0.7
a
 10 ± 1
a
 2.9±0.3
a
 
Pt(IV)-5C 3 ± 1
a
 2.9 ± 0.13
a
 1.8 ± 0.1
a
 1.3 ± 0.6
a
 2.3 ± 0.3
a
 1.6 ± 0.1
a
 
Pt(IV)-6C 2.3 ± 0.2
a
 2.4 ± 0.1
a
 1.1 ± 0.2
a
 0.36±0.02
a
 2.1 ± 0.4
a
 1.1 ± 0.4
a
 
Pt(IV)-8C 3.0 ± 0.6
a
 4 ± 1
a
 2.1 ± 0.2
a
 0.33±0.05
a
 1.5 ± 0.5
a
 3.0 ± 1
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
 
 
Table 5 – 5.  EC50 (µM) of [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] complexes in 
various breast cancer cells post 48 h treatment 
 
HCC38 MCF-7 
MDA- 
MB-231 
SK-BR-3 T-47D ZR-75-1 
CDDP 30 ± 8 34 ± 1 21 ± 3 23 ± 6 35 ± 6 30 ± 8 
Carboplatin ND 800 ± 100
a
 ND ND ND ND 
Pt(IV)-1C >100 >100 >100 80 ± 20
a
 32.0 ± 0.5 >100 
Pt(IV)-2C 30 ± 9 >100 28 ± 7 8.3 ± 0.7
a
 0.95 ± 0.03
a
 17 ± 7 
Pt(IV)-3C 8 ± 1
a
 29 ± 2
a,b
 6.1 ± 0.4
a
 0.9 ± 0.1
a
 0.59 ± 0.01
a
 1.21±0.04
a
 
Pt(IV)-4C 2.1±0.2
a
 2.2 ±0.1
a,b
 1.0 ± 0.2
a
 0.44±0.02
a
 0.33 ± 0.07
a
 0.7  ± 0.2
a
 
Pt(IV)-5C 2.1±0.3
a
 2.0 ± 0.1
a,b
 0.26±0.01
a
 0.30±0.03
a
 0.25±0
a
 0.55±0.07
a
 
Pt(IV)-6C 1.8±0.5
a
 1.6 ± 0.2
a,b
 0.31±0.04
a
 0.21±0.03
a
 0.24 ± 0.01
a
 0.55±0.04
a
 
Pt(IV)-8C 1.6±0.3
a
 1.3 ± 0.3
a,b
 0.9 ± 0.3
a
 0.22±0.03
a
 0.25 ± 0
a
 1.3 ± 0.1
a
 
Values represent the mean ± SD of at least two independent experiments done in 
quadruplicates. ND = no data. 
a
 P < 0.5 compared to CDDP. 
b
 P < 0.05 compared to 
carboplatin. 
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Figure 5 – 8. Pt(IV) complexes induced phosphorylation of H2AX in A549 and DU145 
cells. (A) A549 cells were treated for 6 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)-5C 
and analyzed 12 h post treatment, (B) DU145 cells were treated for 2 h with 10 µM 
Pt(IV)-4C or 2.5 µM Pt(IV)-5C and analyzed 7 h post treatment. Data are representative 
of three independent experiments. 
 
 
5.4.2.2 Detection of DNA damage 
Cisplatin is known to bind DNA and form adducts, which induces cell cycle 
arrest, DNA damage repair, various stress response pathways, and death pathways.  DNA 
damage by cisplatin has been shown to induce phosphorylation of histone H2AX, which 
is believed to be involved in recognition and repair of damaged DNA, and regulation of 
the apoptotic pathway.  Flow cytometry was used to analyze levels of phosphorylated 
H2AX (γH2AX) in A549 and DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C. 
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Representative histograms for each cell line are shown in Figure 5-8. As shown, 
treatment with Pt(IV)-4C and Pt(IV)-5C resulted in an increase of γH2AX in both A549 
and DU145 cells. The increase in γH2AX caused by Pt(IV)-4C treatment was not as high 
as Pt(IV)-5C. Nonetheless, these results indicate that treatment with Pt(IV)-4C and 
Pt(IV)-5C caused DNA damage in A549 and DU145 cells. 
5.4.2.3 Evaluation of apoptosis 
 Cisplatin induced DNA damage has been associated with cell cycle arrest and 
induction of apoptosis.  Since treatment with Pt(IV)-4C and Pt(IV)-5C caused an 
increase in γH2AX in A549 and DU145 cells,  their effects on the cell cycle was 
examined. Flow cytometric analysis of propidium iodide provides information on DNA 
content, which is correlated with the stages in the cell cycle.  Additionally, appearance of 
a sub-G1 peak is an indication of apoptosis. A549 cells treated with Pt(IV)-4C and 
Pt(IV)-5C had a decreased percentage of cells in the G1 phase and a corresponding 
increase in the sub-G1 peak, while the S and G2 phases remained relatively similar to the 
control (Figure 5-9 A).  Treatment of DU145 cells with Pt(IV)-4C and Pt(IV)-5C did not 
affect the cell cycle and a sub-G1 peak was not detected (Figure 5-9 B). A sub-G1 peak 
was not detected even when the treatment time was extended to 2 and 4 h; perhaps these 
treatment duration are not enough to cause fragmentation and leakage of the DNA 
content to produce a sub-G1 peak. Alternatively, the difference between the response of 
A549 and DU145 may be due to differences in p53 status; A549 has wild type p53, while 
DU145 has mutant p53. It is possible that lack of apoptotic features in DU145 cells is the 
result of not having functional p53 to signal the apoptotic pathway. 
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The sub-G1 peak is a measurement of cells with less DNA than cells in the G1 
phase, which is attributed to leakage of DNA content from cells undergoing late 
apoptosis or necrosis. Since the sub-G1 peak is not a clear indication of apoptosis, flow 
cytometric analysis of Annexin V and PI double staining was performed. Annexin V 
binds to exposed phosphatidylserine on the membrane surface, which is an event that 
occurs in early apoptosis. Co-staining with PI, a membrane impermeable dye, allows for 
differentiation between cells with intact membrane and cells with membrane damage, 
which occurs in late stage apoptosis or necrosis. As shown in Figure 5-10, A549 and 
DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C had decreased AnnexinV/PI negative 
cells (Q4, live cells) and a corresponding increase in Annexin V positive (Q3, early 
apoptotic cells) and Annexin V/PI positive cells (Q2, late apoptotic/necrotic cells). These 
changes were higher in Pt(IV)-5C treated cells than Pt(IV)-4C treated cells. A549 cells 
treated with Pt(IV)-5C also had an increase in PI positive cells (Q1, necrotic cells) 
(Figure 5-10 A). DU145 had higher increases of Annexin V/PI positive cells than 
Annexin V positive cells suggesting that they may be in late stage apoptosis or necrosis 
(Figure 5-10 B). Together, these results indicate that Pt(IV)-4C and Pt(IV)-5C induce 
apoptosis in A549 and DU145 cells, although some necrosis was also observed. 
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Figure 5 – 9. Cell cycle analysis of A549 and DU145 cells treated with Pt(IV)-4C and 
Pt(IV)-5C. (A) A549 cells were treated for 5 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)-
5C and analyzed 12 h post treatment, (B) DU145 cells were treated for 1 h with 10 µM 
Pt(IV)-4C or 2.5 µM Pt(IV)-5C and analyzed 12 h post treatment. Data are 
representative of three independent experiments. 
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Figure 5 – 10. Flow cytometry analysis of Annexin V/PI staining in A549 and DU145 
treated with Pt(IV)-4C and Pt(IV)-5C. (A) A549 cells were treated for 5 h with 25 µM 
Pt(IV)-4C or 10 µM Pt(IV)-5C and analyzed 12 h post treatment, (B) DU145 cells were 
treated for 1 h with 10 µM Pt(IV)-4C or 2.5 µM Pt(IV)-5C analyzed 12 h post treatment. 
Q1 = PI+, represents necrotic cells; Q2 = Annexin V/PI+, representing late 
apoptotic/necrotic cells; Q3 = Annexin V+, representing early apoptotic cells; Q4 = 
AnnexinV/PI-, representing live cells. Data are representative of three independent 
experiments. 
 
 Analysis of hoechst (Ho) and PI staining by confocal microscopy was performed 
to detect cell death.  PI stains cells with membrane damage; whereas, Ho stains both live 
and apoptotic cells, but apoptotic cells will have more intense Ho fluorescence.  A549 
cells treated with Pt(IV)-4C and Pt(IV)-5C had increased Ho fluorescence compared to 
control (Figure 5-11). There was no difference between the PI fluorescence of Pt(IV)-5C 
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treated cells compared to the control, but Pt(IV)-4C treated cells had increased PI 
positive cells. Similar results were obtained for DU145 cells, except Pt(IV)-5C treated 
cells had more PI positive staining than Ho staining compared to the control (Figure 5-
12). Additionally, unlike A549, the PI positive cells in Pt(IV)-4C treated cells were 
higher than Pt(IV)-5C treated cells. The increase in PI staining suggests that the cells 
have membrane damage, which indicates that the cells were either at late stage apoptosis 
or were undergoing necrosis. These results correspond to the flow results indicating that 
Pt(IV)-4C and Pt(IV)-5C induce apoptosis and possibly some necrosis.  
 
 
Figure 5 – 11. Confocal microscopy analysis of PI and Ho uptake in A549 cells treated 
with Pt(IV)-4C and Pt(IV)-5C. A549 cells treated for 5 h with 25 µM Pt(IV)-4C or 7.5 
µM Pt(IV)-5C were stained with Ho and PI and images were capture with a confocal 
microscope. Images are from one trial. 
162 
 
 
Figure 5 – 12. Confocal microscopy analysis of PI and Ho uptake in DU145 cells treated 
with Pt(IV)-4C and Pt(IV)-5C. DU145 cells treated for 3.5 h with 10 µM Pt(IV)-4C or 
2.5 µM Pt(IV)-5C were stained with Ho and PI and images were capture with a confocal 
microscope. Images are from one trial. 
 
Finally, detection of cleaved-PARP by flow cytometry was used as an indication 
of apoptosis. PARP is a nuclear poly (ADP-ribose) polymerase that has been associated 
with DNA repair. During apoptosis, PARP is cleaved by caspase-3.
20
 As shown in Figure 
5-13, both A549 and DU145 cells treated with Pt(IV)-4C and Pt(IV)-5C had increased 
levels of cleaved-PARP, suggesting that Pt(IV)-4C and Pt(IV)-5C induced caspase-3 
mediated apoptosis in these two cell lines.  The fold increase of cleaved-PARP in A549 
(~7 fold for both compounds) were higher than DU145 (~2 fold for both compounds). 
Similar to the flow data with PI staining, the differences between A549 and DU145 may 
be due to treatment time or p53 status. 
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Figure 5 – 13. Pt(IV)-4C and Pt(IV)-5C induced cleavage of PARP. (A) A549 cells 
were treated for 5 h with 25 µM Pt(IV)-4C or 7.5 µM Pt(IV)-5C and analyzed 12 h post 
treatment, (B) DU145 cells were treated for 2 h with 10 µM Pt(IV)-4C or 2.5 µM 
Pt(IV)-5C analyzed 7 h post treatment. Data are representative of three independent 
experiments. 
 
5.5 Conclusions 
We have synthesized a series of Pt(IV) derivatives with diacetato axial ligands 
from our recently reported Pt(II) complexes containing 4,4′-dialkoxy-2,2′-bipyridyl 
ligands. Solubility of these Pt(IV) complexes in DMSO was increased compared to the 
Pt(II) precursor. In vitro testing of these Pt(IV) complexes in a panel of human lung, 
breast, and prostate cancer cell lines suggested that these Pt(IV) complexes are generally 
more effective than cisplatin. Similar to the Pt(II) precursors, a structure activity 
relationship was observed in which the compounds had increasing anti-proliferative 
activities with increasing carbon chain length of the dialkoxy substituents. The activities 
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of Pt(IV)-5C–Pt(IV)-8C were similar, but in some cases Pt(IV)-8C was less active.  
Pt(IV)-1C–Pt(IV)-3C were less active than the Pt(II) counterparts and Pt(IV)-4C had 
similar activity to Pt(II)-4C. Pt(IV)-5C and Pt(IV)-6C were more active than their Pt(II) 
counterparts in both the 1 h and the 48h treatment. Pt(II)-8C could not be tested due to 
poor solubility, but the increased solubility of Pt(IV) complexes allowed for the testing of 
Pt(IV)-8C, which had activity in both the 1 h and the 48 h treatment.  
Analysis of cell death using confocal microscopy and flow cytometry staining 
with various dyes and antibodies demonstrated that Pt(IV)-4C and Pt(IV)-5C induced 
DNA damage in A549 and DU145 cells, which led to activation of apoptosis with some 
necrotic response. 
These findings demonstrate that the Pt(IV) complexes have the potential to be 
used as anticancer drugs.   
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CHAPTER 6  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
Platinum-based drugs are currently used worldwide for the treatment of various 
cancers; however, severe side effects and intrinsic or acquired resistance have hindered 
their clinical utility.  Motivated to develop platinum drugs with improved efficacy and 
lower toxicity, three series of platinum(II) and platinum(IV) complexes containing 4,4′-
disubstituted-2,2′-bipyridine ligands have been synthesized and investigated for possible 
anti-tumoral activity.  
The first series that was prepared consisted of seven [Pt(II)Cl2(4,4′-dialkoxy-2,2′-
bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)] 
(where R = –(CH2)n–1CH3, n = 2–6, 8), five of which are novel compounds.  The anti-
proliferative activities of these complexes were examined in a panel of 10 human cancer 
cell lines from lung, prostate, and breast origin. Although the effects of these 
[Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes varies between the different cell 
lines, it can be generalized that all of the novel complexes are more effective than 
cisplatin and carboplatin in the cell lines tested. The superior activity of these novel 
platinum complexes are more evident in the short 1 h treatment than in the extended 48 h 
treatment, suggesting that these novel platinum complexes may reach intracellular targets 
faster than cisplatin.  
The EC50 values for two of the complexes, Pt(II)-1C and Pt(II)-2C, could not be 
determined in some cell lines due to their poor solubility which prevented testing at 
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concentrations above 100 µM. However, comparison of the effects at the concentrations 
tested revealed a correlation between structure and activity; the anti-proliferative activity 
of the complexes increases as the carbon number on the alkoxy substituents increases 
from one (Pt(II)-1C) to four (Pt(II)-4C) carbons. Pt(II)-5C (5 carbons) and Pt(II)-6C (6 
carbons) generally have similar activity to Pt(II)-4C. Pt(II)-8C, which has eight carbons 
on the alkoxy substituents, was not tested due to poor solubility. 
Pt(II)-4C was selected for further investigation due to having consistently low 
EC50 values in all of the cell lines tested. Examination of Pt(II)-4C interaction with DNA 
by UV-Vis analysis with calf thymus DNA, gel electrophoresis with plasmid pBR322 
DNA, and ICP-AES measurement of platinum in Pt(II)-4C cells revealed that Pt(II)-4C 
is able to induce DNA damage. Results from western blotting, flow cytometric 
immunofluorescence, and immunofluorescence microscopy indicate induction of 
apoptosis and activation of p53, histone H2AX (γH2AX), and MAPK members (JNK, 
ERK, and p38). Treatment of cells with Pt(II)-4C in the presence of MAPK inhibitors 
resulted in decreased γH2AX compared to cells treated with Pt(II)-4C alone suggesting 
that activation of H2AX is dependent on MAPKs. Furthermore, cells treated with Pt(II)-
4C in the presence of p53, JNK, or p38 inhibitors had increased cell viability compared 
to cells treated with Pt(II)-4C alone. These results indicate that p53, JNK, and p38 are 
involved in activation of the apoptotic pathway in response to Pt(II)-4C. Moreover, 
Pt(II)-4C induced apoptosis may be regulated by γH2AX in a JNK and p38 dependent 
manner. 
The in vitro data indicate that these complexes have potential clinical utility, thus, 
Pt(II)-4C toxicity was tested in mice. Mice injected with Pt(II)-4C at a dose of 12.5 mg 
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kg
-1
 d
-1
 for 3 d survived the study period of 7 d post injection and did not show any 
abnormal signs. This result indicates that Pt(II)-4C is not toxic in animal models at the 
tested dose; thus, further in vivo studies are warranted.  However, in vivo investigation of 
Pt(II)-4C is complicated by its low solubility in common organic solvents and 
solubilizing agents. 
To improve the solubility of [Pt(II)Cl2(4,4′-dialkoxy-2,2′-bipyridine)] complexes, 
the second series of Pt(II) complexes were developed by modification of the dialkoxy 
substituents to have increasing oxygen which will result in increasing hydrogen bonding 
and water solubility. This series consist of five [Pt(II)Cl2(4,4′-dioligooxyethylene-2,2′-
bipyridine)] complexes of the general formula of [Pt(II)Cl2(4,4′-bis(RO)-2,2′-bipyridine)] 
(where R = –(CH2CH2O)n(CH2)mCH3, n = 1–4, m = 0–3).  The anti-proliferative activities 
of these complexes were also examined in a panel of 10 human cancer cell lines from 
lung, prostate, and breast origin. The results showed varying degrees of activity in the 
cell lines tested.  In some cell lines, the synthesized complexes were as effective as 
cisplatin or less effective, while in others, the synthesized complexes were more effective 
than cisplatin. Although these complexes have improved solubility in organic solvents 
and two have some solubility in water; their anti-proliferative activity is greatly 
diminished compared to the dialkoxy series. 
The third series was then prepared by oxidation of the Pt(II) dialkoxy series to 
Pt(IV), which resulted in seven [Pt(IV)Cl2(OAc)2(4,4′-dialkoxy-2,2′-bipyridine)] 
complexes. The solubility of these Pt(IV) complexes in organic solvents were improved, 
but they still have poor solubility in water. The anti-proliferative activities of these 
complexes were also examined in the same panel of cancer cell lines. Similar to the Pt(II) 
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precursors, these Pt(IV) complexes are generally more effective than cisplatin. Pt(IV)-
1C–Pt(IV)-3C were less active than the Pt(II) counterparts and Pt(IV)-4C had similar 
activity to Pt(II)-4C. Pt(IV)-5C and Pt(IV)-6C were more active than their Pt(II) 
counterparts in both the 1 h and the 48h treatment. Pt(II)-8C could not be tested due to 
poor solubility, but the increased solubility of Pt(IV) complexes allowed for the testing of 
Pt(IV)-8C, which had high anti-proliferative activity for both the 1 h and the 48 h 
treatments.  
Analysis of cell death revealed that Pt(IV)-4C and Pt(IV)-5C induced DNA 
damage in A549 and DU145 cells, which led to activation of apoptosis with some 
necrotic response. These findings demonstrate that the Pt(IV) complexes have the 
potential to be used as anticancer drugs and warrant further investigation.   
6.2 Future directions 
The two Pt(II) series described were prepared by utilizing the 4,4′ positions on the 
2,2′-bipyridyl ligand.  Other series can be made by changing the functional group at these 
positions. A few compounds with —COOR and phosphate groups at the 4,4′ positions 
have been prepared, but their anti-proliferative activities have not been thoroughly 
investigated. Examination of their anti-proliferative activities may provide useful 
information on the structure-activity relationship.  
 New platinum complexes are continuously being made through modifications of 
existing compounds by employing methods to alter the leaving groups and/or the non-
leaving groups.
1
 The structure of the 2,2′-bipyridyl ligand offers many opportunities for 
functionalization to create new compounds. However, it would be interesting to explore 
the effects of replacing the chloride leaving groups with other types of leaving groups on 
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the activity of the 2,2′-bipyridyl platinum complexes.  Compounds in which the chloride 
leaving groups were replaced by a pyrophosphate group have been shown to have better 
or comparable activity to cisplatin and having a different mechanism of action than DNA 
binding.
2,3 
These compounds were also demonstrated to be effective in cisplatin 
resistance cancer cells. This would be an interesting option to modify the disubstituted-
2,2′-bipyridyl platinum(II) and platinum(IV) complexes. Alternatively, modification of 
the axial ligands of the Pt(IV) complexes may result in improvements.
4 
 In addition to the synthesis of new compounds, further investigation of the three 
synthesized series should be done.  Some of the results presented are only from one or 
two trials; thus they need to be repeated to confirm the results. Also, a major concern 
with cisplatin is intrinsic or acquired resistance; thus, these complexes should be tested in 
cisplatin resistant cells. 
Cisplatin induced DNA damage activates many signaling pathways. Although 
activation of p53 and MAPKs by Pt(II)-4C have been demonstrated, it is not exactly 
clear how they are involved. Thus, their upstream and downstream signaling should be 
examined. Additionally, the use of a chemical inhibitor may not provide accurate 
information since they can interact with other biological molecules. Consequently, results 
obtained with the p53 and MAPK inhibitors should be confirmed with knockout 
experiments.  
 Since the Pt(IV) complexes are also highly effective and various data indicate that 
they induce apoptosis, the p53 and MAPK experiments done for the Pt(II)-4C should be 
repeated with Pt(IV)-4C or Pt(IV)-5C. Although the Pt(II)-dioligooxyethylene series are 
not as effective as the other two series, Pt(II)-4O,2C should be examined further since it 
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is water soluble and had comparable activity to cisplatin in some of the tested cell lines. 
Perhaps combination treatment with phytochemicals
4–6
 or photochemical internalization-
mediated delivery may increase the effectiveness of these complexes.
7,9
 Lastly, instead of 
directly modifying the complexes to improve solubility, it might be beneficial to explore 
delivery methods such as incorporation into a macromolecular delivery system.
10–12
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APPENDIX 1  
SUPPORTING INFORMATION FOR CHAPTER 2 
 
 
 
Figure 2S – 1.  13C NMR spectra of ligands and Pt(II)-complexes recorded in A) DMSO-
d6 and B) CDCl3  at temperatures indicated in the experimental section (* solvent peak). 
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Figure 2S – 2. DSC thermograms of A) Pt-3C, B) Pt-5C, C) Pt-6C, and D) Pt-8C 
obtained  in nitrogen at heating and cooling rates of 10 °C/min. 
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APPENDIX 2  
SUPPORTING INFORMATION FOR CHAPTER 3 
 
 
Figure 3S – 1. Flow cytometric analysis of γH2AX.  (A) A549 cells treated for 6 h with 
25 µM Pt(II)-4C, (B) DU145 cells treated for 1 h with 25 µM Pt(II)-4C, and (D) fold 
change in the fluorescence signals compared to control. Histograms are representative of 
three experiments. 
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Figure 3S – 2. Effects of MAPK inhibitors on Pt(II)-4C induced cell death in DU145 
cells.  The cells were treated with increasing concentrations of Pt(II)-4C in the absence 
and presence of 50 µM of MAPK inhibitors (PD: ERK inhibitor, SB: p38 inhibitor, SP: 
JNK inhibitor) for 48 h.  Results are representative of two independent experiments done 
in quadruplicates. 
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APPENDIX 3  
SUPPORTING INFORMATION FOR CHAPTER 4 
 
 
 
 
Figure 4S – 1. 1H NMR of tosylate compounds recorded in CDCl3 at room temperature. 
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Figure 4S –2. 1H (top) and 13C (bottom) NMR spectra of compound L-2O,1C recorded 
in DMSO-d6 at room temperature. 
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Figure 4S –3. 1H (top) and 13C (bottom) NMR spectra of compound L-3O,2C recorded 
in CDCl3 at room temperature. 
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Figure 4S –4. 1H (top) and 13C (bottom) NMR spectra of compound L-4O,2C recorded 
in CDCl3 at room temperature. 
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Figure 4S –5. 1H (top) and 13C (bottom) NMR spectra of compound L-4O,4C recorded 
in CDCl3 at room temperature. 
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Figure 4S –6. 1H (top) and 13C (bottom) NMR spectra of compound L-5O,1C recorded 
in CDCl3 at room temperature. 
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Figure 4S –7. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-2O,1C 
recorded in DMSO-d6 at room temperature. 
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Figure 4S –8. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-3O,2C 
recorded in CDCl3 at room temperature. 
187 
 
 
 
Figure 4S –9. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-4O,2C 
recorded in CDCl3 at room temperature. 
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Figure 4S –10. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-4O,4C 
recorded in CDCl3 at room temperature. 
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Figure 4S –11. 1H (top) and 13C (bottom) NMR spectra of compound Pt(II)-5O,1C 
recorded in CDCl3 at room temperature. 
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APPENDIX 4 
SUPPORTING INFORMATION FOR CHAPTER 5 
 
Figure 5S –1. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-1C recorded 
in DMSO-d6 at room temperature. 
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Figure 5S –2. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-2C recorded 
in DMSO-d6 at room temperature. 
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Figure 5S – 3. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-3C recorded 
in DMSO-d6 at room temperature. 
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Figure 5S – 4. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-4C recorded 
in DMSO-d6 at room temperature. 
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Figure 5S – 5. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-5C recorded 
in CDCl3 at room temperature. 
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Figure 5S – 6. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-6C recorded 
in CDCl3 at room temperature. 
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Figure 5S – 7. 1H (top) and 13C (bottom) NMR spectra of compound Pt(IV)-8C recorded 
in CDCl3 at room temperature. 
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